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Resistência, osteossarcoma, humano, In vitro, In vivo, quimioterapia  
resumo 
 
 
Osteossarcoma é uma doença rara, sendo o tipo mais comum de tumor maligno 
do osso. O pico de incidência ocorre durante a adolescência e desenvolve-se 
principalmente nos ossos longos. Os tratamentos atuais incluem quimioterapia 
antes e após a cirurgia e a ressecção cirúrgica de todos os locais envolvidos 
(tumor primário e metástases quando presente). As metástases, principalmente 
nos pulmões, são um grande problema no diagnóstico (20-30% dos pacientes) 
e durante a história natural do osteossarcoma (cerca de 30% de recaída), afetam 
uma percentagem considerável de pacientes e são considerados os maiores 
problemas desta doença. Biologicamente, os osteossarcomas são um dos 
tumores mais complexos observados nas crianças, no que diz respeito à 
heterogeneidade, anomalias moleculares e cromossómicas e ao seu 
microambiente específico. A resistência aos agentes quimioterápicos utilizados 
no tratamento do osteossarcoma também é um fator prognóstico de alto risco 
de recaída, independentemente da quimioterapia utilizada. É urgente 
compreender os mecanismos relacionados a esses fenómenos e desenvolver 
novos quimioterápicos para superar esses problemas e aumentar a taxa de 
sobrevivência do paciente. 
O desenvolvimento de novos fármacos requer múltiplos modelos pré-clínicos 
adequados para mimetizar a complexidade genómica do osteossarcoma que se 
desenvolve-se num microambiente ósseo e metastático nos pulmões, apesar 
dos tratamentos quimioterápicos habituais. Nesta tese, foram desenvolvidos e 
caracterizados diferentes modelos pré-clínicos clinicamente relevantes in vitro e 
in vivo, incluindo modelos resistentes bioluminescentes, de modo a melhor 
compreender esta doença e alguns dos mecanismos de resistência 
relacionados. 
Desenvolvemos, em primeiro lugar, dois modelos ortotópicos 
xenotransplantados derivados de linhas celulares (CDX) bioluminescentes 
(Luc/mKate2), capazes de desenvolver metástases espontaneamente. As 
células bioluminescentes foram injetadas ortotopicamente, em diferentes 
contextos: imune (estirpes de ratinhos de laboratório - nude e NSG) e ósseo 
(intratibial e paratibial com ativação do periósteo). O sistema IVIS SpectrumCT, 
combinando tomografia computadorizada longitudinal (TC) e bioluminescência, 
foi utilizado para acompanhar o crescimento primário do tumor e a disseminação 
metastática em tempo real. O contexto imune murino, o contexto genético dos 
dois modelos CDX e o contexto ósseo (intratibial ou paratibial) influenciaram o 
enxerto tumoral, o crescimento primário do tumor e o comportamento agressivo 
local (osteocondensação e osteólise), bem como a disseminação metastática 
para os pulmões, ossos e baço (uma localização incomum em seres humanos).  
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(cont.) 
 
 
Observou-se também que a estirpe de ratinhos NSG e a injeção intratibial 
apresentam melhores características para o desenvolvimento de modelos que a 
injeção paratibial ou a estirpe de ratinhos nude. Seguidamente, desenvolvemos 
modelos resistentes bioluminescentes in vitro, aos principais medicamentos 
utilizados no osteossarcoma, nomeadamente metotrexato (5modelos) e 
doxorrubicina (1modelo), por exposição contínua a esses medicamentos. 
Realizando o mesmo procedimento, não foi obtida resistência à mafosfamida. 
Investigamos os mecanismos da resistência adquirida relacionados com estas 
drogas e observamos comportamentos diferenciais in vitro e in vivo (com 
modelos CDX ortotópicos bioluminescentes) das linhas resistentes e respetivas 
linhas parentais. Um mecanismo de resistência na linha celular resistente à 
doxorrubicina foi observado, nomeadamente a indução da proteína PgP. 
Mostramos diferentes mecanismos de resistência adquirida ao metotrexato de 
acordo com o backgroud genético das linhas celulares, que afetam a expressão 
génica e provocam alterações no número de cópias ao nível dos cromossomas. 
Foram observados diferentes comportamentos dos modelos resistentes 
bioluminescentes ortotópicos (CDX) in vivo em comparação com as respetivas 
linhas parentais. 
Finalmente, utilizando amostras de osteossarcoma humano provenientes de 
biópsias de pacientes em recidiva após a quimioterapia habitual, foram 
desenvolvidos modelos resistentes xenotransplantados derivados do paciente 
(PDX), quer subcutaneamente quer ortotopicamente (no osso). A caracterização 
desses modelos está em curso, em particular a comparação das características 
moleculares destes (sequenciamento completo do exoma e sequenciamento do 
ARN) com as do tumor do paciente na recaída e do mesmo no diagnóstico. 
Todos esses modelos desenvolvidos em diferentes contextos in vitro e in vivo 
trazem informações complementares para outros tipos de modelos de 
osteossarcoma já existentes. Estes modelos são necessários para obter mais 
informações sobre os diferentes processos que envolvem o desenvolvimento 
inicial, a progressão e a sensibilidade/resistência ao tratamento no 
osteossarcoma. Permitem ajudar ainda a avaliação de novos quimioterápicos, 
de modo a encontrar soluções para a atual falta de terapias eficientes no 
osteossarcoma. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
keywords Resistance, osteosarcoma, human, In vitro, In vivo, chemotherapy   
abstract 
 
 
 Osteosarcoma is a rare disease and the most common type of malignant bone 
tumor. The peak incidence occurs during the adolescence and the disease 
develops mainly in long bones. Current treatments include chemotherapy before 
and after surgery and surgical resection of all the involved sites (primary tumor 
and metastasis when present). Metastases mainly in the lungs are a major 
challenge at diagnosis (20-30% of the patients) and during the natural history of 
osteosarcoma (around 30% of relapse, most being metastatic), affect a 
considerable percentage of patients with osteosarcoma, being considered the 
biggest problem of this disease. Biologically, osteosarcomas are one of the most 
complex tumours in children in regard to tumour heterogeneity, molecular and 
chromosomal abnormalities, and their specific microenvironment. Resistance to 
the chemotherapeutic agents used in osteosarcoma is also a prognostic factor 
of high risk of relapse, whatever the chemotherapy used. It is urgent to 
understand the mechanisms related with these phenomena and develop new 
drugs in order to overcome these challenges and increase patient survival.  
New drug development requires suitable multiple pre-clinical models to better 
mimic the genomic complexity of osteosarcoma which develops in a bone 
microenvironment and in a metastatic setting in the lungs, despite usual 
chemotherapeutic treatments. In this thesis, we developed and characterised 
different and clinically relevant in vitro and in vivo preclinical models, including 
bioluminescent resistant models in order to understand better this disease and 
some of the resistant mechanism related. 
First, two bioluminescent (Luc/mKate2) cell line derived xenograft (CDX) models 
were developed in an orthotopic bone setting able to spontaneously metastasize. 
Bioluminescent cells were injected orthotopically, in different immune (nude and 
NSG mouse strains) and bone (intratibial and paratibial with periosteum 
activation) contexts. IVIS SpectrumCT system, combining longitudinal computed 
tomography (CT) and bioluminescence, was used to follow primary tumor growth 
and metastatic spread in real-time. The murine immune context, the genetic 
background of the two CDX-models, and the bone context (intratibial or 
paratibial) influenced tumor engraftment, primary tumor growth and local 
aggressive behavior (osteocondensation and osteolysis) as well as metastatic 
spread to lungs, bone, and spleen (an unusual localization in humans). It was 
also observed that intratibial injection in NSG mice showed better characteristics 
for model development than paratibial injection or nude mice recipient. We 
further developed in vitro bioluminescent models that were resistant to the main 
drugs used in osteosarcoma, methotrexate (5 models) and doxorubicin (one 
model), by continuous exposure to these drugs. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
  
abstract 
(cont.) 
 
 
 With the same technique no resistance was obtained for mafosfamide. We 
explored the mechanism of the acquired resistance to these drugs and observed 
the differential in vitro and in vivo behaviors (with CDX bioluminescent orthotopic 
models) of the resistant lines and their parental counterpart. A multidrug 
phenomenon by PgP induction was observed in the doxorubicin resistant cells. 
We show different mechanisms of acquired resistance to methotrexate according 
to the genetic background of the cell lines affecting either gene expression and 
copy number abnormalities. Different in vivo behavior of the resistant 
bioluminescent orthotopic CDX models compared to their parental counterparts 
were observed. 
Finally, using human biopsy samples of osteosarcoma relapsing after usual anti-
osteosarcoma chemotherapy were developed resistant patient-derived xenograft 
(PDX) models, either in subcutaneous as in orthotopic bone setting. The 
characterization of these models are still ongoing, in particular the comparison 
of their molecular characteristics, i.e. using whole exome and RNA sequencing, 
in comparison with the patient tumor at relapse and with the same patient tumor 
at diagnosis. 
All these multiple models developed in different in vitro and in vivo contexts bring 
complementary information to other types of existing osteosarcoma models. 
They are needed to get more insight into the different processes involving 
osteosarcoma initiation, progression and in particular treatment 
sensitivity/resistance. They will further help drug testing to find solution to the 
current lack of efficient new drugs in osteosarcoma. 
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1.1. Bone  
1.1.1. General Characteristics of the bone  
Bones are a mineralized specialized connective tissue that supports the body and 
are constantly undergoing modeling during life1,2. Bones are characterized by their 
rigidity, hardness, and power of regeneration and repair3,4. The bones of the 
skeleton support and protect muscles, vital organs and structures, allow movement 
and locomotion by providing levers for the muscles, provide maintenance of mineral 
homeostasis (eg. calcium) and acid-base balance, serve as a reservoir of growth 
factors and cytokines, and provide an environment for marrow (both blood formation 
and fat storage)1,3–5. Bones support different processes throughout life to help on 
the adaptation to biomechanical force changes, as well as on the remodeling 
(remove microdamaged bone and replace it with new), becoming mechanically 
stronger bones to help on the bone strength preservation1,3,4.           
Bones are classified in four general categories (Fig.1.1): long bones, short bones, 
flat bones, and irregular bones. Long bones are found in the arms (humerus, ulna, 
radius) and legs (femur, tibia, fibula), as well as in the fingers (metacarpals, 
phalanges) and toes (metatarsals, phalanges) and the short bones include the 
carpal and tarsal bones. Flat bones include the skull, mandible, scapulae, sternum, 
and ribs and irregular bones for example the vertebrae1. 
Different types of cells are present in the bone (Fig.1.2): such as osteogenic cells 
(e.g stem cells), osteocytes, osteoblasts and osteoclasts, the two last cell types act 
continuously in the bones and they are responsible for the formation of new bone 
(osteoblasts) and old bone remodeling (osteoclasts)1,3,4,6.  
 
 
 
 
 
 
 
 
 
  
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Classification of the bones in four groups: Long, short, flat and irregular bones7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Cell types found within bone tissue. Osteogenic cells are undifferentiated cells 
and develop into osteoblasts. Osteoblasts are responsible to form new bone. Osteocytes 
maintain mineral concentration of matrix. Osteoclasts develop from monocytes and 
macrophages and are responsible for the bone resorption6. 
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1.1.2. Long Bones: structure, formation and growth 
Long bones function as levers and have cylindrical shape (being longer than it is 
wide) (Fig.1.3). They are formed by thick outside layer of compact bone (cortical) 
and an inner medullary cavity containing bone marrow1. They are divided in 
epiphysis, metaphysis and diaphysis. Epiphysis and metaphysis are composed of 
trabecular meshwork bone surrounded by a relatively thin shell of dense cortical 
bone whereas diaphysis is composed primarily of dense cortical bone. Embryos 
develop a cartilaginous skeleton and various membranes from sheets of 
mesenchymal connective tissue and during development these are replaced by 
bone during the endochondral (from cartilaginous cells) and membranar (from 
mesenchymal cells) ossification processes. In children and adolescent, the 
epiphyseal plate is the area of growth in long immature bones. It is composed of 
hyaline cartilage with its epiphyseal side which forms cartilage and its diaphysal 
side which forms new ossified bone to increase diaphysis length. It adult, this area 
is totally calcified and appears as the epiphyseal line without length growth 
potential1,3,6. Two ossification types are described. The intramembranous 
ossification for flat bone formation is characterized by laying down of bone into the 
primitive connective tissue (mesenchyme). Endochondral ossification occurs in long 
bone through a cartilage forming bone model. Both ossification processes can be 
involved in fracture healing.  
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Figure 1.3: Long bone anatomical characteristics. A– Components of a growing bone. B– 
Interior components of a mature bone, epiphyseal plate progresses to an epiphyseal line. 
Adapted from6 
 
 
Up to early adulthood, bone will undergo longitudinal growth (occurs at the growth 
plates, increasing in length), and throughout life, radial growth (increasing in 
diameter) and modeling (change of the general bone shape influenced by 
physiological or mechanical forces) and remodeling (bone renewal to maintain 
mineral homeostasis and bone strength)1–3,6 (Fig.1.4).  
All these processes depend on the balanced actions between the opposite function 
of two cellular types (osteoblasts and osteoclasts), controlled by several hormones 
(e.g. growth, thyroid and the sex hormones) cytokines (e.g. RANK/RANKL) and 
growth factors4.  
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Osteoblasts originate from osteoprogenitor (osteoblast precursor) previously 
originated by mesenchymal stem cells of the bone marrow stroma are responsible 
for the three steps of new bone formation process also called ossification or 
osteogenesis, with synthesis of extracellular organic matrix (composed by 85 to 90% 
collagenous proteins, mainly type I collagen, and a 3D organization are the main 
component of the bone)1, matrix mineralization leading to the formation of bone (by 
releasing small, membrane-bound matrix vesicles that concentrate calcium and 
phosphate and enzymatically destroy mineralization inhibitors such as 
pyrophosphate or proteoglycans) and remodeling of bone by resorption and 
reformation1,3.   
 
Osteocytes 
Osteocytes originate from osteoblasts when these ones have been incorporated into 
the bone matrix. Surrounded by and buried within matrix, osteoblasts become 
osteocytes with an extensive canalicular network remaining in contact with bone 
surface lining cells, osteoblasts, and other osteocytes, via gap junction-coupled 
(required for osteocyte maturation, activity, and survival) cell processes passing 
through the matrix via small channels (canaliculi), that connect the cell body-
containing lacunae with each other and with the outside world. Osteocytes express 
several matrix proteins that support intercellular adhesion and regulate exchange of 
mineral in the bone fluid within lacunae and the canalicular network. They are also 
active during osteolysis and may function as phagocytic cells (contain lysosomes)1,8 
Osteocytes represent terminally differentiated osteoblasts and function within 
syncytial networks to support bone structure and metabolism, more specifically 
osteocytes are possible actively involved in bone turnover; the osteocyte network 
is, through its large cell-matrix contact surface, involved in ion exchange; and 
osteocytes are the mechanosensory cells of bone, playing a pivotal role in functional 
adaptation of bone1,8.  
Bone-lining cells may regulate influx and efflux of mineral ions into and out of bone 
extracellular fluid, thereby serving as a blood-bone barrier, but retain the ability to 
redifferentiate into osteoblasts upon exposure to parathyroid hormone or 
mechanical forces. Bone-lining cells within the endosteum lift off the surface of bone 
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before bone resorption to form discrete bone remodelling compartments with a 
specialized microenvironment1,8.  
 
Osteoclasts derive from mononuclear precursor cells, hematopoietic stem cells 
that give rise to monocytes and macrophages4 and are responsible for bone 
resorption. The resorption area is limited by osteoclasts through a rearrangement 
of its cytoskeleton that forms a sealing zone wherein the degradation of bone tissue 
occurs5,9. Bone resorption depends on osteoclast secretion of hydrogen (H+) ions 
and cathepsin K enzyme. H+ ions acidify the resorption compartment beneath 
osteoclasts to dissolve the mineral component of bone matrix, whereas cathepsin K 
digests the proteinaceous matrix (mostly composed of type I collagen)1. 
Osteoclasts activity can be inhibited for example by the osteoblasts, when they are 
stimulated to increase bone mass3,4. 
Bone modeling and remodeling is particularly highly dependent on the coupled 
action of osteoclasts and osteoblasts that sequentially break down and remove old 
bone and replace it with newly synthesized and mineralized bone matrix. The 
ongoing balance between osteoblasts and osteoclasts is responsible for the 
constant but subtle reshaping of bone, any imbalance in the osteoblast physiology 
may cause severe damages in the bone structure3,4. Damages on these important 
processes can result in disease. 
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Figure 1.4: Osteoblasts and osteoclasts evolution and bone modeling (shows activated 
osteoclasts resorbing the underlying bone) and remodeling (shows formation phase where 
the osteoclasts are replaced by osteoblasts with underlying new osteoid matrix process). 
Adapted from3 
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1.2. Osteosarcoma  
Sarcomas are a very heterogeneous group of malignant neoplasms of connective 
tissues, including bone and soft-tissues10. 
Conventional osteosarcoma or osteogenic sarcoma is, according the World Health 
Organization (WHO) Classification of Tumors, a primary mesenchymal malignant 
bone tumor; high-grade and intra-osseous, in which the neoplastic cells produce 
bone11–14. 
 
1.2.1. Epidemiology and etiology 
Osteosarcoma is a rare disease, with approximately 900 new cases/year reported 
in the United States or 300 in France, with a bimodal incidence. Extremely rare 
before 5th years of age11,12,15,16, osteosarcoma has an initial peak of incidence 
during adolescence, around 14 years (during the pubertal growth spurt), and a 
second peak (smaller) after the 6th decade of life, usually on an abnormal bone12,16. 
Indeed, adolescent and young adult (AYA) osteosarcomas are nearly always 
primary osteosarcomas, while 30-50% of the adult tumors are secondary tumors 
either post-irradiation or on pathological bone (e.g. Paget disease or, less 
commonly, other benign bone lesions). Exposure to radiation is the only well-
established environmental risk factor already associated with osteosarcoma13,17, 
and usually develops more than 10-20 years after radiation exposure13,18,19.  
 
We will focus our review and studies on the usual adolescent and young adult 
osteosarcoma (5-50 years). Boys are reported to be affected more frequently than 
girls (boys:girls ratio, 1.43:1). Girls have an osteosarcoma peak incidence a little 
earlier than boys, corresponding to the earlier age of growth spurt13,18,20. A slight 
ethnic influence is observed in American population with a higher incidence in 
Asian/Pacific Islanders (5.3 per million of people), blacks (5.1 per million), Hispanics 
(4.9 per million) and whites (4.4 per million), compared to American Indian/Alaskan 
natives (3.0 per million)11–13. 
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1.2.2. Clinical and radiological presentation 
Osteosarcoma arises in children and adolescents with a typical metaphyseal 
location in long bones (80-90% of the cases) of the extremities (rapid bone growth 
areas), usually close to the knee (50%, distal femur and proximal tibia) and far from 
the elbow (proximal humerus)11–13,15,16,21,22. In individuals over the 60 years old, low-
grade tumors are typically found in axial sites23. These differences may suggest 
different underlying mechanisms for the development of osteosarcoma in younger 
and older patients.  
Pain is the most common and early symptom (2-4 months before diagnosis) of 
osteosarcoma and might appear after physical exercise or trauma, originated by the 
periosteum stretching or by bone deterioration due to stress fractures11,24. Some 
patients also complain about swelling, related to soft tissue extension. Patients 
generally have symptoms for several months (average, 3–4 months, frequently 
more than 6 months) before a confirmed diagnosis11,24. 
Diagnosis is suspected on standard X-ray radiographs (or computed tomography) 
which detect aggressive bone lesions (cortical disruption), osteocondensation 
within the bone but also in the soft-tissue part of the tumor (new calcified material 
formation) as well as some osteolysis (bone destruction) (Fig.1.5).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: X-ray of proximal tibia and knee joint showing diaphyseal osteosarcoma of tibia 
with sclerosis (arrow), cortical destruction (arrow heads) and new bone formation in the soft 
tissues. Adapted from13 
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Magnetic resonance imaging (MRI) allows to better evaluate tumor extension 
through the growth plate, the articulation and soft-tissue extension to vessel and 
nerves, that will help to plan appropriate surgical resection11,13,25,26.  
Distant metastases are present in 20-30% of patient at diagnosis, mainly in the lung 
(90% of metastases)23. A systematic thoracic CT-scan is performed at diagnosis. 
Metastatic bone localization is more rarely observed at diagnosis (<15%) and are 
usually detected by T99m bone scintigraphy. The occurrence of multiple bone 
metastases may actually reflect multifocal primary tumors, and constitute a distinct 
poorly known entity called osteosarcomatosis11. “Skip metastases” small bone 
metastasis outside the reactive zone, but within the same bone can be detected 
only by RMI and not always seen in bone scintigraphy. Other metastatic 
localizations (e.g. lymph node, central nervous system) are extremely rare11,24.  
                                       
1.2.3. Histological diagnosis 
Tumor biopsy prior to any treatment is mandatory for the diagnosis of osteosarcoma. 
No specific marker exists and the diagnosis is made on the detection of osteoid 
matrix formed by the malignant cells11,13,22,26. Confrontation between histology and 
imaging is required. 
Several sub-types are described according to the predominant type of stroma 
(osteoblastic, chondroblastic, fibroblastic, telangiectatic)14. Osteoblastic 
osteosarcoma is the most frequent sub-type (70% of the patients) and is 
characterized by the production of osteoid or bone as the main type of matrix and 
the presence of malignant plasmacytoid to epithelioid osteoblasts11,27. 
Chondroblastic osteosarcomas (10% of the patients) present a predominant 
chondroid matrix with malignant cells within the lacunae. Fibroblastic 
osteosarcomas (10% of the patients) are composed of malignant spindle cells with 
scarce osteoid. In addition to these three conventional osteosarcoma subtypes, 
telangiectatic, giant cell-rich, anaplastic, and small cell osteosarcomas subtypes can 
be more rarely observed19.  
 
  
31 
 
1.2.4. Treatment and outcome 
In the first half of the 20th century, when treated with limb amputation only, patients 
with osteosarcoma had lung metastases within the first two years and a survival 
rate of less than 20%28. In the ‘70s-‘80s, osteosarcoma chemosensitivity to various 
agent was demonstrated in phase-II trials (methotrexate/MTX, cisplatinum, 
doxorubicin, ifosfamide, etoposide), with response rate of 19 to 40 % 29 (Fig.1.6 and 
Table.1.I). These drugs are the principal chemotherapeutic agents used in the 
osteosarcoma treatment (Table.1.II). Neither complete surgical resection alone4,15, 
neither chemotherapy alone are able to control osteosarcoma metastatic spread21. 
In addition to the gradually-improved surgical techniques, the introduction of these 
chemotherapeutic agents variously combined in multi-chemotherapy regimen, first 
in an adjuvant setting permitted to decreased metastasis occurrence, then in a 
neoadjuvant setting permitted to improved survival for patients with localized 
osteosarcoma to approximately 60%15,21,30–32. The osteosarcoma radioresistance 
at standard doses, limited its use to unresectable tumors21,26. 
 
 
Figure 1.6: Osteosarcoma survival between 1960 and 2000. Kindly provided by Nathalie 
Gaspar 
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Table 1.I: Osteosarcoma phase-II trials (methotrexate, cisplatinum, doxorubicin/adriamycin, 
ifosfamide, etoposide), with response rate of 19 to 40 % 29. 
 
 
 
Table 1.II: The five principal chemotherapeutic agents used on the osteosarcoma treatment 
and the respective mechanism of action. Adapted from 24,33.  
 
 
 
 
 
 
Agent  Mechanism of action  
 
Doxorubicin  
Intercalates at point of local uncoiling of the DNA double helix and inhibits 
the synthesis of DNA and RNA (eg. DNA topoisomerase II-mediated DNA 
cleavage)  
  Cisplatin  
Binds directly to tumor DNA and inhibits the synthesis of DNA through the 
formation of DNA cross-links  
Ifosfamide  
Causes crosslinking of DNA strands, inhibiting the synthesis of DNA and 
protein  
Methotrexate  
Inhibits the synthesis of purine and thymidylic acid by binding dihydrofolate 
reductase  
 
Etoposide 
Poisons the TopoII cleavage complexes (TopoIIcc) and inhibits the second 
step of the reaction (i.e. DNA religation), has also a high-affinity for 
chromatin and histones, in particular H1 
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Since the last 40 years, the first-line treatment of osteosarcoma includes 
neoadjuvant and adjuvant post-operative chemotherapy associated with surgical 
resection of the primary tumor and metastasis if present23,26,32,34. MAP-based 
combinations (high-dose MTX, doxorubicin and cisplatin) are the most frequently 
used regimen35, without adaptation to risk factors. In France, chemotherapy 
regimens depend on age. Patients <25 years receive MTX-etoposide/ifosfamide (M-
EI) to avoid anthracycline cardiotoxicity and cisplatin ototoxicity; and patient from 18 
years are offered API-AI (Doxorubicin/Platinum/Ifosfamide-Doxorubicin/Ifosfamide) 
by medical oncologist fear of methotrexate neurological and renal toxicities32, 
patients between 18-25 years are treated based on the clinical center of 
hospitalization. Chemotherapy is adapted to high risk factors of relapse after surgery 
to allow patients to receive all major anti-osteosarcoma drugs32. However, whatever 
the chemotherapy regimen used, and despite different attempt to modify 
chemotherapy, no improvement in survival has been observed and some patients 
have a persistent dismal outcome: patients at diagnosis with inoperable tumors36,37 
or metastatic disease32,38, tumors with poor response to neoadjuvant chemotherapy 
define as 10% of more persistent viable tumor cells in the surgical primary resection 
after neoadjuvant chemotherapy38,39, and patients with refractory or recurrent 
disease40. Several prospective phase-III trials have attempted to introduce 
additional agents targeting the immune or bone microenvironment, for either all 
patients or certain risk groups without further success; mifamurtide (a macrophage 
stimulating agent) in the controversial INT-0133 trial41,42, interferon IFNα in localized 
osteosarcoma in EURAMOS-1 trial35, zoledronic acid (bisphosphonate, osteoclast 
activity inhibitor) in OS2006 trial32 (Fig.1.7).  
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Figure 1.7: Different therapies used in osteosarcoma considering the microenvironment. 
Kindly provided by Nathalie Gaspar 
 
 
 
Relapses remain the major problem experienced by one third of the patients, mainly 
at lung metastatic site43. The five-year overall survival rate (5y-osteosarcoma) after 
relapse is dismal, below 30% 43–46. However, some patients will survive multiple 
relapses and some might be cured by complete surgical resection only, in particular 
after a local relapse or a unique pulmonary relapse47. In addition, there is no 
standard treatment for osteosarcoma relapses. The benefit associated with 
conventional chemotherapy43,44,46, high-dose chemotherapy48 or radiotherapy49 
remains controversial. In the last decade, phase-II trials in relapse osteosarcoma 
have been disappointing50 and new drugs are urgently needed to improve 
osteosarcoma outcome. 
 
1.2.5. Osteosarcoma oncogenesis 
The current understanding of osteosarcoma oncogenesis remains uncompleted 
and how osteosarcoma cells originate, develop and spread are subject of 
exploration on many fronts. Rarity and genomic/epigenetic complexity, the marked 
intratumoral and intertumoral heterogeneity, have challenged the molecular 
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characterization of osteosarcoma. This fact together with the role of bone and 
immune microenvironment and the incomplete understanding of the metastatic 
spread program in these tumors might have participated to the lack in therapeutic 
advances in the last 40 years. 
 
1.2.5.1. Osteosarcoma genetic susceptibility 
Historically, several de novo and hereditary syndromes predisposing to cancers, 
are known to predispose to osteosarcoma, and involve genes implicated in DNA 
replication and repair, and cell cycle: Li-Fraumeni syndrome (autosomal dominant 
disorder characterized by a germline mutation of TP53), hereditary retinoblastoma 
(autosomal recessive disorders with germline mutation in the tumor suppressor 
gene RB), Rothmund-Thomson and RAPADILINO syndromes (autosomal 
recessive disorders with germline mutations of the DNA helicase RECQL4), Bloom 
syndromes (autosomal recessive disorders with germline mutations of the DNA 
helicase BLM or RECQL3), Werner syndrome (germline mutation of the RECQL2 
gene), among others13,19,22.  
More recently, human population-based studies, known as genome-wide 
association studies (GWAS), have reported 3 genetic variants (single nucleotide 
polymorphisms; SNPs) associated with risk for the development of osteosarcoma51 
comparing genotypes of 941 human osteosarcoma cases with those of 3291 
controls: rs1906953 (P = 8.1×10-9) located at 6p21.3 within intron 7 of the glutamate 
receptor metabotropic 4 (GRM4) gene. The metabotropic glutamate receptors are 
a family of G protein-coupled receptors linked to the inhibition of the cyclic AMP 
signaling cascade. In mice, a cAMP-dependent protein kinase (Prkar1α) is an 
osteosarcoma tumor suppressor gene involved in tumorigenesis53, suggesting the 
cAMP pathway is important in osteosarcoma. rs7591996 (P=1.0×10−8) and 
rs10208273 (P=2.9×10−7) located at 2p25.2 in an intergenic region that neither 
contain active regulatory elements or transcription factor binding sites. This signal 
requires further investigation to determine which variants will be optimal for 
functional studies needed to explain the direct association.  
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1.2.5.2. A complex somatic genomic/ epigenetic landscape 
Osteosarcomas are characterized by a highly complex genetic landscape that 
varies significantly between tumors (high genetic heterogeneity).  
The development of osteosarcoma is best characterized by its disorganized 
genome. Osteosarcoma presents a high chromosomal instability with a high degree 
of losses and gains of full chromosomes or large chromosomal segments, 
associated with loss of function in cell cycle checkpoint and DNA damage response 
pathways (RB pathway> 80%, TP53 pathway> 75%, CDKN2A, and others as 
RECQL4 and WWOX) and/or gain of function of oncogenes (e.g. E2F3 60%, CDK4 
10%, MDM2, MET, RUNX2, and VEGFA)54.   
The different mechanisms sustaining this complex genomic comprise: point 
mutations which are likely the result of errors in DNA replication and subsequent 
proof reading; aneuploidy which is the result of errors in chromosomal segregation 
during cell division and chromothripsis a phenomenon by which tens to hundreds 
of genomic rearrangements occur during cancer development in a one-off cellular 
crisis54. 
In addition, BRCA1/2 (breast cancer gene 1/2 - important players in homologous 
recombination pathway) deficiency associated characteristics in single base 
substitutions, and large-scale genome instability signatures are evident in >80% of 
osteosarcomas55. This suggests the possibility of an early defect in DNA 
repair/surveillance as a mechanism for osteosarcomagenesis and the resultant 
bizarre aneuploidy15.   
A recent comprehensive assessment of somatic copy number alterations (SCNAs) 
performed in 160 osteosarcoma samples revealed recurrent genomic loss spatially 
clustered in certain locations, termed “broken regions”, containing tumor suppressor 
genes such as LSAMP, CDKN2A, RB1 and TP53 and most frequent gains at sites 
including the oncogene MYC and the gene RUNX2 an important player in 
osteogenic differentiation56. Chromosomal breakages in these regions occurred 
early and were influenced by local genomic context. Both aneuploidy and 
chromothripsis like pattern occurrence were found to be correlated with clinical 
outcome of patients with osteosarcoma. Chromosomal aberrations in TP53, RB1, 
WWOX and DLG2 genes are strongly associated with chromothripsis-like pattern 
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in osteosarcoma and hyperploid had a greater chance to harbor chromothripsis 
events and less favorable outcomes56. 
 
Epigenetics is a more recent field, yet not fully explored in osteosarcoma. Which 
includes the regulatory mechanisms affecting the expression of DNA templates 
without altering the sequences themselves through DNA methylation, histone 
modification, nucleosome remodeling, and RNA mediated events (Non-coding 
RNAs)54. Gene silencing through promoter hypermethylation is a phenomenon 
implicated in osteosarcoma and affecting suppressor gene function of the Rb1 and 
TP53 pathways and other proteins involved in DNA repair (e.g. GADD45). The 
expression and role of lysine-specific demethylase 1 (LSD1) been shown in 
osteosarcoma54. LSD1 demethylates histone H3 at lysine 4 inducing transcriptional 
repression and gene expression suppression57, and demethylates, stabilizes58 and 
inactivates non-histone proteins such as TP53 and DNMT1 59 and destabilized other 
proteins (e;g. MYPT1, a negative regulator of RB1 phosphorylation)60. Alterations 
on ATRX gene, which is part of a multiprotein complex that regulates chromatin 
remodeling, nucleosome assembly, and telomere maintenance were also detected 
in osteosarcoma61. ATRX point mutations or focal deletions affecting the coding 
region of the gene were described in osteosarcoma61. Somatic ATRX gene 
mutations have been observed as recurrent alterations in osteosarcoma and the 
ATR-X syndrome was reported as a potential factor of osteosarcoma 
development62. MicroRNAs (miRNAs) act to fine-tune gene expression by binding 
to messenger RNA transcripts and inhibit translation or induce degradation. The 
miRNAs expressed in osteosarcoma include members of signaling pathways that 
are key to osteosarcoma pathogenesis, including Ras, Wnt, mitogen-activated 
protein kinase (MAPK), and Notch. Long noncoding RNAs (lncR-NAs) are defined 
as any non-protein-coding transcripts over 200 base pairs in length and are key 
regulators of a number of critical biological processes. lncRNAs LOC285194 and 
BC040587 were associated with copy number alteration (usually deletion) in 80% 
of osteosarcomas, resulting in reduced expression of the associated lncRNAs 
across osteosarcoma samples54. 
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1.2.5.3. Cell of origin 
Each cell of osteoblastic lineage can be a target for malignant transformation, 
leading to a large panel of more or less differentiated phenotypes for 
osteosarcomas. Adolescents and Young Adults rather develop osteosarcoma in 
bone growth areas of long bones 11,12,15,16,22.  
More recent data suggest that the osteosarcoma-transforming event occurs in 
multipotent mesenchymal stem cells54. Bone marrow-derived mesenchymal stem 
cells (BMSCs) are proposed as the cells of origin of several subtypes of 
osteosarcoma (Fig.1.8) and an attractive hypothesis is that oncogenes and/or tumor 
suppressors regulate the lineage choices of BMSCs and, thus, the subtypes of 
osteosarcoma19,27.  
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Figure 1.8: (A) Osteogenic differentiation. Mesenchymal stem cells (MSCs) can give rise to 
several cell types such as myocytes, adipocytes, chondrocytes, and osteocytes, with 
appropriate stimuli, presumably by activating proper lineage-specific regulators, eg, MyoD, 
PPARγ, Sox9, or Runx2/Osterix.  Osteogenic differentiation can be monitored by using 
alkaline phosphatase as an early marker and osteocalcin and osteopontin as late markers. 
(B) Disruption of osteogenic differentiation, due to genetic defects (eg, activation of 
oncogenes or inactivation of TP53 and RB tumor suppressor genes) and epigenetic 
alterations at different stages may lead to OS development. Defects at the early stages may 
lead to the development of more aggressive and undifferentiated OS. The cells filled with 
black color indicate cancer-initiating cells19. 
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1.2.5.4. Importance of the bone and immune microenvironment 
In addition to the complexity of osteosarcoma cells, the microenvironment plays an 
important role in the osteosarcoma pathogenesis, once is dynamic and variable, 
with a complex bone extracellular matrix (ECM) and diverse cell populations 
implicated15,63. Osteosarcoma microenvironment contributes in several processes, 
participating to osteosarcoma aggressiveness: the dysregulation of bone 
remodeling (bone niche), the induction of a tolerant environment (immune niche), 
and the facilitation of the transport of gas and nutrients to cancer cells and 
extravasation to their metastatic location (vascular niche) (Fig.1.9)63,64.  
 
 
 
Figure 1.9: Osteosarcoma and its niches (bone, immune and vascular niche). Adapted 
from63. 
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Bone-tumor vicious cycle  
Osteosarcoma microenvironment is characterized by abundant transforming growth 
factor-β1 (TGF-β1) and hypoxia, resulting on the acquisition of cancer stem cell 
characteristics by the non-stem-like osteosarcoma cells (eg. self-renew capacity, 
proliferation), promoting tumorigenesis and chemoresistance15,65. The bone is 
relatively hypoxic in comparison with other tissues (≤2% O2). What in conjunction 
with a rather high proliferation capacity of cancer cells, resulting in increased 
hypoxia levels that can often lead to poor prognosis in osteosarcoma. Low oxygen 
tension may be important for the development of osteosarcoma but also for other 
solid tumors, particularly in those that grow rapidly. In tumor areas of low 
oxygenation, reduced cell division can be observed which might result in resistance 
to both radiotherapy and chemotherapy. Cellular responses to hypoxia are 
commonly regulated by the hypoxia inducible factor (HIF) family of transcription 
factors15,65,66. 
Once an osteosarcoma develops in the bone, tumor cells are capable of secreting 
factors that initiate osteoclast-mediated bone destruction, and matrix-derived growth 
factors, especially TGF-β1 (released from bone matrix). At this time, osteosarcoma 
cells also release TGF-β1 directly. TGF-β1 is a pleiotropic cytokine that acts as a 
mediator upon the tumor to promote further tumor expansion, metastasis, and 
cytokine production. Recent findings suggest that genetic and epigenetic events 
mediate the acquisition of oncogenic activity by TGF-β1, as do the aberrant 
alterations within the tumor microenvironments15,65,66.  
The molecular OPG/RANKL/RANK triad (osteoprotegerin/ Receptor activator of 
nuclear factor kappa-Β ligand/ Receptor activator of nuclear factor kappa-Β) plays 
an important role in physiological management of the bone niche (Fig.1.9)63,64. Its 
dysregulation in osteosarcoma causes exacerbated local bone remodeling. In a 
normal bone, the RANK receptor is expressed at the surface of osteoclasts and 
precursors, while OPG and RANKL are secreted by osteoblasts and/or stromal cells. 
In a bone tumor environment, RANKL can also be produced by other normal cell 
types (e.g. fibroblasts, epithelial cells, or T-lymphocytes) or by tumor cells in 
response to chemokines, cytokines, hormones, and growth factors. In addition, a 
reduced OPG production might aggravate the vicious cycle between osteosarcoma 
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cells and bone niche63,64. Such high levels of RANKL and RANK and low levels of 
OPG are associated with worse outcomes in osteosarcoma63,64.  
 
Immune microenvironment 
Although the immune microenvironment of osteosarcoma is not fully understood yet, 
some evidences suggest its huge importance in acquisition of metastatic phenotype 
and outcome. It has been reported that localized tumors at diagnosis might present 
higher levels of tumor-infiltrating macrophage (TAM, CD68+ or CD14+) with M1-
polarisation67 associated to low levels of tumor infiltrating lymphocytes (TIL) with a 
balance in favor of CD8 effectors68. These data associated with low metastases risk 
and improved outcome. Conversely, metastatic disease might present primary 
tumor with M2-polarised TAM (CD163+ IL10+) harboring immunosuppressive, 
tissue remodeling and pro-antigiogenic properties69. Their immunosuppressive 
effect is mediated by exhaustion/energy of CD8+ TIL70 and a balance favoring 
FOXP3+ T regulator lymphocytes (Treg)68. This pro-tumor immune contexture 
appears increased in lung metastasis samples67,71. 
High expression levels of immunosuppressive molecules such as PD-L171, B7-H372, 
and indoleamine 2,3-dioxygenase (IDO)73, high peripheral levels of CSF174, and 
high expression of intra-tumor IL34 (another CSF1R ligand)75 in tumors at diagnosis 
have been associated with poor metastases-free and overall survival. 
Rather than a clear situation of dichotomy, a continuum between both states might 
better mimic the reality of osteosarcoma microenvironment explaining some 
apparent recent conflicting results76. 
 
Vascular niche 
The vascular niche regulates osteogenesis and hematopoiesis and support the self-
renewal of Hematopoietic Stem Cells (HSCs). Vascular niche was also associated 
with tumor cell extravasation/migration to their metastatic location (e.g. lung, bone 
and liver), facilitating the transport of gas and nutrients to cancer cells63,77,78. 
Similarly to other tumor types that have their own vascular system, osteosarcoma 
has abundant blood vessels. Increased vasculature has been reported as a poor 
prognostic factor in human OS15. Bone vasculature might regulate multiple cellular 
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and developmental processes, including, stem cell and progenitor cell proliferation 
and cancer cell metastasis, and is involved in several steps of the metastatic 
cascade68,70. Complex microenvironment involving multiple cell populations (eg. 
endothelial cells), vessels (extensive vascularization of the skeletal tissue) as well 
as matrix and growth factors (eg. transforming growth factor beta-TGFβ) abundant 
in vascular bone microenvironments, not only provide a fertile soil for the metastatic 
growth but also support the dormancy of Disseminated Tumor Cells (DTCs) and 
their reactivation. During the later stages of the disease, blood vessels enhance the 
metastatic outgrowth by mediating higher delivery of oxygen, nutrients and growth 
factors77,80. Angiogenesis, a dynamic and programmed process in which new blood 
vessel are formed from preexisting vessels induced by different triggers (e.g., 
hypoxia), has been described as a major process in the development of tumor 
vascularization system, which supplies cancer cells with blood15,81. A study based 
on a cohort of 131 osteosarcoma samples suggested that patients with low OS 
vascularization have a prolonged survival and good response to neoadjuvant 
chemotherapy15. 
The vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are key 
inducers of physiological or pathological angiogenesis by promoting endothelial cell 
growth, migration, and survival from pre-existing vasculature. Besides that, VEGF 
mediates vessel permeability, and more recently, was associated to mobilization of 
endothelial progenitor cells from the bone marrow to distant sites of 
neovascularization15,81. Elevated expression of VEGF in primary OS promotes 
angiogenesis, leading to higher rate of pulmonary metastasis14, and is also 
associated to drug sensitivity15,81. Platelet-derived growth factor (PDGF) and is 
receptor PDGFR have been also associated with poor prognosis. PDGF-AA 
expression in osteosarcoma patient samples associate with decreased disease-
survival82. Others suggest that osteosarcoma-platelet interactions induce the 
release of PDGF from platelets, which promotes the proliferation of osteosarcomas 
by activating the PDGFR and then Akt83.  
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1.2.6. Metastatic spread and resistance in osteosarcoma 
The different steps and some of the key elements required for metastatic spread 
are starting to be known in osteosarcoma. But the understanding of the timing of 
events leading to metastatic progression and the events themselves are far from 
complete. Osteosarcoma metastatic potential and the ways of targeting it, are active 
research fields. 
The metastatic cascade (Fig.1.10) represents a series of processes that start as a 
cell leaves the primary tumor and invades the surrounding tumor microenvironment, 
leading to intravasation. In osteosarcoma, intravasation is mediated by  integrin 
α584, ANGPTL2 through integrin α5β1, p38 MAPK and MMPs, such as MMP9 
expression85, and promoted by increased TGF-βs expression86) into existing or new 
vascular structures, survival in the circulation, and eventual arrest and extravasation 
at distant secondary sites, followed by the development or recruitment of a blood 
supply and growth at the secondary site54. Cells must then rapidly adapt to this new 
and maybe hostile environment to survive, usually the lung in osteosarcoma.  
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Figure 1.10: Metastatic cascade. Initially, tumor cells migrate into adjacent tissues 
(invasion), involving the breakdown of the basement membrane and invasion into the 
surrounding ECM. Intravasation then allows cells to enter the circulation. In blood vessels, 
circulating tumor cells exist as single cells or clusters, coated with platelets. They need to 
survive shear stress and evade clearance by the immune system to successfully reach 
distant organs. Tumor cells then attach to endothelial cells, which facilitates their 
extravasation. After settling in the metastatic target organ, tumor cells must survive in this 
foreign environment and establish micrometastases. These disseminated tumor cells can 
remain dormant for many years before proliferating into large macrometastases in a process 
termed colonization. The primary site also regulates the development of metastasis via 
secretion of factors (such as cytokines) that can prime a pre-metastatic niche and support 
survival of disseminated tumor cells87.  
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Although osteosarcoma resistance to chemotherapy phenomenon is not fully 
known65, several mechanisms have been described, depending on the cell state, 
the microenvironment of the osteosarcoma cells and the drug pressure.  
Resistance mechanisms might intervene at different levels: 
1- Reduced drug accumulation in tumor cells can be due to either a reduced 
drug uptake, an increase of drug efflux, or an increase of drug detoxification. As an 
example, methotrexate resistance by low expression of the reduced folate carrier 
(RFC) without gene deletion. Such decreased RFC expression is found in 65% of 
tumor biopsies at diagnosis65,88,89. Multidrug resistance to increased vinca alkaloids, 
epipodophyllotoxins, anthracyclines, taxanes, and kinase inhibitors have been 
observed following increased expression of multidrug resistance proteins such as 
PgP=MDR1=ABCB1, MRP1=ABCC1 and others65,88,90–93 (Fig.1.11). Finally, 
resistance to cisplatinum by GSH (Glutathione S-transferase) xenobiotic 
detoxification pathway65,94 with increased GSTP1 (Glutathione S-transferase P1) 
levels94, resistance to methotrexate95 by increased levels of UGT1A (UDP 
glucuronosyltransferase family 1 member A) an enzyme inactivating different 
xenobiotics through covalent addition of glucuronic acid96; ifosfamide resistance by 
increased CYP (Cytochrome P450) system90). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Drug-resistance mechanisms (such as PgP, MRP, BCRP, LRP, TP53, bcl-
2, and Topo 2) in tumor cells88. 
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2- Drug target molecular abnormalities can induce resistance to a specific drug 
or a class of drug. For example, methotrexate resistance may be due to an 
increased expression of DHFR (dihydrofolate reductase), a key enzyme for 
intracellular folate metabolism. An increased DHFR expression was found  in 10% 
of tumor biopsies at diagnosis84,85,92. Resistance to topoisomerase inhibitors, 
doxorubicin and etoposide, may be due to low expression levels of topoisomerase 
II (TOPO2) through gene mutation/alteration98. 
3- Drug action impairment by specific cellular characteristics might result from 
alterations of the inter-related cell cycle and DNA repair processes, from resistance 
to apoptosis or to autophagy, or from activation of survival stimulatory genes. For 
example, TP53 mutations99 or STAT365 and G2/M arrest allow DNA repair, whereas 
alterations in expression levels of AARS, AURKA, AURKB, CENPA, CCNB1, 
CCNE2 and CDK100 are linked to MTX resistance. Alteration in the Wnt signaling 
pathway by repression of syndecan-2 expression influences both caspases-
dependent and independent apoptosis in response to doxorubicin101. Finally, 
overexpression of BAX, BCL2 or Survivin confers resistance to cell death65,102.  
Inter-relations between all these mechanisms of resistance are complex and not yet 
completely elucidated. The activity of key factors may be regulated at a gene level 
through several molecular alterations in their coding sequences such as 
deletion/amplification (e.g. DHFR amplification in many osteosarcoma cell lines103 
but rarely found in patient samples89), mutation (e.g. mutation in RFC observed in 
9,2% osteosarcoma samples results in serine-to-asparagine substitution at amino 
acid 46)104, epigenetic modulation and miRNA regulation (e.g. decreased 
expression level of miR-15b is linked to doxorubicin resistance on osteosarcoma 
cells105).  
4- Osteosarcoma cancer stem cells (CSC). There is growing evidence that 
osteosarcoma may arise from cancer stem cells (CSCs). Using CD117 and Stro-1 
as potential candidates for CSC markers106,66, some positive cells have been 
detected in osteosarcoma cell lines and in biopsies of human tumors65.  These 
osteosarcoma CSCs have the potential for self-renewal, the ability to proliferate and 
differentiate65. They also present resistance to chemotherapy, and several 
mechanisms have been identified : increased PgP/MDR1 or GST expression, low 
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levels of topoisomerase II expression, increased DNA repair capacity and anti-
apoptotic protein overexpression65,98,106,107,  capacity to maintain in a quiescent state 
for prolonged periods of time (resting in G0)106,66. Hypoxia is also reported to 
instigate inflammation-like conditions in the tumor microenvironment which are 
generally favorable to survival of (stem-like) cancer cells65.   
5- Metastatic cells, even at diagnosis and before any drug exposure, present 
higher chemoresistance compared to primary tumor cells89,108. For example, they 
present increased PgP expression comparatively to primary tumors, increased 
DHFR expression (10% at diagnosis in primary tumors and 62% in metastatic 
lesions); decreased RFC expression (65% at diagnosis and 45% at definitive 
surgery and relapse)89,108.The capacity of tumor cells to metastasize reflect their 
aggressiveness and their ability to adapt to a different niche (bone niche for the 
primary tumor and lung niche for metastases). How this selection might influence 
the differential drug sensitivity between metastatic and from primary tumor, is not 
known. At diagnosis, non-detectable and non-proliferating (dormant) single cancer 
cells or micrometastases might already be present in tumors defined as “localized”, 
and may be responsible for a number of relapses. Non-proliferating cells present 
natural resistance to agents requiring an active cell cycle to be fully active (e.g. DNA 
damaging agents).  
6- Induced chemotherapy drug resistance. In addition to intrinsic resistance 
detectable even in the absence of treatment, resistance to therapy can as well be 
acquired during/after treatment with chemotherapeutic agents65,107. Exposure to the 
drug may cause clonal selection or induced resistance mechanisms, detectable in 
surgical samples of patients with poor histological response to neoadjuvant 
chemotherapy after induction chemotherapy or at relapse (e.g. DHFR levels 10% in 
primary tumor sample at diagnosis and 62% in relapse samples89).  
The inter-relation between metastatic process beginning and cells acquire 
resistance to chemotherapy are not clear but their possible occurrence at different 
time point might explain different osteosarcoma behavior. Micrometastases at 
diagnosis might explain metastatic relapse in patients with a good histological 
response or after amputation alone. The metastatic process during pre-operative 
chemotherapy might lead to drug selection process by the metastatic process itself 
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and/or by drug pressure. At the end, metastatic relapse might present a mix of all 
these different mechanisms of resistance and improving outcome in osteosarcoma 
would require to target several of the key steps of the metastatic process and 
resistance phenomena at the same time. Preclinical models for drug testing would 
need to reflect all this diversity to approach at best the real effect to be expected in 
patients. 
 
 
1.3. Osteosarcoma pre-clinical Models  
Preclinical in vitro and in vivo models are important tools in cancer research, to 
identify etiologic factors, to provide insight into the molecular mechanisms of tumor 
growth and metastases, as well as for drug screening, development of new 
therapies and understanding the mechanisms of resistance109.   
Fully representing the genetic complexity and tumor heterogeneity, the unique 
clinical (rapid bone tumor growth, local aggressiveness, lung and bone metastases) 
and biological behavior (expression of osteoblastic biomarkers such as alkaline 
phosphatase (ALP), osteocalcin (OCN), or osteopontin (OP), and osteoid 
production) of human osteosarcoma in pre-clinical models has proven to be 
particularly difficult under practical lab conditions and requires multiples models from 
different origins110,111.  
Several osteosarcoma models, issued from animal or human sources have been 
developed and characterized in the last decades (Fig. 1.12)110. Those models have 
been generated or implanted in different animal species (immunocompetent or 
variously immunocompromised), and in different in vivo setting (e.g. heterotopic and 
orthotopic).  
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Figure 1.12: Existing osteosarcoma models. References are provided for each model110. 
 
 
Animal osteosarcoma models were used for different purposes, from 
understanding osteosarcoma oncogenesis to study the role of the immune system 
in this tumor. However, neither isolated cells or tumors derived from these animal 
models, might accurately reflect the human disease112,113. Transgenic models, 
genetically engineered/knock-out mouse to mimic the human disease at the 
molecular level, have been successfully used to study the importance of a particular 
gene in cancer development and progression (e.g. TP53 or RB1 genes in 
osteosarcoma)113,114. However, tumors that develop in transgenic models tend to be 
less heterogeneous, which may influence their progression and metastatic 
behavior113. Syngeneic models, issued from murine cancer cells induced by 
chemical or surgical intervention are subsequently implanted/injected into 
immunocompetent mice (same mouse strain)112,113, showed appropriate interaction 
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of introduced malignant cell lines with host stroma elements and retains full 
immunoreactivity allowing immune microenvironment studies112,115.  In vivo 
spontaneous osteosarcoma animal models exist in mice and in dogs, allowing 
studying osteosarcoma in the full in vivo context with the bone, immune and vascular 
niches. Again, they might not reflect the whole human disease. Indeed, spontaneous 
osteosarcoma in dogs affects mainly geriatric dogs, while the peak of incidence in 
human disease occurs during adolescence, and dogs are not easy to use for 
laboratory research114.  
 
To overcome these pitfalls, several in vitro and in vivo human osteosarcoma models 
have been developed, issued from human tumor samples and their description are 
detail below. 
 
1.3.1. In vitro human osteosarcoma models  
The development of cell isolation and culturing techniques conducted to the 
emergence of multiple cancer cell culture models issued from patient samples. They 
are easy to grow, form the basis for study numerous cellular processes, general 
tumor cell biology, and help to identify promising therapeutic agents and novel 
targets for new treatments109,110,116. They allow the control of most experimental 
variables and permit quantitative analysis. They could be used as excellent in vitro 
models as long as they are representative of the original tumor (molecular profiles 
of a large number of human cancer cell lines available in the Cancer Cell Line 
Encyclopedia, to be compared to the profiles of human tumors, compiled as part of 
the Cancer Genome Atlas Research Network)109. However, cancer-cell in vitro 
models have reduced physiological relevance, capturing only limited aspects of the 
tumor microenvironment.  
Osteosarcoma cell lines derived from patient samples usually retain many markers 
of the osteoblast phenotype and present most of their parental tumors 
characteristics117,118. They are used as in vitro osteosarcoma models for their altered 
molecular background and high proliferative rate, despite the questioning about the 
additional genetic alterations acquired in vitro and the extent of their 
representativeness of the original tumors they are issued of117.  In vitro culture has 
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an inherent risk of selection of certain cellular sub-clones (e.g. through changes in 
cellular adhesion properties or proliferation rates), as a consequence of ongoing 
genomic instability119.  
The Eurobonet consortium has characterized 19 human osteosarcoma cell lines, 
mainly issued from primary tumor biopsy at diagnosis (n=12) of female patients (sex 
ratio M/F = 9/10, with the most frequently used osteosarcoma cell lines being issued 
from females, while male patients are more frequent), of a teenage age (around 13 
years-old, range 7 to 41 years; one patient below 10 and 3 patients above 25 years 
old). These cell lines usually present an osteoblastic subtype and different essential 
genetic alterations implicated in osteosarcoma oncogenesis (eg. TP53, RB 
pathways) (table 1.III)117,120,121. Very few cell lines were issued from metastasis 
samples (n=4) or resistant tumors after drug exposure (post-operative or relapse 
samples), which usually present less sensitivity to chemotherapy (e.g. 
IOR/OS18)29,38–40,122. Some of these cell lines have been continuously exposed to 
increasing drug concentration of different agent to select resistant clone to these 
agents (eg. Saos-2 resistant to doxorubicin, U2OS resistant to methotrexate; U2OS 
resistant to cisplatin)123.   
These cell lines have been widely used and proven to be useful to understand 
osteosarcoma oncogenesis, to dissect different cellular mechanisms linked to 
osteosarcoma aggressiveness (proliferation, migration/invasion, apoptosis/ 
autophagy) and to test sensitivity/resistance to different drugs and to analyze the 
underlying mechanisms120,124,125. However, studying osteosarcoma metastatic 
behavior and the interactions with the microenvironment further requires in vivo 
models. 
 
In the current thesis, several of these established human osteosarcoma cell lines 
were used: MG-63, Saos-2, U2OS, HOS, HOS-143B and IOR/OS18. We checked 
that their described in vitro characteristics were present in our culture conditions: 
performing copy number analysis by array-based Comparative Genomic 
Hybridization (aCGH) (Fig.1.13):  our cell batches presented similar aCGH profiles 
to those described in the literature122, the hierarchical clustering classified our cell 
lines with the respective cell lines of the literature. Two different culture flasks of 
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Saos-2 showed slight differences in aCGH profile and we carried on the experiment 
with both, calling the second one Saos-2-B. The main loss of CDKN2A, TP53 and 
RB1 status were retained in our cells (Table 1.IV). 
- observing their proliferative, migratory and invasive potential (Incucyte) under 
basal in vitro culture conditions (DMEM supplemented with 10% FBS and 
incubated at 37˚C in a humidified atmosphere -5% CO2 and 95% air) (Table 1.V) 
- their in vitro drug sensitivity to classical anti-osteosarcoma chemotherapeutic 
agents (doxorubicin, methotrexate, cisplatinum, mafosfamide, etoposide) (Table 
1.VI).   
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Table 1.III: Characteristics of Osteosarcoma cell lines.  Patients and samples characteristics from where the cell lines were derived, the principal 
genetic alterations and the in vivo development111,117,119,121,122,126–130. F-female, M-male, OB-osteoblastic, FB-fibroblastic, NA-not available, PT- 
primary tumor, Met- metastases, a- in SCID mice126, b-in Nude mice, IM-Intramuscular, SC-Subcutaneous, PO-Para-osseous
Cell line 
Patients and samples characteristics Principal Genetic alterations In vivo mice models 
Gender Age Subtype 
Tumor 
sample 
TP53 RB1 CDKN2A ATRX 
Orthotopic 
In SCIDa or nudeb 
SC in nude 
PT Met PT Met 
U2OS F 15 OB/FB Primary biopsy from tibia Normal Normal 
Hemizygous 
deletion 
Deleted 
Yes 
(IM)b 
No 
(IM)b 
Yes 
(SC) 
No 
(SC) 
MG-63 M 14 FB Primary biopsy 
First intron 
Rearrangements 
NA 
Homozygous 
deletion 
Homozygous 
deletion 
Yes 
(PO)a 
No 
(PO)a 
No 
(SC) 
No 
(SC) 
IOR/OS18 M 33 OB Metastatic biopsy Del>EX3/EX4 Normal 
Homozygous 
deletion 
NA 
No 
(IM)b 
No 
(IM)b 
No 
(SC) 
No 
(SC) 
Saos-2 F 11 NA Primary biopsy Del>EX4/EX8 Mutated Normal Normal 
Yes 
(PO)a 
Yes 
(PO)a 
No 
(SC) 
No 
(SC) 
HOS F 13 NA Primary biopsy from distal femur 
Mutated 
(p.Arg156Pro) 
Normal 
Homozygous 
deletion 
NA 
Yes 
(PO)a 
No 
(PO)a 
No 
(SC) 
No 
(SC) 
HOS-143B F 13 NA 
Ki-ras oncogene transformation of 
the HOS 
Mutated 
(p.Arg156Pro) 
Normal 
Homozygous 
deletion 
NA 
Yes 
(PO)a 
Yes 
(PO)a 
Yes 
(SC) 
Yes 
(SC) 
HOS-MNNG F 13 NA 
HOS transformation with 0.01 mcg/ml 
MNNG (a carcinogenic nitrosamine) 
Mutated 
(p.Arg156Pro) 
Normal 
Homozygous 
deletion 
NA 
Yes 
(PO)a 
Yes 
(PO)a 
Yes 
(SC) 
No 
(SC) 
IOR/MOS F 13 OB Primary biopsy 
Mutated 
(c.249_572del) 
Mutated Normal NA 
No 
(IM)b 
No 
(IM)b 
No 
(SC) 
No 
(SC) 
IOR/OS9 M 15 OB Metastatic biopsy Normal NA 
Homozygous 
deletion 
NA 
Yes 
(IM)b 
No 
(IM)b 
Yes 
(SC) 
No 
(SC) 
IOR/OS10 F 10 FB Primary biopsy 
Mutated 
(splicing ex9/10) 
Heterozygous 
deletion 
Homozygous 
deletion 
NA 
No 
(IM)b 
No 
(IM)b 
No 
(SC) 
No 
(SC) 
IOR/OS14 M 13 OB Primary biopsy Normal NA Normal NA 
Yes 
(IM)b 
No 
(IM)b 
Yes 
(SC) 
No 
(SC) 
IOR/OS15 F 12 OB Primary biopsy Normal NA 
Homozygous 
deletion 
NA 
No 
(IM)b 
No 
(IM)b 
No 
(SC) 
No 
(SC) 
OSA M 19 FB Primary biopsy from femur Normal NA 
Hemizygous 
deletion 
NA 
Yes 
(IM)b 
No 
(IM)b 
Yes 
(SC) 
No 
(SC) 
SARG M 25 NA Primary biopsy 
Mutated 
(p.Tyr205X) 
copy number 
increase (breakpoint) 
Hemizygous 
deletion 
NA 
No 
(IM)b 
No 
(IM)b 
No 
(SC) 
No 
(SC) 
KPD F 7 OB Primary biopsy Normal NA Normal NA 
No 
(IM)b 
No 
(IM)b 
No 
(SC) 
No 
(SC) 
OHS M 14 OB Primary biopsy 
Mutated 
(p.Glu286Lys) 
NA Normal NA 
Yes 
(IM)b 
No 
(IM)b 
Yes 
(SC) 
No 
(SC) 
HAL M 16 NA Bone marrow Normal NA Normal NA 
No 
(IM)b 
No 
(IM)b 
No 
(SC) 
No 
(SC) 
ZK-58 M 21 OB NA Normal NA Normal NA 
No 
(IM)b 
No 
(IM)b 
No 
(SC) 
No 
(SC) 
MHM F 41 FB Metastatic biopsy Normal NA 
Hemizygous 
deletion 
NA 
Yes 
(IM)b 
No 
(IM)b 
Yes 
(SC) 
No 
(SC) 
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Figure 1.13: aCGH hierarchical clustering of the osteosarcoma cell lines used compared to the literature data. Unpublished data from the lab. 
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Table 1.IV: Basal characteristics of the most used osteosarcoma cell lines obtained by 
aCGH analysis. Where zero, positive and negatives values represent respectively normal, 
a gain or a loss status of the gene. Unpublished data from the lab.  
 
 
 
 
 
 
 
 
 
 
 
- 
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Table 1.V: In vitro characteristics of osteosarcoma cell lines, namely proliferative, invasive and migratory capacities obtained through Incucyte, 
cell cycle phase arrest and apoptosis rate by flow cytometry under the most used chemotherapeutical agents for 72h using the IC50 for 
treatment (observed in table 1.VI): DOXO- doxorubicin, MTX- methotrexate, ETOP- etoposide, MAF- mafosfamide, CISP- cisplatin. 
Unpublished data from the lab. 
 
Cell line 
In vitro characteristics   
Proliferation 
rate 
Invasion 
capacity  
Migration 
capacity 
Cell cycle( IC50, 72h) arrest Apoptosis (%death cells IC50, 72h) 
DOXO MTX ETOP MAF CISP DOXO MTX ETOP MAF CISP 
U2OS ++++ - +++ G2 G1 G2 G2 G2 10% 15% 22% 38% 30% 
MG-63 ++++ ++ ++++ G2 G1 G2 G2 G2 10% 20% 19% 15% 15% 
IOR/OS18 +++ ++ ++++ G2 G1 G2 G2 G2 15% 20% 24% 34% 26% 
HOS ++++ - +++ G1 G1 G2 G1 G2 40% 18% 23% 8% 29% 
143B +++++ ++ +++++ G1 G1 G1 G1 G2 15% 10% 17% 10% 11% 
Saos-2 ++ - ++ G2 G1 G2 G2 G2 40% 13% 36% 42% 25% 
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Table.1.VI: IC50 of the different cell lines to the most used chemotherapeutic agents 
obtained at 72h by MTS assay. Unpublished data from the lab.  MTX- methotrexate, DOXO- 
doxorubicin, ETOP- etoposide, CISP- cisplatin, MAF- mafosfamide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2. In vivo human osteosarcoma models  
In vivo models might allow to better capture the complexity of the metastatic process 
in a living system as well as the influence of the microenvironment on tumor 
behavior109. Indeed, cancer cells migrate through vastly different 
microenvironments: stroma, blood vessel endothelium, vascular system, and tissue 
at a secondary site. Their ability to successfully form metastases depends on the 
interactions between the cancer cell and the local microenvironment18,109. Another 
advantage of in vivo models is to allow to access to in vivo response to various 
therapeutic agents, not only at the primary site, but also in terms of the metastatic 
development111. They also provide valuable tools to investigate the underlying 
mechanisms of sensitivity and resistance to drugs18,109.  
Different in vivo models exist, depending on the integrity of the source of 
osteosarcoma cells (spontaneous osteosarcoma models, osteosarcoma cell 
derived from either human or non-human osteosarcoma), on the recipient animal 
species (e.g. mice, rats, dogs), or immune system status (immune-competent or 
immune-compromised), and the implantation localization in animal (heterotopic or 
orthotopic). 
 
 
IC50 (µM) 
MTX DOXO ETOP CISP MAF 
HOS Parental 0.04 0.05 0.70 4.80 12.70 
HOS-143B Parental 0.04 0.04 0.68 1.68 14.30 
Saos-2 Parental 0.05 0.05 2.97 4.28 17.60 
Saos-2-B Parental 0.05 0.06 2.80 5.20 20.30 
MG-63 Parental 0.05 0.10 2.00 2.48 13.30 
U2OS Parental 0.05 0.10 4.40 10.00 33.00 
IOR/OS18 Parental 1.30 0.18 5.86 4.62 27.13 
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Several in vivo xenogeneic human osteosarcoma models were developed in the 
last decades, issued from human cancer cells implanted in immune-deficient mice. 
Although several animals have more similarity to humans with regard to genetics 
and morphology, rodents are frequently chosen as they are easy to manipulate in 
laboratory facilities. They reproduce easily, in a short time period, with low cost and 
can be manipulated genetically111,113,131 (Table.1.VII). Swiss nude mouse strains 
result from a homozygous recessive mutation of FOXN1nu gene111, born without 
thymus and hair. They present a T cell depletion, with some innate immunity 
preserved (with age an increase in NK cells and αβTCR lymphocytes maturation is 
observed)132. Several more immune compromised SCID (severe combined 
immunodeficient) models exist with lack of mature T and B lymphocytes, and 
defective dendritic and macrophage cells however present functional NK cells132. 
The NSG mouse strains (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) are more immune-
compromised, presenting deficient B, T and NK cells and defective for macrophages 
and dendritic cells, minimizing the risk of xenograft rejection 131,132,133. 
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Table 1.VII: Characteristics of some mouse strains used for in vivo models establishment. NA- not available. Adapted from132.   
 
 
 
 
Common name NSG SCID Outbred Nude 
Major Phenotypes NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
BALB/c SCID: 
CbySmn.CB17-Prkdcscid/J 
Swiss Nude: 
Crl:NU(Ico)-Foxn1nu 
Mature B cells Absent Absent Present 
Mature T cells Absent Absent Absent 
Natural killer cells Absent Present Present 
Dendritic cells Defective Present Present 
Macrophages Defective Present Present 
Hemolytic 
complement 
Absent Present Present 
Leakiness Very low Low  NA 
Radiation tolerance Low  Low  High  
Spontaneous tumor 
incidence (type) 
Low  High (thymic lymphoma) Low  
Medial survival >89 weeks Not determined Not determined 
Features and 
research applications 
-No functional B, T, NK cells 
-Best engraftment of primary cells, tissues and 
tumors 
-Permits long-term experiments 
 
-No functional B, T cells 
-Engrafts hematopoietic cancer cells lines, 
some primary cells 
-Suitable for therapeutic antibody testing due 
to functional complement 
 
-Athymic and T cells deficient 
-Engraftment of solid cancer cell lines  
-Hairless  
-Outbred to maximize genetic diversity and 
hybrid vigor 
Limitations  Poor radiation tolerance 
-NK activity limits engraftment 
-Poor radiation tolerance 
 
-Innate immunity intact 
-Little engraftment of hematopoietic cancer 
cells 
-Not suitable for primary cells 
Degree of 
immunodeficiency 
 
 
Highest                                                                                                                                                                Lowest 
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The main source of osteosarcoma cells used to create human xenograft models 
were  cell lines established from patients tumor and cultured in vitro  before injection 
into immune-compromised mice leading to osteosarcoma cell-line-derived 
xenograft (CDX) models110,134. Several osteosarcoma cell lines have been used to 
develop CDX models (Table.1.III), in nude mice and with a subcutaneous 
heterotopic implantation (implantation in a different site of tumor origin), rending 
tumors easier to detect. But their tumorigenic rate (6/17 osteosarcoma cells lines) 
and metastatic potential (1/6 tumorigenic osteosarcoma cells lines) are low117, 
poorly reflecting human osteosarcoma behavior. In this context, some human 
osteosarcoma cell lines have been engineered, like HOS virally transformed (Ki-
RAS oncogene) to 143B and chemically transformed to MNNG cell lines, becoming 
successfully tumorigenic and metastatic in vivo117. Others highly metastatic 
osteosarcoma cell lines were derived from their low metastatic parental cells through 
single clone selection in cell culture (Hu09-H3 derived from Hu09 parental cell 
line)126 or in vivo selection in the mouse (LM7 derived from Saos-2 by repeated 
cycling through the lungs of nude mice135; MG-63.2 derived from MG-63 through 
serial passages in nude mice via intratibial injections136; MG-63.3 derived from MG-
63.2 by a process of experimental metastasis126; Hu09-M112 and Hu09-M132 
derived from Hu09 cells injected subcutaneously in nude mice137). To increase 
tumorigenicity of the osteosarcoma cell lines, other methods have been used such 
as implantation in a different, more physiological area, either heterotopic (eg. 
subcutaneous) or orthotopic (implantation in the site of tumor origin, the bone for 
osteosarcoma, either para-osseous (eg. paratibial) or intra-osseous (eg. intratibial) 
implantation; Fig.1.14), as well as implantation in more immune compromised 
animals (e.g. NSG mice). 
 
 
 
 
 
 
Figure 1.14: Illustration of the different orthotopic injection (intraosseous and paratibial) and 
implantation (transplantation, normally used for the PDXs) models. Adapted from28.  
  
62 
 
Intramuscular injection in nude mice did not massively increase the tumorigenicity 
and metastatic potential of osteosarcoma cell lines117. The more recent orthotopic 
osteosarcoma CDX-models (paratibial and intraosseous), especially in NSG mice, 
in addition to develop more easily, present several advantages. They develop in the 
bone, better mimicking the initial tumor site including the osseous 
microenvironment, and reveal different tumor behavior in terms of primary tumor 
growth, metastatic potential and response to treatment as observed in 
patients117,138–140. The disadvantage of these orthotopic osteosarcoma models is 
that primary tumor detection is more difficult in vivo.  Several imaging techniques 
have been developed and used for real time in vivo (live mice) or ex vivo (dead 
animals or isolated parts like bones/organs) CDX detection, such as the IVIS 
spectrumCT system. This system combines longitudinal computed tomography 
(CT), bioluminescence (luciferase/luciferin) real-time detection, and a 3D image 
reconstruction141 (Fig.1.15). It detects and quantifies the signal produced (photons) 
by an enzymatic reaction in which the substrate luciferin is oxidized by luciferase 
expressing tumor cells, in the presence of oxygen and ATP138,142. The IVIS 
spectrumCT system allows the detection in real time of in vivo CDX primary tumor 
growth and metastatic spread, as well as the analysis of tumor-induced bone 
alterations141 in a non-invasive manner, leading to the reduction of the number of 
animals used.  
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Bioluminescence detection and 3D reconstruction using the IVIS spectrumCT 
system. Adapted from141.   
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CDX models proved to be excellent models, allowing the study of the tumor cells 
and microenvironment interaction, of the metastatic potential and others 
mechanisms, and more importantly for drugs screening110,117, once cell lines 
adequately represents the tumors where they are originating from, especially at the 
genetic level117. However, these models are derived from in vitro cultured cells that 
sometimes can suffer several alterations (eg. cells selection, genetic alterations, 
cross-contamination)117. Furthermore, their representativeness compared with the 
original tumors is being questioned, once these cells have been cultured in the 
absence of stroma, hence lacking the proper microenvironment and the original 
tissue architecture117. They also not fully reflected tumor heterogeneity observed in 
osteosarcoma patients. 
 
More recently, to better approach the human disease, patient-derived xenograft, 
(PDX) models were developed by direct transplantation of a tumor fragment issued 
from human patient disease(or circulating tumor cells, CTCs) into immune-
compromised mice134 (Fig.1.16). There are still few PDXs models, mainly by lack of 
available cancer material. However, international effort through several programs 
are now trying to increase the availability of these PDX models, either for adult 
cancers (EuroPDX consortium, the Public Repository of Xenografts, and the 
National Cancer Institute Patient Derived Models Repository)143 or more recently for 
pediatric cancer (MAST protocol, NCT01050296143; MAPPYACTS protocol, 
NCT02613962144; and IPI-4).  
 
Figure 1.16: Preclinical Cancer Models (CDX and PDX) derived from human patients, using 
immunocompromised mice. Adapted from134  
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PDXs allow the tumor cells to grow in their own stroma, which is essential for the 
tumor behavior110 and the preservation of tumor heterogeneity, and in some cases, 
the tumor histomorphology and global gene expression profile18,109. These PDX 
models might further help to identify and validate predictive biomarkers of sensitivity 
to different molecularly targeted therapeutics143. Beside these advantages, 
engraftment into a mouse or matrix material exerts a selection pressure that may 
changes the clonal composition, and infiltration by  mouse cells may also influence 
human tumor cell properties110,109.  
Few osteosarcoma PDX models have been published yet. Between 2010 and 2015, 
the Molecular Analysis of Solid Tumors (MAST) protocol (NCT01050296), collected 
192 fresh tumors samples of 15 different types of tumors  from 168 patients to 
establish PDX models143. Comparing the PDXs tumors with the originating tumor 
from the patient, PDXs models retained the molecular and cellular features, the 
epigenetic landscape of their developmental origins and clonal preservation143. This 
cohort included 31 osteosarcoma patient samples (from diagnosis n=17 and relapse 
n=14) that were inserted into the intercondylar femur of NSG female mice, after both 
mechanic and enzymatic dissociation. The engraftment rate was 48% (n=15/31), 
from either diagnostic primary tumor samples (n=8) or recurrence (n=7, including 2 
local relapses). The metastatic potential of these models were not described and no 
drug testing was performed. 
 
All these in vivo CDX or PDX orthotopic models, allow better understanding the bone 
microenvironment influence, metastatic potential, and tumor heterogeneity (in PDX 
models). However, in these immune-deficient animals the immune contexture is not 
preserved. New models are being developed such as humanized PDX models to 
mimic the human immune system145. Up to now no osteosarcoma humanized PDX 
models have been published.  
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1.4. Aim of the study and conceptual framework 
The natural evolution of osteosarcoma without chemotherapy is to metastasize, 
even when the primary tumor has been removed. Metastatic progression/relapse is 
the main cause of failure to current anti-osteosarcoma strategy with chemotherapy 
plus surgery, whatever the chemotherapy used 26,146. The main factors which 
prognoses this metastasis risk are the absence of primary tumor removal 
(inoperable tumor), a disease that has already spread at primary bone tumor 
distance (metastasis at diagnosis) and an observed resistance to chemotherapy 
(poor histological response at the end of neoadjuvant chemotherapy)34,106. 
“Chemoresistant” osteosarcoma cells, by not being killed by chemotherapy, will 
then have free space to express their metastatic program. Understanding 
osteosarcoma metastatic potential and timing, osteosarcoma chemoresistance 
(intrinsic or acquired) and the interconnection of these two phenomena is then 
crucial to improve osteosarcoma outcome.  
Getting more appropriate and numerous pre-clinical models in vitro and in vivo will 
help to access the complexity and heterogeneity of the disease, with the objective 
to find new drugs that can target the metastatic phenotype and chemoresistant 
osteosarcoma cells. Thus, the general objective of my thesis was to develop and 
characterize in vitro and in vivo models that mimic the patients disease (eg. 
metastases), including resistant models, in order to:  
• Understand osteosarcoma resistant and metastatic phenotype 
• Test new therapies to overcome these problems and improve survival  
 
Specific objectives: 
• Chapter 1- Evaluation of different parameters in order to improve our 
in vivo models development 
• Chapter 2 – Development of bioluminescent resistant models in vitro 
and in vivo and understand the resistant mechanism involved  
• Chapter 3 – Development of models derived from patients samples at 
relapse in different sites, including orthotopic site and molecular 
characterization  
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After chapter 1 which introduced the problematic and in order to perform this work, 
different approaches were carried out.  
Firstly, we developed and characterized in vivo orthotopic bioluminescent CDX 
models derived from the Saos-2-B parental cell line by two different methods 
(paratibial and intratibial injections), into different mice strains (NSG and Swiss nude 
mice) in order to evaluate which are the best techniques to develop orthotopic 
osteosarcoma models. We used a second parental cell line (HOS) with different 
genetic background, and we analyzed the different behavior of both lines (Chapter 
2).  
We then established and characterized in vitro chemoresistant models and their in 
vitro and in vivo behavior. Several cell lines were selected to be rendered resistant 
in vitro to MTX and doxorubicin, and from these, two were selected to developed 
orthotopic bioluminescent CDX models (derived from the parental and resistant lines 
- Saos-2-B and HOS) and further analysis of their in vivo primary tumor and 
metastatic behavior (Chapter 3). 
We finally established in vivo models directly derived from patients biopsy/surgery 
at the relapse time and characterized three patient derived xenografts (PDX) models 
in both subcutaneous and paratibial setting. A molecular (WES and RNAseq) 
comparison between the established PDX sample and the patient sample at relapse 
but also at diagnosis is also planned (Chapter 4). 
Finally, the conclusion and final remarks/perspectives are presented in chapter 5.  
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Abstract  
Osteosarcoma is one of the most common primary bone tumors in childhood 
and adolescence. Metastases occurrence at diagnosis or during disease evolution 
is the main therapeutic challenge. New drug evaluation to improve patient 
survival requires the development of various preclinical models mimicking at 
best the complexity of the disease and its metastatic potential. We describe here 
the development and characteristics of two orthotopic bioluminescent  
(Luc/mKate2) cell-derived xenograft (CDX) models, Saos-2-B-Luc/mKate2-CDX 
and HOS-Luc/mKate2-CDX, in different immune (nude and NSG mouse strains) 
and bone (intratibial and paratibial with periosteum activation) contexts. IVIS 
SpectrumCT system allowed both longitudinal computed tomography (CT) and 
bioluminescence real-time follow-up of primary tumor growth and metastatic 
spread, which was confirmed by histology. The murine immune context influenced 
tumor engraftment, primary tumor growth, and metastatic spread to 
lungs, bone, and spleen (an unusual localization in humans). Engraftment in 
NSG mice was found superior to that found in nude mice and intratibial bone 
environment more favourable to engraftment compared to paratibial injection. 
The genetic background of the two CDX models also led to distinct primary 
tumor behaviour observed on CT scan. Saos-2-B-Luc/mKate2-CDX showed 
osteocondensed, HOS-Luc/mKate2-CDX osteolytic morphology. Bioluminescence 
defned a faster growth of the primary tumor and metastases in Saos-2-
BLuc/mKate2-CDX than in HOS-Luc/mKate2-CDX. The early detection of primary 
tumor growth and metastatic spread by bioluminescence allows an improved 
exploration of osteosarcoma disease at tumor progression, and metastatic spread, 
as well as the evaluations of anticancer treatments. Our orthotopic models with 
metastatic spread bring complementary information to other types of existing 
osteosarcoma models. 
 
Key words: human osteosarcoma, In vivo orthotopic, cell-derived xenograft, 
bioluminescenc
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Introduction 
Osteosarcoma is a rare although the most frequent primary malignant bone tumor 
with a peak incidence in adolescence and young adulthood1. The survival of patients 
with osteosarcoma has not improved in the last 30 years since the introduction of 
chemotherapy in the 70s-80s1–3. The development of metastasis, mainly lung 
metastases, remains the main cause of treatment failure4. The main prognostic 
factors of relapse are the metastatic status at diagnosis and the histological 
response to neoadjuvant chemotherapy (surrogate marker of osteosarcoma 
chemosensitivity)5,6. Several aspects might have participated in this disappointing 
situation, the insufficient understanding of osteosarcoma oncogenesis, the non-
optimal phase-II clinical trial designs7 and the unsatisfactory low number of 
preclinical osteosarcoma models. 
Due to the complex osteosarcoma genetic background and the importance of bone 
and immune microenvironment in this tumor type8–10, multiple osteosarcoma models 
representative of the human disease in different in vitro and in vivo contexts are 
needed to get more insight into different processes involving osteosarcoma 
initiation, progression especially metastatic and treatment sensitivity. The 
EuroBoNeT (European Network of Excellence on bone tumors) consortium has 
characterized 19 osteosarcoma cell lines9,11,12 and described their tumorigenic 
capacities under simplified conditions (subcutaneous and intra-muscular/paratibial 
xenograft conditions) to identify technically practical models9. Although covering a 
large panel of osteosarcoma genetic abnormalities, these mice models might not be 
fully clinically relevant because osteosarcoma cells are not spontaneously arisen 
and do not grow in the proper site. It can be hypothesized that in vivo models in an 
orthotopic setting might reveal different tumor behavior: primary tumor growth, 
metastatic potential and response to treatment13–15, by better mimicking the initial 
bone site of the disease in patients. The major difficulty in using these preclinical 
orthotopic bone models is the measurement of the disease burden in a non-
accessible site, which requires the use of non-invasive techniques such as 
radiography16, computed tomography (CT), magnetic resonance imaging (MRI) or 
bioluminescence13,14.  
  
90 
 
In this work we used cell lines transduced with luciferase (bioluminescence) and CT 
imaging to facilitate in vivo follow-up of primary tumor growth, changes in bone 
microarchitecture and metastatic development. Therefore, we developed and 
characterized distinct orthotopic Cell-Derived Xenograft (CDX) human 
osteosarcoma models in mice with different immune backgrounds with metastatic 
potential. 
 
Methods 
Cell culture 
A panel of 7 human osteosarcoma cell lines (HOS, 143B, U2OS, MG-63, Saos-2, 
Saos-2-B and IOR/OS18) mycoplasma free were used. The 143B cell line was 
purchased from the American Type Culture Collection. All other osteosarcoma cell 
lines were kindly provided within the scope of the European Consortium Innovative 
Therapies for Children with Cancer (ITCC). Testing Saos-2 issued from two different 
culture flasks, we observed two slightly different CGH profile. We continued the 
experiments with both, and named the second one Saos-2-B. 
The cell lines were cultured, using early passages in Dulbecco’s modified Eagle 
medium (DMEM, GIBCO/Invitrogen, Saint Aubin, France) supplemented with 10% 
(v/v) fetal bovine serum (FBS, GIBCO/Invitrogen, Saint Aubin, France) at 37˚C in a 
humidified atmosphere (5% CO2 and 95% air). Mycoplasma test was performed 
each month by PCR. 
 
Transfection and cell transduction with Luc/mKate2 (transgene) in vitro     
Procedures were performed in sterile and safe conditions. The procedures using 
genetically modified organisms (GMO) were approved by the Ministry of Higher 
Education and Research and performed under the conditions established according 
to Decree n°2011-1177. Lentiviral particles were produced by transfecting HEK 
293T cells 24 hours after plating, with transfection solution containing jetPRIME 
Transfection Reagent kit (Polyplus-transfection, Illkirch, France), envelope 
plasmids - 29.4 µg of VSVG (pMD2G) and 54.6 µg of GAGPOL (psPax2) and 48 µg 
of plasmid Plvx-CAG-luc-2A-mKate2 that contains the gene of interest. Plasmids 
were provided by David Castel from UMR8203 Research Unit, at Gustave Roussy17. 
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The supernatant containing the virus was collected 48h later and centrifuged for 5 
min at 5000 rpm and 4ºC, the pellet was discarded and the supernatant was 
centrifuged at 22,000 rpm and 4ºC for 70 minutes. The pellet was resuspended in 
PBS, incubated under agitation for 1h at 4ºC, centrifuged 1 min at 5000 rpm and 
4ºC and aliquoted at -80ºC.   
For virus titration, serial dilutions of supernatants had been tested on HCT116 cells, 
which were then analyzed for mKate2 detection by cytometry (BD Biosciences, Le-
Pont-De-Claix, France), 4/5 days post-infection. 
All 7 cell lines were plated at 1x105 cells per well in a 6-well plate and infected with 
viral supernatant with a high multiplicity of infection (MOI). After cells reached 
confluency a selection of the cells marked with Luc/mKate2 was performed by flow 
cytometry using FACSDiva version 6.1.3.  software (BD Biosciences, Le-Pont-De-
Claix, France). The cells expressing the transgene were amplified for further use.  
Expression and activity were measured by bioluminescence using IVIS SpectrumCT 
system (Perkin Elmer, Courtaboeuf, France).   
 
In vivo bioluminescent CDX orthotopic models 
Animal experiments were approved by the CEEA26, CEEA PdL N°6 Ethics 
Committee and the Ministry of Agriculture (approval number: APAFIS#1648-
2015090713516480) and performed under the conditions established by the 
European Community (Directive 2010/63/UE).  
We have established osteosarcoma orthotopic models derived from two human cell 
lines, using two different 7 week-old immunodeficient mouse strains and two 
different types of bone injection conditions. 
Osteosarcoma cell lines used for CDX. Two cell lines were used for in vivo CDX 
establishment based on it’s different genetic background, tumorigenic and 
metastatic capacity depending on mouse strains and injection type, Saos-2-B-
Luc/mKate2 and HOS-Luc/mKate2. The non-bioluminescent human Saos-2-B 
osteosarcoma cell line was established from a primary osteosarcoma of an 11-year 
old Caucasian female patient.  In Saos-2-B cell line, TP53 (del2>EX4-EX8) gene is 
deleted, Rb1 mutated and CDKN2A normal9,11,18. Non-bioluminescent human HOS 
osteosarcoma cell line was established from a primary tumor of a 13- year-old 
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female patient. HOS (TP53 mutation p.Arg156Pro and CDKN2A homozygous 
deletion)11. 
Immunodeficient mouse strains. Swiss Nude and NSG mouse strains were 
purchased at Gustave Roussy (Villejuif, France) They were born and bred at the 
animal facilities at Gustave Roussy and maintained under controlled conditions. 
NSG mouse strains are deficient in B and T lymphocytes and with low NK cell 
activity19, minimizing the chance of xenograft rejection, while nude mouse strains 
have T cell depletion, but with age an increase in NK cells and αβTCR lymphocytes 
maturation is observed. Innate immunity of the nude mice is less compromised than 
in the NSG strain19. 
Paratibial and Intratibial injection. 1.5x106 Saos-2-B-Luc/mkate2 or HOS-
Luc/mkate2 cells were injected in a total volume of 10 µl Matrigel (Corning, 
Wiesbaden, Germany) solution at 4 mg/ml, whatever the injection method used. 
Procedures were performed under a sterile atmosphere and with the mice being 
anesthetized using 3% isoflurane. Paratibial injection with periosteum denudation 
and intratibial injection were performed according Uluçkan et al, with some 
modifications20. 
Paratibial injection was performed applying a 30G needle perpendicular to the tibia 
after a 0.5 cm skin incision. Before cell injection, periosteum was gently activated 
with the needle (periosteum denudation). 
For intratibial injection, a 0.5 cm skin incision was performed just below the knee 
joint and cells were injected into the intramedullary cavity of the tibia with a 30G 
syringe, then skin was sutured. To avoid bone pain, an analgesic (buprenorphine at 
0.3 mg/kg) was applied in addition to general anesthesia.  
Mice were clinically monitored every week, for general symptoms, weight, and tumor 
size. They were euthanized at the onset of general symptoms (e.g. weight loss, 
difficulty to walk).  
 
In vivo bioluminescence and CT imaging 
Images were acquired using IVIS SpectrumCT (Perkin Elmer, Courtaboeuf, France). 
This multimodality imaging system allows the detection of tumors and metastases 
in X-ray tomography co-registered with optical images of tagged tumor cells without 
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image adjustment for anatomical correspondence.  As light is only emitted by tumor 
cells without any background signal, bioluminescence is a highly specific and 
sensitive methodology for tumor detection and follow up over time13. For optical 
detection, mice were injected intraperitoneally with 150 mg/kg of D-luciferin (Beetle 
luciferin, Promega, Charbonnières, France) and then anesthetized with 3% 
isoflurane. For primary tumor detection, the lower section of the body (area of the 
lower legs) was imaged. For metastatic spread, especially lung metastases, primary 
tumor was covered to exclude its signal and chest was imaged. For primary tumors 
as for metastases, acquisition parameters were automatically computed by the 
SpectrumCT software in order to optimize bioluminescence signals (photons per 
second (p/s)) detection.  
 
Ex vivo organs imaging  
After sacrifice, anatomical parts (legs, lungs, and spleen) were collected and 
immersed in 150 µg/mL of D-luciferin, then imaged individually for luciferase 
detection using IVIS SpectrumCT system. 
 
Histology 
Organs were fixed in 4% paraformaldehyde, and embedded in paraffin. Tissues 
were stained with hematoxylin-eosin-safranin (HES) for morphology. Paraffin 
sections were processed following heat-induced antigen retrieval using a mouse 
anti-firefly luciferase monoclonal antibody (1:200, ThermoFisher Scientific, 
Waltham, MA, USA). The cytoplasmic signal was revealed with klear mouse kit (GBI 
labs). Slides were examined using light microscopy (Zeiss, Marly-Le-Roy, 
France).  IGR-N91-Luc neuroblastoma cells21 were used as positive control. Single 
representative whole tumor tissue section from each animal was digitized using a 
slide scanner NanoZoomer 2.0-HT (C9600-13, Hamamatsu Photonics). Histology 
was reviewed by an expert pathologist of human bone.  
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Statistical analysis  
In vitro and in vivo bioluminescence intensity is shown as the mean ± standard error 
of mean (SEM) using Graphpad Prism® Software version 5.00 (Graphpad Software 
Inc, La Jolla, CA, USA). 
 
Results 
Osteosarcoma cell transduction  
All 7 osteosarcoma cell lines were successfully transduced with a rate above 90% 
of Luc/mKate2 positive cells (Fig.2.1; supplementary Fig.2.S1), including HOS and 
MG-63 cell lines after selection by flow cytometry. Data are shown for Saos-2-B-
Luc/mKate2 and HOS-Luc/mKate2 which were also used for the in vivo model 
establishment (Fig.2.1). Cell transduction with Plvx-CAG-luc-2A-mKate2 plasmid 
using the viral vector resulted in 98% and 68% of luciferase/mKate2 positive cells 
for Saos-2-B and HOS, respectively. HOS cells were subjected to an additional 
selection using mKate2 positivity by flow cytometry which resulted in a 99% rate of 
HOS positive cells (Fig.2.1A). Using IVIS system, we were able to detect 
bioluminescence >105 photons/sec in both Luc/mKate2 transduced cells at a 
concentration of 1000 cells. Bioluminescence intensity increased with the number 
of cells in both bioluminescent cell lines in the presence of luciferin substrate 
(Fig.2.1B). No genetic alterations were observed by aCGH between the cell lines 
without and with the luciferase gene (data not shown). 
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Figure 2.1: Characterization of luciferase-transduced osteosarcoma cells. A- 
mKate2 (FL3-A) selection by flow cytometry of transduced Saos-2-B-Luc/mKate2 
and HOS-Luc/mKate2 cells showed a rate of more than 90% positive cells. B- 
Bioluminescence detection using IVIS SpectrumCT system showed increased 
bioluminescence signal paralleling the increase numbers of Plvx-CAG-luc-2A-
mKate2 transfected osteosarcoma cells Saos-2-B and HOS (black ▲ and ●, 
respectively) in the presence of luciferin, but not without luciferin (grey ▲ and ●, for 
Saos-2-B and HOS, respectively). 
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Tumorigenicity and metastatic potential of osteosarcoma cell lines in an 
orthotopic setting to the bone using bioluminescence in vivo 
We first developed the Saos-2-B-Luc/mKate2 cell line model. Saos-2-B engraftment 
rate appeared higher (Fig.2.2A) and primary tumor (Fig.2.2B) and metastases 
growth (Fig.2.2C) were faster in NSG than in nude mice. Bioluminescence was 
detectable much earlier than clinical deformation of the leg. 
Primary tumor bioluminescence was detectable in vivo as early as 5 days after 
Saos-2-B-Luc/mKate2 cell injection (the first evaluation time point) for both mouse 
strains and both injection conditions used (Fig.2.2B). Bioluminescence >1010 was 
reached at 40-50 days and 90-163 days in NSG and nude mice, respectively. 
Between paratibial and intratibial injection, no difference in primary tumor growth 
was observed in NSG mice. In nude mice, primary Saos-2-B-Luc/mKate2 tumors 
showed an initial decrease in bioluminescent signals with a subsequent recovery of 
tumor growth. This phenomenon was more prominent for intratibial injection 
(Fig.2.2B), resulting in delayed tumor growth. Bioluminescence allowed to detect 
metastases that occurred earlier in NSG than in nude mice (26-42 and 78-104 days 
after intratibial and paratibial injection in NSG and Nude, respectively) (Fig.2.2C). In 
nude mice, metastases occurred earlier after paratibial injection than intratibial 
injection, as observed for the primary tumors (Fig.2.2C). In NSG mice, intratibial 
injection seemed slightly favorable for metastatic growth as compared to paratibial 
Saos-2-B-Luc/mKate2-CDX with first detection at 26 and 42 days, respectively 
(Fig.2.2C). 
Consistent with the bioluminescent observations, clinical deformation of the leg 
appeared later in nude as compared to NSG mice (100 and 40 days, respectively) 
and later after intratibial injection as compared to paratibial one in NSG mice (60 
and 40 days, respectively). Difficulties in moving led to NSG mice sacrifice between 
67 and 77 days after paratibial and intratibial injections, respectively, and for nude 
mice between114 and 191 days after paratibial and intratibial injections respectively.  
 
For the HOS-Luc/mKate2 cell line, we used the best conditions observed with Saos-
2-B-Luc/mKate2-CDX, i.e. intratibial injection in NSG mice. Primary tumors 
developed in all 5 mice injected (Fig.2.2A) but barely grew locally (Fig.2.2B). 
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Bioluminescence values were 107-108 at day 0 and 3.5x109 at day 160 when mice 
were sacrificed. However, lung metastases were detected 26 days after injection in 
4 out of 5 animals (Fig.2.2C). In total, the growth rate of primary tumors and 
metastases of the intratibial HOS model were slower than those seen with intratibial 
Saos-2-B-Luc/mKate2-CDX in NSG. Metastasis bioluminescence values reached 
>108 at 110 and 70 days, respectively. 
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Figure 2.2: In vivo tumor growth and metastatic potential of Saos-2-B-Luc/mKate2-CDX and 
HOS-Luc/mKate2-CDX orthotopic bioluminescent models. A-Primary tumor growth 
engraftment and metastatic rate according to osteosarcoma cell line, mouse strain, and 
type of injection. B- Primary tumor in vivo bioluminescence detection overtime. C- 
Metastases in vivo bioluminescence detection overtime. Orthotopic osteosarcoma 
bioluminescent models: Saos-2-B-Luc/mKate2-CDX in Nude (left panel) and NSG mice 
(central panel); HOS-Luc/mKate2-CDX in NSG mice (right panel). 1.5×106 Luc/mKate2 
transduced cells were injected in NSG mice by intratibial injection (black) for both cell lines 
(Saos-2-B and HOS). Saos-2-B-Luc/mKate2 was also injected by paratibial injection (grey) 
on the left tibia for NSG as well as in nude with intratibial and paratibial injection. NSG and 
Nude mice were imaged for bioluminescence with IVIS SpectrumCT system until 67 or 77 
days (paratibial or intratibial) and 114 or 191 days (paratibial or intratibial), respectively in 
Saos-2-B-Luc/mKate2-CDX and 160 days for NSG in HOS-Luc/mKate2-CDX. ND=Not 
done. 
 
 
2/2 
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Radiological and morphological characteristics of the orthotopic Saos-2-B 
and HOS osteosarcoma Luc/mKate2-CDX models  
CT-imaging allowed real-time detection of tumor growth and modifications of the 
bone structures in the CDX models (Fig.2.3A), but did not detect lung or any other 
metastases. Saos-2-B-Luc/mKate2-CDX scans revealed tumor-bearing tibia bone 
structure abnormalities similar to those observed in the human disease. Aggressive 
bone lesions (cortical rupture, periosteal reaction), detection of aberrant new bone 
formation extending within the extra-osseous mass (osteocondensation, new 
calcified material), and some osteolysis (bone destruction) were found as shown in 
Fig.2.3A when mice were sacrificed at day 67 and 77 for paratibial and intratibial, 
respectively. Osteocondensation was also observed inside the bone of intratibial 
models, but less in paratibial models (Fig.2.3A). These changes were first noted 41 
days after Saos-2-B-Luc/mKate2 injection in NSG mice and 78 days in nude mice, 
independently of injection localization (data not shown). In HOS-Luc/mKate2-CDX 
intratibial model, bone structure alterations had more osteolytic characteristics 
(Fig.2.3A, lower panel) and were detected later (> day 100) with slight 
osteocondensation only inside the bone detected even later. Overlying the in vivo 
bioluminescence analysis and the CTscan images allowed to confirm that CT 
abnormalities correspond to the injected human osteosarcoma cells transduced with 
luciferase in both models (Fig.2.3B). 
For both Saos-2-B-Luc/mKate2-CDX and HOS-Luc/mKate2-CDX, HES staining 
confirmed the osteosarcoma nature of primary tumors (osteoid formation), mostly 
osteoblastic with some fibroblastic components in some animals (Fig.2.3C, Table I). 
Ex vivo bioluminescence analysis (data not shown) and luciferase positive staining 
(Fig.2.3C) in bone paraffin embedded sections confirmed that histological features 
correspond to the injected human osteosarcoma cells transduced with luciferase in 
both models. 
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Figure 2.3: Primary bone tumor - morphological and histological characteristics of Saos-2-
B-Luc/mKate2-CDX and HOS-Luc/mKate2-CDX orthotopic models in NSG mice. 
Orthotopic osteosarcoma bioluminescent models in NSG mice at sacrifice time: paratibial 
Saos-2-B-Luc/mKate2-CDX (top panel), intratibial Saos-2-B-Luc/mKate2-CDX (middle 
panel) and intratibial HOS-Luc/mKate2-CDX (bottom panel). A- In vivo CTscan imaging by 
IVIS SepectrumCT system of the normal leg (N) and Primary tumor (PT), by sagittal and 
axial view showing osteocondensation (plain arrow) and osteolysis (dotted arrow). B- In vivo 
bioluminescence imaging by IVIS SepectrumCT system of the primary tumor (left leg) 
compared to the control leg (right leg). C- Histology using Hematoxylin Eosin Saffron (HES) 
and luciferase stainings of the primary tumor and normal bone at 16x magnification.
  
101 
 
Table 2.I: Morphological and histological characteristics of all osteosarcoma bioluminescent orthotopic CDX. BLI-Bioluminescence; CT-
Computed Tomography; FB-fibroblastic subtype; HG-High-Grade osteosarcoma; N.A-Not Available; OB-Osteoblastic subtype; + -Positive 
detection; - -Negative detection; Met-Metastases 
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Ex vivo bioluminescence and histology (HES and luciferase staining) also confirmed 
the presence of lung metastases in both models (Fig.2.4). Saos-2-B-Luc/mKate2-
CDX pulmonary metastases were more frequent and more numerous (range 6-32) 
when injected intratibially than paratibially in NSG mice as detected by 
bioluminescence in vivo (Fig.2.4A) and ex vivo (Fig.2.4B-C). However, lung 
metastases in the paratibial model could not be confirmed by histology, despite in 
vivo and ex vivo bioluminescent positivity (Fig.2.4D-E-F top panel; Table I). In 
intratibial Saos-2-B-Luc/mKate2-CDX, lung metastases were visible even 
macroscopically (Fig.2.4G). For intratibial HOS-Luc/mKate2-CDX, lung metastases 
were also frequent and numerous (<29) but of smaller size than those in intratibial 
Saos-2-B-Luc/mKate2-CDX in NSG mice (Fig.2.4D-E-F; Table I). Spleen 
metastases were detected in all model types, except in Saos-2-B-Luc/mKate2-CDX 
nude mouse model (Fig.2.4H-I). Histology also revealed a unique bone metastasis 
on the opposite leg (not injected) in two Saos-2-B-Luc/mKate2-CDX NSG mice (one 
after intratibial and one after paratibial injections), and one in the homolateral femur 
of one HOS-Luc/mKate2-CDX model detected by in vivo and ex vivo 
bioluminescence which could not be detected histologically (Fig.2.4J-K).  
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Figure 2.4 (previous page): Metastases - morphological and histological characteristics of 
Saos-2-B-Luc/mKate2-CDX and HOS-Luc/mKate2-CDX orthotopic models in NSG mice. 
Orthotopic osteosarcoma bioluminescent models in NSG mice at sacrifice time: paratibial 
Saos-2-B-Luc/mKate2-CDX (top panel), intratibial Saos-2-B-Luc/mKate2-CDX (middle 
panel) and intratibial HOS-Luc/mKate2-CDX (bottom panel). In vivo bioluminescence of 
metastases (A). Ex vivo bioluminescence of spleen (B) and lungs (C).  Lung Hematoxylin 
Eosin Saffron (HES) (D) and luciferase staining (E) at 0.24x and 0.26x magnification for 
paratibial and intratibial Saos-2-B-Luc/mKate2-CDX respectively and 0.22x magnification 
for intratibial HOS-Luc/mKate2-CDX. Lung HES staining at 10x magnification (F). Lung 
macroscopic view (G). Spleen HES (H) and luciferase stainings (I) at 2x magnification 
(paratibial and intratibial Saos-2-B-Luc/mKate2) and 10x HOS-Luc/mKate2 intratibial. Bone 
of not injected leg HES (J) and luciferase stainings (K) at 10x and 4x magnification for 
paratibial and intratibial respectively. Plain arrows showed metastases. Dotted arrows 
showed the intraosseous osteoid matrix. Met=metastases 
 
 
Discussion 
We developed two novel bioluminescent osteosarcoma orthotopic xenograft models 
with spontaneous metastatic spread, derived from two osteosarcoma cell lines 
(Saos-2-B and HOS). 
We used IVIS SpectrumCT, a multimodality imaging system combining X-ray 
tomography (CT scan) with optical detection (bioluminescence), and showed 
advantages of this technique in our orthotopic bone CDX osteosarcoma models.  
The bioluminescence was valuable and presents advantages to detect and follow in 
real-time without animal sacrifice, both showed bone primary growth and spread to 
metastatic sites, especially in the lung. The signal appears before clinical and 
radiological detection capacity, as previously described21. We had more difficulties 
in detecting other metastatic localizations (e.g. bone, spleen) when the in vivo 
bioluminescent signal was close to the background noise, then either ex vivo 
bioluminescent detection or histological confirmation at mice sacrifice were required 
for metastases detection 21.  
CT scans were also valuable and efficient for the analysis of important tumor-
associated bone modifications induced by primary tumor growth, either bone 
destruction (osteolysis) or aberrant new bone formation (osteocondensation)14. 
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However in our models, lung metastases were not detectable by CT scan. IVIS X-
rays capacities are not as good as those reached with a specific X-ray tomography, 
giving lower limit detection and resolution. Because of resolution and signal to noise 
ratio, tumor volumes under 1 mm remain difficult to detect which could explain the 
absence of lung metastases detection in CT scans observed in our study.  
The combination of different techniques, in vivo and ex vivo bioluminescence 
detection, CT scan and histology using HES and luciferase staining allowed us to 
verify that bone alterations and metastases were due to the presence of the human 
osteosarcoma cells injected. Thus, these cell lines have the potential to develop 
primary tumors that mimic different osteosarcoma primary tumors within the in vivo 
bone environment and usual metastases in lung and bone which are the typical 
metastatic homing observed in patients.  
Using the osteosarcoma cell line Saos-2-B-Luc/mKate2, we compared CDX 
engraftment and metastatic potential within different immune (nude and NSG mice) 
and bone (intratibial and periosteum-denuded paratibial injections) contexts. We 
observed a differential impact of these conditions on the in vivo primary bone tumor 
and metastatic behavior, as reported in other models22.  
The NSG mouse strain used proved to be excellent recipients for osteosarcoma 
orthotopic xenografts allowing bone tumor engraftment in almost 100% of Saos-2-
B-Luc/mKate2-CDX injected animals in a shorter period of time and more rapid 
metastatic spread compared to nude mice. The NSG strain also allowed intratibial 
HOS-Luc/mKate2-CDX engraftment in all tested animals and metastatic spread, 
while the literature reports lack of engraftment in nude mice (subcutaneous and 
intra-muscular injections)9 and no metastatic potential in SCID mice (paratibial 
injection)23. The more profound immune-deficiency of NSG mice compared to nude 
mice (B-cell preserved and some innate immunity as macrophages, dendritic cells 
and NK cells) not just maximize the chance of xenograft engraftment19 but favored 
osteosarcoma primary tumor growth and metastatic spread14,21,24. Lung metastases 
in Saos-2-B-Luc/mKate2-CDX models were indeed more frequent in NSG than in 
nude mice as well as the unusual spleen metastases, not observed in a human 
context. Spleen metastases were also observed in HOS-Luc/mKate2-CDX NSG 
mice. Others unusual metastatic localizations such as kidney metastases were 
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previously described in 143B-intratibial CDX Nu/Nu mice models13, or lymph nodes, 
liver, adrenal gland, kidney or ovary in Saos-2 paratibial CDX in SCID mice23. These 
findings suggest the importance of macrophages and innate immunity in 
osteosarcoma oncogenesis and metastatic potential. Indeed, macrophages intra-
tumor environment is an important aspect of osteosarcoma aggressiveness. High 
tumor-associated macrophage (TAM) infiltrates were found associated with better 
survival and lower risk of metastases25. Thus, NSG strains might represent an 
advantage in having osteosarcoma models rapidly developing and spreading to test 
new drugs. However, therapeutics targeting the immune environment cannot be 
tested appropriately in these immune-deficient mice strains. 
Bone is a site composed of many distinct cell types (e.g. osteoblasts, osteoclasts, 
immune cells) leading to a complex bone microenvironment. This complexity 
influences the development and progression of osteosarcoma tumors26,27. The bone 
microenvironment allows engraftment and metastatic spread with Saos-2-B-
Luc/mKate2-CDX model in nude mice, while Saos-2 was described as non -
tumorigenic after subcutaneous and intramuscular injection in this mouse strain9. 
The different bone microenvironment of the primary tumor in Saos-2-B-Luc/mKate2-
CDX model influences primary tumor engraftment and growth behavior as well as 
metastatic spread. Intratibial models better mimic primary bone tumor, reflecting the 
range of radiological (CT scan) changes seen in patients with osteosarcoma and 
developed early, frequent, numerous and visible lung metastases. In the paratibial 
setting, lung metastases were not confirmed by histology, although detected by both 
in vivo and ex vivo bioluminescence analysis. The metastases might have been 
missed by the slide sampling, due to their small size. In HOS-Luc/mKate2-CDX NSG 
mouse models, we observed barely any primary bone growth but rapid metastatic 
spread from day 30, while when injected subcutaneously in NSG mice a fast primary 
growth within 20 days was described24, and when injected para-osseous in SCID 
don’t show metastatic potential23, highlighting different behaviors in distinct 
microenvironment context. Recently, tumor microenvironment has been shown to 
influence drug sensitivity in osteosarcoma MOS-J syngeneic model using C57BL/6J 
mice, where a higher response to doxorubicin was observed in intratibial model 
compared to intra-muscular model for tumor growth and necrosis15. 
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The genetic background of osteosarcoma may also have influenced the in vivo 
behavior in terms of local and metastatic potential. Saos-2-B-Luc/mKate2-CDX 
does not express the TP53 gene, exhibits RB1 mutation and normal CDKN2A 
whereas HOS-Luc/mKate2-CDX is TP53 mutated and has CDKN2A homozygous 
deletion11,18, hallmarks of aggressive osteosarcoma. When comparing the same in 
vivo conditions (intratibial in NSG mice), Saos-2-B has a high local growth potential 
leading to big osteocondensated aggressive bone tumors while HOS grew very 
slowly and is more osteolytic. Lung metastases developed at the same time in both 
models but grew faster with Saos-2-B-Luc/mKate2-CDX than in HOS-Luc/mKate2-
CDX.  Genetic transformation of these cell lines (Ki-RAS transformed HOS cell line, 
143B11,13 and in vivo metastatic selection of Saos-2 leading to LM7 cell line23) led to 
CDX models with higher metastatic potential than the parental cell line:  143B-
subcutaneous-CDX models in nude mice presented tumorigenic and metastatic 
potential while parental HOS was not tumorigenic11,13, LM7 paratibial-CDX was 
more metastatic then the parental Saos-2 in SCID mice23.  
 
Conclusion 
 Our two CDX orthotopic osteosarcoma bioluminescent models with different 
primary bone behavior and metastatic potential completed those previously 
published, the “aggressive” HOS-143B intratibial model in nude mice13, and the 
Saos-2 intrafemoral model in NSG mice14. These orthotopic models might further 
help to better follow osteosarcoma human disease in terms of tumor, progression, 
and metastatic spread, especially under different treatment conditions. They might 
bring complementary information to other types of existing osteosarcoma models 
(sub-cutaneous CDX, syngeneic models in mice or spontaneous osteosarcoma in 
dogs)28, with the advantage of real-time in vivo follow-up in orthotopic and metastatic 
conditions. Several programs (e.g MAPPYACTS, IMI2-P4) are also developing 
patient-derived xenograft (PDX) models29, which are missing in this disease, as well 
as humanized models. In osteosarcoma, all these multiple models developed in 
different in vitro and in vivo contexts are needed to get more insight into the different 
processes involving osteosarcoma initiation, progression and treatment 
sensitivity/resistance.  
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Supplementary Data  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure.2.S1: Characterization of luciferase-transduced osteosarcoma 
cells. mKate2 (FL3-A) selection by flow cytometry of transduced U2OS-luc/mKate2, 
143B-luc/mKate2, MG-63-luc/mKate2, Saos-2-luc/mKate2 and IOR/OS18-luc/mKate2 
cells showed a rate of more than 90% positive cells. 
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Abstract  
Osteosarcoma is the most common malignancy of the bones with peak incidence at 
adolescence. Despite current treatment strategies including chemotherapy and 
surgery, the long-term survival rate has reached a plateau; chemoresistance and 
metastatic spread remaining the major problems. Our aim was to develop and 
characterize in vitro and in vivo bioluminescent resistant models to usual anti-
osteosarcoma chemotherapy, and analyze their behavior comparatively to their 
parental counterparts, as well as understand the resistance mechanisms involved.  
Cells were selected in vitro for resistance to methotrexate and doxorubicin, by 
continuous exposure to these drugs. Five methotrexate-resistant and one 
doxorubicin-resistant in vitro models were obtained. P-glycoprotein was the main 
mechanism detected in the HOS-R/DOXO. Different mechanisms of acquired 
resistance specific to methotrexate according to the genetic background of the cell 
lines were observed. Differential analysis of gene expression (RNAseq) and copy 
number abnormalities (aCGH) also revealed modulation of different pathways 
implicated in cell mobility. Two parental (HOS and Saos-2-B) and their counterpart 
resistant cell lines (HOS-R/MTX, HOS-R/DOXO and Saos-2-B-R/MTX) were 
transduced with luciferase/mKate2 and injected intratibially into NSG mice. 
Resistant bioluminescent orthotopic CDX models (HOS-R/MTX, HOS-R/DOXO and 
Saos-2-B-R/MTX) injected intratibially into NSG mice at primary site showed similar 
behavior compared to their parental counterpart (HOS and Saos-2-B) with HOS 
showing slightly difficulties to adapt initially. Resistant CDX-models retained 
resistance without drug pressure, showing a slower and lower metastatic spread.  
These models may further help on new therapies development and testing in 
osteosarcoma, as well as to better understand the resistance mechanisms involved, 
in order to improve patients survival. 
 
 
Key words: osteosarcoma, in vivo, in vitro, Saos-2-B, HOS, bioluminescence, 
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Introduction 
Osteosarcoma (OS) is the first primary malignant bone tumor that predominantly 
occurs during adolescence1,2. Standard treatment of osteosarcoma combines 
neoadjuvant and post-operative chemotherapy with complete surgery of all involved 
sites (primary tumor and metastases when present). Osteosarcoma prognosis has 
not improved in almost four decades, and treatment failure is usually due to 
metastatic relapse after first-line chemotherapy. The risk factors of relapse during 
the first-line treatment are the presence of metastases at diagnosis and poor 
response to neoadjuvant chemotherapy1,3–5. Resistance to therapy, both intrinsic 
(phenomenon present prior to chemotherapy administration) and acquired 
(phenomenon revealed after administration of chemotherapeutic agents), 
participate to the treatment failure leading to recurrence. Several mechanisms of 
chemoresistance have been descried in osteosarcoma, from decreased intracellular 
drug accumulation mediated by RFC or PgP, drug inactivation by GSTP1, enhanced 
DNA repair by APE1 or ERCC, perturbations in mTOR or IGF-IR signal transduction 
pathways, apoptosis and autophagy-related chemoresistance, miRNA 
dysregulation and cancer stem cell-mediated drug resistance, as well as interaction 
between osteosarcoma cells and their microenvironment6.  
The aim of this work was to develop and characterize osteosarcoma models 
resistant to usual chemotherapeutic agents in vitro, and analyze their behavior 
comparatively to their parental counterparts in vitro and in vivo in a bone orthotopic 
setting (bioluminescent cell-derived xenograft CDX-models). 
 
 
Methods  
Cell line culture  
A panel of osteosarcoma cell lines with different genetic background were used: 
HOS (TP53 mutation and homozygous loss of CDKN2A), 143B (HOS virally 
transfected with Ki-ras oncogene), Saos-2 (TP53 deleted, RB1 mutated and normal 
CDKN2A), MG-63 (homozygous deletion of CDKN2A, normal RB1 and first intron 
rearrangements in TP53) and IOR/OS18 (TP53 deletion>EX3/EX4 and CDKN2A 
homozygous loss, normal RB1)7,8. Mycoplasma test was performed each month by 
PCR. The Human 143B was purchased from the American Type Culture Collection 
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and HOS, Saos-2, IOR/OS18 and MG-63 osteosarcoma cell lines were kindly 
provided in the frame of the European Consortium Innovative Therapeutics for 
Children with Cancer (ITCC). Testing Saos-2 issued from two different culture 
flasks, we observed two slightly different CGH profile (Supplementary Fig.3.S1). We 
carried on the experiments with both, and named the second one Saos-2-B.  
The cell lines were cultured, using early passages in Dulbecco’s modified Eagle 
medium (DMEM, GIBCO/Invitrogen, Saint Aubin, France) supplemented with 10% 
(v/v) fetal bovine serum (FBS, GIBCO/Invitrogen, Saint Aubin, France) at 37˚C in a 
humidified atmosphere (5% CO2 and 95% air). 
 
Compounds 
Doxorubicin (DOXO), Methotrexate (MTX), Cisplatin (CISP), Etoposide (ETOP), 
Vincristine (VCR) and Verapamil (VER) were purchased from Sigma Aldrich (St 
Louis, MO, USA), mafosfamide from Toronto Research Chemicals Inc (TRC) 
(Toronto, Canada) and cabozantinib from LC Laboratories (US, Canada). 
Compounds were diluted in dimethyl sulfoxide (DMSO) (Sigma Aldrich, St Louis, 
MO, USA) except cisplatin diluted in N,N-dimethylformamide (DMF) (Sigma Aldrich, 
St Louis, MO, USA) and stored at -20ºC at 10mM stock solution.  
 
In vitro development of chemotherapy resistant osteosarcoma cell lines. 
Early passage of osteosarcoma cell lines were seeded into T75 flasks. The different 
human cell lines were serially passaged in DMEM in one flask as an untreated 
control along with chemotherapy treated cells cultured in DMEM supplemented with 
10% FBS and containing an initial concentration of 0.01 µM for DOXO or 0.07 µM 
for MTX. Cells were exposed continuously to the compound until 80% confluent and 
then passaged. The medium was changed every three days. When treated cells 
were able to tolerate and grow at this concentration, the compound concentration 
was progressively increased, along the passages, up to 1 µM of MTX for all cell 
lines, except MG-63 (maximum concentration used of 0.03 µM) and 1.3 µM of 
DOXO for HOS. After resistance confirmation of cells under drug pressure (Drug 
ON) was confirmed, cultures in drug-free medium for at least nine weeks (Drug OFF) 
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before being used for further experiments were established. The same was 
performed with mafosfamide.  
 
In vitro doubling time, proliferation (MTS assay) and migration assay 
For doubling time determination, cellular proliferation rates were analyzed by live-
cell imaging using the Incucyte system (Essens Bioscience, Birmingham, UK). Cells 
were seeded in a 96-well plate and placed in the Incucyte. Phase-contrast 
photographs (4 per well) were taken automatically every four hours for 72h.  
Growth inhibition was determined using the CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay (MTS assay) (Promega Corporation, Charbonnieres, France), 
according to the manufacturer instructions. Parental and resistant derived-HOS and 
143B cell lines were seeded at 5,000 cells/well, and parental and resistant derived-
Saos-2 and Saos-2-B cell lines at 10,000 cells/well in a 96-well plate and left to settle 
overnight at 37 ºC in DMEM with 10% FBS. The cells were treated with different 
drugs at concentrations ranging from 0 to 100 μM (doxorubicin, etoposide, 
mafosfamide and cabozantinib), or 0 to 50 μM (cisplatin) or 0 to 500 μM (MTX) or 0 
to 10 μM (Vincristine). Verapamil was used at 5 μM and cabozantinib at 0.1 μM, to 
revert PgP function. Cell viability was determined 72 hours after treatment by MTS 
assay. The cell proliferation was measured at an emission wavelength of 490 nm in 
an automatic plate reader (Elx808; Fisher Bioblock Scientific SAS, Illkirch, France). 
The IC50 was calculated as the drug concentration that inhibits cell growth by 50% 
compared with control. The resistance index (RI) was defined by the ratio of IC50 
resistant line/IC50 parental line. 
Cellular motility was assessed by in vitro scratch assay. All the cell lines were 
seeded in a 96-well ImageLock tissue culture plate (Essen BioScience 4379) at an 
appropriate density and incubated in a standard cell incubator for 24h. The cells 
were then scraped with the WoundMaker™ to create precise and reproducible 
wounds and treated with 0.01 µM (MTX, Doxorubicin, Cisplatin and etoposide) or 
0.2 µM (Mafosfamide), IC50 and 10xIC50. The 96 well plate was placed into the 
IncuCyte™ system (Essens Bioscience, Birmingham, UK) and two images per well 
were taken automatically every 3 h for 48 h. The data analyses were performed with 
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Graphpad Prism® Software version 5.00 (Graphpad Software Inc, La Jolla, CA, 
USA). 
 
Transfection and cell transduction with luc/mkate2 (transgene) in vitro     
The procedures were performed in sterile and safety conditions as described 
before9.  
 
In vivo parental and resistant bioluminescent CDX models 
Animal experiments were approved by the CEEA26, CEEA PdL N°6 Ethics 
Committee and the Ministry of Agriculture (approval number: APAFIS#1648-
2015090713516480) and performed under the conditions established by the 
European Community (Directive 2010/63/UE).  
Orthotopic bioluminescent cell derived xenograft (CDX) models were established in 
7 week-old immunodeficient NSG mice by intratibial injection, as previously 
described9,10. Two parental cell lines (HOS-Luc/mKate2 and Saos-2-B-Luc/mKate2) 
and their counterparts resistant to either MTX (HOS-Luc/mKate2/MTX and Saos-2-
B-Luc/mKate2/MTX) or DOXO (HOS-Luc/mKate2/DOXO) were used. The NSG 
mice were purchased at Gustave Roussy (Villejuif, France). Intratibial injection was 
performed as previously described9 under a sterile atmosphere. Briefly, 1.5x106 
cells were injected in 5-10µl Matrigel (Corning, Wiesbaden, Germany) solution at 4 
mg/ml into anesthetized (3% isoflurane) NSG mice. A 0.5 cm skin incision was 
performed and cells were injected into the tibia intramedullary cavity, skin was 
sutured right after. Buprenorphine at 0.3 mg/kg was applied in addition to the 
general anesthesia.  
The mice were monitored clinically every week for general symptoms (weight and 
tumor size by bioluminescence and CT scan). They were euthanized at the onset of 
general symptoms (e.g. weight loss, difficulty to walk). At the sacrifice day, a sample 
from one in vivo primary tumor of resistant cell lines was cultured.  
 
In vivo and ex vivo imaging, CT scan and bioluminescence and histology 
In vivo and ex vivo images were acquired using an IVIS SpectrumCT (Perkin Elmer, 
Courtaboeuf, France) as previously described9. Briefly, NSG mice were injected 
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intraperitoneally with 150 mg/kg of D-luciferin (Beetle luciferin, Promega, 
Charbonnières, France) and under anesthesia (3% isoflurane) body imaged for 
primary tumor detection and for metastatic spread was performed. After sacrifice, 
ex vivo anatomical parts imaging was also performed (legs, lungs, and spleen) 
immersed in 150 µg/ml of D-luciferin and imaged individually.  
Anatomical parts were fixed in a 4% paraformaldehyde, and embedded in paraffin. 
Tissues were stained with hematoxylin-eosin-safranin (HES) for morphology. 
Paraffin sections were processed after heat-induced antigen retrieval using a mouse 
anti-firefly luciferase monoclonal antibody (1:200, ThermoFisher Scientific, 
Waltham, MA, USA). The cytoplasmic signal was revealed with the Klear mouse kit 
(GBI labs). Slides were examined using light microscopy (Zeiss, Marly-Le-Roy, 
France).  Single representative whole tumor tissue section from each animal was 
digitized using a slide scanner NanoZoomer 2.0-HT (C9600-13, Hamamatsu 
Photonics). Histology was reviewed by a human bone expert pathologist.  
 
Acid nucleic extraction  
Human osteosarcoma cell lines samples (parental, drug ON and drug OFF), were 
frozen in liquid nitrogen until the moment of extraction. DNA and RNA were isolated 
using AllPrep DNA/RNA mini kit (Qiagen, Germany) according manufacturer's 
instructions. 
 
Oligonucleotide aCGH assay 
In all experiments, sex-matched normal DNA from a pooled human female or male 
(Promega, Madison, WI, USA) was used as a reference. Oligonucleotide aCGH 
processing was performed as detailed in the manufacturer’s protocol (version 7.5; 
http://www.agilent.com). Equal amounts (500 ng) of tumor and normal DNAs were 
fragmented with AluI and RsaI (Fermentas, Euromedex, France). The fragmented 
DNAs were labelled with cyanine Cy3-deoxyuridine triphosphate (dUTP) or Cy5-
dUTP. Hybridization was carried out on SurePrint G3 Human CGH Microarray 
4x180K (Agilent Technologies, Santa Clara, CA, USA) arrays for 24 h at 65°C in a 
rotating oven (Robbins Scientific, Mountain View, CA) at 20 rpm. The hybridization 
was followed by appropriate washing steps. Scanning of glass microarrays was 
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performed with an Agilent G2505C DNA Microarray scanner at 100% PMT with 3 
µm resolution at 20°C in low ozone concentration environment. Data were extracted 
from scanned TIFF images using the Feature Extraction software (v11.5.1.1, 
Agilent), along with protocol CGH_1105_Oct12. All further data manipulation were 
performed under the R statistical environment in v3.4 (http://cran.r-project.org).  
Raw intensities were normalized according to their dye composition (Cy3 fitted over 
Cy5). Data were transformed to log2(Test/Ref) and normalized according to their 
local GC content through a lowess regression. Resulting profiles were segmented 
with the CBS algorithm11 implemented in the DNAcopy package (v1.42) using 
default parameters. Profiles were centered using the most centered out of the three 
most populated peaks of the smoothed log2(Test/Ref) distribution density. 
Aberration levels were called by setting a log2(Test/Ref) threshold automatically 
adapted to the internal noise for each profile, considered as one-fourth of the median 
value of the absolute differences between consecutive log2(Test/Ref) measures 
along the genome. Segmented, called profiles were then aggregated and 
hierarchically clustered using the Pearson distance and Ward aggregation method. 
Profiles comparisons were performed, for each pair, first by performing a linear 
regression of the profile with the lowest dynamics (measured as its interquartile 
range) to the profile with the highest one; the probe-to-probe direct difference of the 
log2(Test/Ref) of the two profiles was then computed, and the differential profile was 
segmented and called as described previously. Genomic regions called as different 
in the pair of profiles were annotated using the UCSC annotation tables 
(cytoBandIdeo, cpgIslandExt, wgRna, refGene, dgvMerged), corresponding to the 
hg19 genome build. 
 
RNA sequencing 
RNA sequencing analysis was performed as previously described12. RNA 
sequencing libraries were prepared with TruSeq Stranded mRNA kit following 
recommendations: the key steps consist of PolyA mRNA capture with oligo dT 
beads 1 µg total RNA, fragmentation to approximately 400 bp, DNA double strand 
synthesis, and ligation of Illumina adaptors amplification of the library by PCR for 
sequencing. Libraries sequencing was performed using Illumina sequencers 
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(NextSeq 500 or Hiseq 2000/2500/4000) in 75 bp paired-end mode. Quality of 
stranded pair-ended RNA-seq libraries was evaluated with fastqc. Reads were 
mapped with Salmon v0.8.1 12 using GRCh37 ENSEMBl mRNA dataset as 
reference sequences. Differential mRNA expression was measured with DESeq2 R 
package from raw read count table13. 
Differential mRNA expression lists were compared using Venn diagrams produced 
by Venny 2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny/). Toppfun website was 
used for functional enrichment analysis (https://toppgene.cchmc.org/enrichment.jsp). 
 
Reverse Transcription-quantitative PCR (RT-qPCR) 
The Parental and Resistant cells were collected in 450 µl of RLT solution + β-
mercaptoethanol (10% final concentration).  Total RNA was isolated using the Trizol 
reagent (ThermoFisher Scientific, Waltham, MA, USA) and reverse transcribed. 
TOPO2A, MDR1 and MRP1 amplification was monitored with StepOnePlus PCR 
System (AB Applied Biosystems, Villebon-sur-Yvette, France) using Maxima SYBR 
Green/ROX qPCR (ThermoFisher Scientific, Waltham, MA, USA) according to 
manufacturer's instructions. The primers used are described in Supplementary 
Table.3.SI. Samples were run in triplicate relative abundance of each target was 
normalized using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
expression levels. Fold changes for transcripts normalized using the 2–
ΔΔCt formula14. 
 
Results  
Development of In vitro osteosarcoma lines resistance  
Acquired resistance to MTX developed in 5 lines within 2-3 months, up to 14xIC50 
(1 µM) for HOS, Saos-2, Saos-2-B, 25 xIC50 (1 µM) for 143B and 5xIC50 (0.03 µM) 
for MG-63 (more sensitive to MTX), after 8-9 months exposure (Fig.3.1A). IC50 of 
parental and resistant line are given in Supplementary Table.3.SII. No further 
resistance was obtained in primary resistant IOR/OS18 cell line. No morphologic, 
growth rate or migration differences was seen between the acquired-MTX-resistant 
lines and their parental counterparts, under basal condition without drug 
(Supplementary Fig.3.S2A/B/C). Under continuous drug pressure (Drug ON), all 
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lines had high RI to MTX > 40. Without MTX treatment (Drug OFF), MG-63-R/MTX 
RI normalized in two weeks (RI=2), HOS-R/MTX RI decreased from 100 to 40 in 9 
weeks, and RI remained stable up to 9 weeks for the other cell lines. 
Acquired resistance to doxorubicin developed only in HOS, after a longer exposure 
time (3-4 months). HOS-R/DOXO was resistant up to 5xIC50 (1.3 µM) (Fig.3.1A). 
No morphological difference between parental/resistant cell lines was seen. HOS-
R/DOXO grew and migrated more slowly than its parental line (doubling time=45h 
and 25h respectively) (Supplementary-Fig.3.S2A/B/C). HOS-R/DOXO Drug ON had 
a high RI=212 which decreased to 87 in the absence of doxorubicin pressure (Drug 
OFF) for 9 weeks. 
Despite continuous exposure to mafosfamide up to 2 months, none of the lines 
developed resistance. IC50 of the parental lines for mafosfamide were higher (7-27 
µM) than those for methotrexate and doxorubicin (data not shown). 
 
Cross-resistance to other chemotherapeutic agents   
RI to other chemotherapeutic agents and to the multi-tyrosine kinase inhibitor 
cabozantinib were similar on drug ON and drug OFF cells, except for R/MTX MG-
63. Only results from the drug ON resistant cell lines are shown in Fig.3.1B.  
No cross-resistance was observed with any compound tested in the MTX-resistance 
lines drug ON (Fig.3.1B), as for drug OFF condition, except in MG-63-R/MTX which 
had increased RI (between 5-10) for MAF, CISP and ETOP, only in drug OFF 
condition (data not shown). 
In HOS-R/DOXO, cross-resistance with etoposide oriented toward a multi-drug 
resistance phenomenon, such as PgP (MDR1=ABCB1) protein, confirmed by cross-
resistance with vincristine (another PgP substrate). In HOS-R/DOXO, verapamil, a 
PgP inhibitor, partially reverted DOXO and VCR resistance (Fig.3.1C) but not ETOP 
or MTX cross-resistance (data not shown). The weaker PgP inhibitor) cabozantinib 
did not modify the RI of any drug tested (data not shown). Increased MDR1 mRNA 
(RT-qPCR) and protein (WB) level (Fig.3.1D) and decreased TOPO2A protein level 
(WB) were confirmed lower in the HOS-R/DOXO cell line comparatively to the 
parental cell line (Fig.3.1E).  
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Figure 3.1: Acquired in vitro resistance to methotrexate and doxorubicin in osteosarcoma 
cell lines and cross-resistance to other chemotherapeutic agents used in osteosarcoma. RI 
values were obtained thought the Ratio IC50 Resistant / IC50 Parental. A - Resistance 
Index (RI) values of the resistant cell lines to MTX and to DOXO Drug ON and Drug OFF 
as well the RI of the resistant cell lines to DOXO treated with Etoposide and Vincristine 
(VCR). Resistance selection was performed for IOR/OS18, however was not possible to 
obtain a resistant cell line. B- RI presented for resistant cell lines to MTX and to DOXO Drug 
ON treated with doxorubicin, methotrexate, etoposide, cisplatin, mafosfamide, cabozantinib 
and vincristine. C- RI of HOS-R/Doxo treated with vincristine or doxorubicin alone or in 
combination with Verapamil (VER - PgP inhibitors). D- MDR1 (PgP) expression in HOS-
R/DOXO drug ON and drug OFF obtained by RT-qPCR.  E- Topoisomerase IIa (TOPO2A) 
expression in HOS parental, HOS-R/DOXO drug ON and drug OFF obtained by Western 
blot.  ND-Not done.  
 
 
 
 
 
 
 
 
B 
A 
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Copy number and gene expression differential analysis between resistant and 
parental lines 
Differential analysis of aCGH and RNA sequencing revealed that copy number 
abnormalities (CNA; Fig.3.2A) and gene expression (GE; Fig.3.2B) profiles of the 
resistant lines were more closely related to their parental counterparts than with any 
other line.  
Common acquired CNA were seen in MTX-resistant lines issued from similar 
genetic background (HOS/143B and Saos-2/Saos-2-B, respectively). MTX-resistant 
HOS-R/MTX and 143B-R/MTX acquired gains on chromosomes 5q (5:71,484,019-
96,791,800; containing DHFR), 9q, and 12p; acquired losses on chromosome 21q 
(containing SLC19A1 located on chr21: 46,934,628-46,962,385), 2q (3 regions, 
including one with small variation containing UGT1A), 20q; and had no CNA in 
region initially gained in the parental counterpart line (chromosome 7p, 15q, 18p 
and 20p) (Fig.3.2A and supplementary Fig.3.S1). For 143-R/MTX line, two different 
losses in SCL19A1=RFC gene suggested a break in the gene.  MTX-resistant Saos-
2-R/MTX and Saos-2-B-R/MTX acquired common CNA with less amplitude but 
different from those seen in HOS-R/MTX and 143B-R/MTX. MTHFR locus 
(chr1:564,423-17,221,943) was slightly gained, while DHFR locus was not modified. 
SCL19A1=RFC locus was lost in Saos-2-R/MTX (Diff.l2r=-0,335) and not modified 
in Saos-2-B-R/MTX. In MG-63-R/MTX a gain in DHFR-containing region, without 
modification on SCL19A1=RFC, MTHFR and UGT1A regions.  
Fourteen genes were differentially expressed in GE analysis (Fig.3.2C) between all 
resistant line drug OFF versus parental lines. Nine gene had a known function and 
seven have been previously involved in MTX metabolism and sensitivity 
(SCL19A1=RFC; XYLT1, xylosyltransferase enzyme catalyzes transfer of UDP-
xylose to serine residues of an acceptor protein substrate)16, osteosarcoma 
predisposition (COL18A1)17, osteosarcoma metastatic potential (ANKRD1)18, 
osteosarcoma oncogenesis (RTN1)19, bone metabolism (BMP6, secreted ligand of 
the TGF-beta), and extracellular matrix (ADAMTSL1), and two other (FOXA2, 
AFF3). All MTX-resistant-lines had acquired decreased mRNA SCL19A1=RFC 
expression, irrespective of MTX pressure (Drug ON and OFF, except for the HOS-
R/MTX drug OFF which had increase SCL19A1=RFC expression compared to drug 
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ON) (Fig.3.2D), and irrespective of the CNA changes observed. RFC mutations 
know to inactivate (Leu291Pro) or decrease (Ser46Asn, Ser4Pro and Gly259Trp) 
RFC activity and implicated in MTX-resistance, were not found in our lines by 
RNAseq analysis. DHFR mRNA expression levels showed few changes, except in 
HOS-R/MTX and 143B-R/MTX drug OFF where mRNA expression was increased 
mainly in MTX-resistant cells drug OFF (Fig.3.2D). Protein levels of DHFR (WB) 
increased in all the MTX resistant cell lines drug ON compared to parental 
counterpart, especially in MG-63, 143-B and HOS (Fig.3.2E). DHFR protein level 
decreased in drug OFF condition to the parental levels, except for HOS-R/MTX and 
143B-R/MTX which had a gain in the DHFR region and where protein levels 
remained higher than in parentals. MTHFR mRNA expression did not changed.  
Between other genes with mRNA variation, CAN variations are seen only in 
COL18A1 in HOS and 143B with two levels of loss suggesting a break in the gene.   
The acquired CNA in the unique doxorubicin resistant line HOS-R/DOXO regions 
were enriched in genes down-regulated in ME-A cells (breast cancer) undergoing 
apoptosis in response to doxorubicin (MSigDB C2: CGP Curated Gene Sets, v6.0) 
and in genes implicated in cisplatin resistance of human Ovarian Li09 (GeneSigDB). 
The main regions gained were on chromosomes 7:86,259,619-88,276,590 (Diff.l2r 
+4.7369) containing ABCB1=MDR1=PgP and ABCB4, and on chromosomes 
11:102,449,766-103,152,951 (Diff.l2r +3.1626) containing several matrix 
metalloproteinases (MMPs). Several other regions with acquired CNA contained 
multiple multidrug resistance genes (on chromosomes 1, 2, 4, 6, 7, 10, 11, 16, 17, 
21 and X), including ABCC1. Low ABCC1 (MRP1) mRNA levels observed by RT-
qPCR showed that MRP1 mechanism  maybe is not link to the doxorubicin 
resistance in our HOS-R/DOXO cell line (data not shown). All gained regions in 
HOS-R/DOXO were enriched in genes involved in cell adhesion (GO:0007156 and 
GO:0098742), Cadherin and Wnt pathways. The lost regions in HOS-R/DOXO were 
enriched in genes involved in the immunity (type I interferon receptor binding, 
GO:0005132 and CXCR chemokine receptor binding, GO:0045236). 
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Figure 3.2: (previous page) Differential analysis of aCGH and RNA sequencing of the 
resistant and parental cell lines as well as DHFR and RFC expression. A- copy number 
abnormalities (CNA); B - gene expression (GE - PCA); C- differentially expressed in GE 
analysis; D- DHFR and RFC mRNA expression and CNA values; E- DHFR expression at 
protein level obtained by Western-blot. Nd- CAN not different in resistant and parental cell 
lines. 
 
 
In vivo bioluminescent orthotopic parental and resistant CDX models of HOS 
and Saos-2-B 
The parental and resistant osteosarcoma cell lines were successfully transduced 
with a rate above 90% of Luc/mKate2 positive cells after selection by flow cytometry 
(Supplementary Fig.3.S3), then injected in an orthotopic setting (intratibial). Primary 
tumor uptake/growth and the metastatic behavior of parental and resistant models 
were followed using IVIS SpectrumCT system. In vivo and ex vivo bioluminescence, 
CT scan images and histology (HES and luciferase staining), confirmed that the 
imaging changes correspond to the injected human osteosarcoma cells 
(Supplementary Table.3.SIII). The different models revealed tumor-bearing tibia 
bone structure abnormalities similar to those observed in the human osteosarcoma 
disease. In vivo metastases were not detected by CT scan due to its resolution. HES 
staining confirmed the osteosarcoma nature of primary tumors and metastasis. We 
then compared the in vivo behavior between the parental and resistant models. 
 
In vivo primary tumor characteristics of the resistant orthotopic cell-derived 
bioluminescent osteosarcoma xenograft models  
Bone engraftment rates of resistant and their respective parental counterpart were 
similar, except for the HOS-R/DOXO-CDX that had a lower engraftment rate 
(Fig.3.3A). HOS-resistant lines adaptation to the in vivo bone environment was more 
difficult than for the parental, with an initial decrease in in vivo bioluminescent 
detection (up to day 27), then followed by faster growth than the HOS-Parental-CDX 
(Fig.3.3B). Saos-2-B-R/MTX-CDX behaved as its parental counterpart for primary 
tumor growth. The resistant models retained the primary tumor-induced bone 
abnormalities of their parental counterpart in CT scan (Fig.3.4). The slow growing 
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osteolytic HOS-CDX-models were confined to bone, while the fast growing Saos-2-
B-CDX-models induced aggressive osseous and extraosseous mass with 
osteocondensation deforming the leg. HES reveal the osteoblastic nature of all 
models with some fibroblastic component (Fig.3.4) with no morphological 
differences between parental and resistant CDX.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: In vivo growth and metastatic behavior of the resistant orthotopic bioluminescent 
osteosarcoma cell line derived xenografts compared to their parental counterpart. In vivo 
tumor growth and metastatic potential of HOS-parental-CDX, Saos-2-B-parental-CDX, 
HOS-R/MTX-CDX, Saos-2-B-R/MTX-CDX and HOS-R/DOXO-CDX orthotopic 
bioluminescent models. A- Primary tumor growth engraftment and metastatic rate according 
to osteosarcoma cell line (Parental and Resistant). B- Primary tumor in vivo 
bioluminescence detection overtime. C- Metastases in vivo bioluminescence detection 
overtime.  
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Figure 3.4: (previous page) In vivo primary tumor characteristics of the bioluminescent 
parental and resistant orthotopic cell-derived osteosarcoma xenograft models in NSG mice 
by intratibial injection. Orthotopic osteosarcoma bioluminescent models in NSG mice at 
sacrifice time: HOS-CDX (top panel), Saos-2-B-CDX (bottom panel); Both parental-CDX 
(left panel), both R/MTX-CDX (middle panel) and HOS-R/DOXO-CDX (right panel). In vivo 
bioluminescence imaging (BLI) by IVIS SpectrumCT system of the primary tumor (left leg) 
compared to the control leg (right leg). In vivo CT scan imaging (CT) by IVIS SpectrumCT 
system of the normal leg (N) and Primary tumor (PT), showing osteocondensation (plain 
white arrow) and osteolysis (dotted white arrow), changes were first noted 63, 91 and 77 
days after injection for HOS-parental-CDX, HOS-R/MTX-CDX, HOS-R/DOXO-CDX and at 
day 41 and 49 days after injection for Saos-2-B-parental-CDX and Saos-2-R/MTX-CDX, 
respectively. Histology (Histo) using Hematoxylin Eosin Saffron (HES) and luciferase 
staining of the primary tumor and normal bone at 7.45x magnification, showing osteoid 
matrix (big black arrow) and infiltration by the tumor cells in the bone (small black arrow). 
 
 
 
In vivo metastatic behavior of the resistant orthotopic cell-derived 
bioluminescent osteosarcoma models  
Metastases were detected by in vivo bioluminescence in all CDX models 30 days 
after injection, except for HOS-R/MTX-CDX where no metastases were detectable 
(Fig.3.3C). Metastases in parental-CDX models grew faster than in resistant-CDX 
models, without correlation with the primary tumor growth rate and size (Fig.3.3C). 
At mice sacrificed time (day 84 and 127 for parental and Saos-2-B-resistant-CDX, 
respectively, and day 160 for all HOS models), combined ex vivo bioluminescence 
and histology confirmed lung metastases in all models (Fig.3.5), although detectable 
only by ex vivo bioluminescence in HOS-R/MTX-CDX (Fig.3.5). Lung metastases 
were bigger, more frequent and numerous in the Saos-2-B-parental-CDX than in 
HOS-parental-CDX models, and in parental-CDX models compared to their 
resistant-CDX counterparts. Unique bone metastases on the opposite leg (not 
injected) and unusual spleen metastases were detected in all models except in 
HOS-R/MTX-CDX. HES did not detect morphological differences between parental 
and resistant CDX.  
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Figure 3.5: (previous page) In vivo metastatic behavior of the resistant orthotopic cell-
derived xenografts bioluminescent osteosarcoma models comparatively to their parental 
counterpart in NSG mice by intratibial injection. Orthotopic osteosarcoma bioluminescent 
models in NSG mice at sacrifice time: HOS-CDX (top panel), Saos-2-B-CDX (bottom panel); 
Both parental-CDX (left panel), both R/MTX-CDX (middle panel) and HOS-R/DOXO-CDX 
(right panel). In vivo (A) and ex vivo bioluminescence of lung (B) and spleen (E) metastases 
(BLI). Lung Hematoxylin Eosin Saffron (HES) (C) and luciferase staining (D) at 1.5x 
magnification for all HOS-CDX and 0.21 and 10.8x magnification for Saos-2-B-parental-
CDX and Saos-2-B-R/MTX-CDX, respectively. Spleen HES (F) and luciferase staining (G) 
at 10.8 and 0.36x magnification for HOS-parental-CDX and both Resistant-CDX, 
respectively, and 3x for all the Saos-2-B-CDX models. Plain arrows showed metastases. 
 
 
In vivo resistance mechanisms  
PgP and MRP1 mRNA expression levels in the parental-CDX in vivo samples were 
increased compared to the levels observed in vitro in parental cell line they are 
issued of. PgP was higher in the Saos-2-B-CDX parental model (especially in the 
metastases comparatively to the primary tumor) and MRP1 higher in the parental 
HOS-CDX model. TOPO2A mRNA expression levels were decreased in both CDX 
models compared to the in vitro cells (metastases Saos-2-B showed slightly lower 
expression than primary tumor) (Fig.3.6A). PgP protein in IHC was detected in HOS-
R/DOXO-CDX (Fig.3.6B) but not in the parental and HOS-R/MTX-CDX (data not 
shown) primary tumors.   
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Figure.3.6: Resistance mechanism observed in the in vivo CDX models.  A- MDR1 (PgP), 
MRP1 and TOPO2A expression in in vivo PT (Saos-2-B-parental and HOS-parental CDX 
modes) and in Metastases (Saos-2-B-parental-CDX model) normalized with the 
respectively in vitro parental cell line performed by RT-qPCR. B- MDR1 (PgP) expressed in 
the positive control (normal human kidney - image surrounded with black lines) and in HOS 
Parental (B1) and in HOS-R/DOXO (B2) CDX models in the PT tissue obtained by 
immunohistochemistry.  PT- primary tumor, Met- metastases 
 
  
In vitro behavior of the in vivo orthotopic cell-derived bioluminescent 
osteosarcoma models  
After sacrifice, cell derived from primary tumors of each resistant-CDX models were 
cultured in vitro and the drug sensitivity analyzed. All the resistant-CDX grew in vitro 
and remained drug resistance, with RI similar (Saos-2-B-R/MTX-CDX-cells; RI=37 
and 34), decreased (HOS-R/DOXO-CDX-cells RI=212 and 42), or increased (HOS-
R/MTX-CDX-cells; RI 156 and >2000), before and after in vivo injection, respectively 
(Fig.3.7).  
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Figure.3.7: Resistance phenotype of the orthotopic resistant osteosarcoma CDX models 
cultured in vitro after mice sacrifice (HOS-R/MTX-CDX-cells, HOS-R/DOXO-CDX-cells and 
Saos-2-B-R/MTX-CDX-cells), comparatively to the respective parental and resistant drug 
ON cell line in vitro. A- Proliferation of each model treated with the respectively drug to 
which they are resistant: R/MTX – treated with MTX; R/DOXO – treated with doxorubicin. B 
– IC50 and RI of each model. Parental and Resistant drug ON before introduction in the 
mice and resistant drug ON cell line after injection in NSG mice and cultured in vitro after 
mice sacrifice. * Before or after injection of the cell lines in NSG mice. NA – Not available 
 
 
 
Discussion 
We developed in vitro osteosarcoma models resistant either to doxorubicin (HOS) 
or MTX (HOS, 143B, MG-63, 2 closely related Saos-2/Saos-2-B lines), by 
continuous in vitro exposure to these chemotherapeutic agents, adding new models 
to those described in the literature2,20–23.  
 
Resistant 
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Acquired in vitro resistance establishment was influenced by initial sensitivity to the 
drugs, and other potential factors24. In primary resistance lines, no further acquired 
resistance could be obtained (IOR/OS18 resistant to all drugs, mafosfamide high 
IC50 in all lines). In primary sensitive cells, MTX induced high resistance levels in 
all lines while doxorubicin resistance was more difficult to obtain and occurred in 
one line.  
Modifications induced by in vitro acquired resistance affect both GE and CNA, in a 
drug and cell line dependent manner24, with different mechanisms of resistance. As 
previously observed, doxorubicin-resistant line showed up-regulation of the 
multidrug drug resistant protein PgP by ABCB1 gain25. However, PgP up-regulation 
in HOS-R/DOXO might not explain the whole resistant phenotype, several multiple 
multidrug resistance genes in CNA gained regions are candidates, as other genes 
implicated in the apoptotic response to doxorubicin. Mechanisms of acquired-MTX-
resistance involved down-regulation of SCL19A1 mRNA coding for the ubiquitous 
transporter for folates (RFC)26 and increased DHFR protein expression26, with 
variation depending on the genetic background of osteosarcoma cells20. Mechanism 
of resistance persisted despite drug removal, although at lower level for HOS-
R/MTX, but not for MG-63-R/MTX where the resistance was lost after two weeks 
without drug. This resistant phenotype paralleled the mRNA level of SLC19A1, 
irrespective of the CNA variation observed. DHFR protein increased was dependent 
on the presence of the MTX in culture with involvement of post-transcriptional 
regulation as mRNA levels were up-regulated in the resistant lines drug OFF, and 
irrespective of the gain of DHFR region (present in HOS, 143B and MG-63, but not 
in SaOS-2 or Saos-2-B), The link between RB1 expression and MTX-resistance 
mechanisms previously reported with increased DHFR by gene amplification in 
RB1-positive osteosarcoma cell lines and RFC expression decrease without DHFR 
involvement in RB1-negative lines20, does not totally applied to our models.  
 
The incidence and mechanism of resistance acquired to these drugs differently 
affect other treatments used. As expected, the multi-drug resistant phenotype of 
HOS-R/DOXO decreased in vitro sensitivity of other anti-osteosarcoma drugs 
substrate of PgP (Etoposide, vincristine)27. But other induced-changes in our 
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doxorubicin-resistant line might affect other drug sensitivity not necessarily linked to 
PgP. Indeed, MTX sensitivity was decreased as previously observed in other 
models20 and associated with RFC expression down-regulation. Cisplatin sensitivity 
was not impacted25 in the continuous shot exposure drug assay (72 hours). 
However, CNA analysis revealed an enrichment in genes involved in cisplatin 
resistance, which questioned the impact of concomitant long term administration of 
both drugs as used in patient first-line treatment5,28. The impact on the clinical 
efficacy of ABCB1/ABCC1 inhibitor was shown to revert in vitro resistance in other 
doxorubicin-resistant osteosarcoma lines27, will also have to be followed, on a 
multidrug treatment context. Cabozantinib was shown to inhibit PgP activity in 
hepatoblastoma cells29, but did not revert resistance in our HOS-R/DOXO cell line. 
With our highly MTX-resistant lines (RI> 40), no cross-resistance was found with the 
other tested drugs. However, cross-resistance with doxorubicin and ifosfamide, 
(also with epirubicine, theprubicin and paclitaxel) but not with cisplatin, has been 
observed in low and intermediate MTX-resistant Saos-2 lines (RI of 4.87 and 12.73, 
respectively) with low RFC expression30. The significance for the patients is unclear 
and probably more complexity is added by other potential cellular/molecular 
programs modified on acquired resistant lines, not directly linked to the mechanism 
of action and metabolism of one drug. Indeed, several more general, cellular and 
biological pathways were modulated in the resistant lines, implicated in cell 
adhesion, extra cellular matrix and immunity, which cannot fully be access in vitro 
but might modify the resistant-cell behavior in vivo.  
 
The bone microenvironment is known to have an important role in osteosarcoma 
progression31, has been shown to influence drug sensitivity in osteosarcoma 
syngeneic models32 and might influence resistance phenotype24. We developed in 
vivo orthotopic bioluminescent parental and resistant CDX models, with the same 
experimental procedure used for our previous parental-CDX models in NSG mice9. 
The different in vivo primary tumor bone behavior (slow growing osteolytic HOS-
CDX, fast growing osteocondensed Saos-2-B-CDX), metastatic potential (faster 
metastatic spread in Saos-2-B-CDX) and morphology9 were retained by the 
resistant lines. However, these resistant lines showed clear in vivo behavior 
modifications. HOS-R/DOXO had lower engraftment rate. HOS-resistant-CDX had 
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initial adaptation difficulties to the bone microenvironment then their growth rates 
were faster than in parental line. Most importantly all resistant-CDX presented 
different metastatic behaviors, with a slower and lower lung metastatic spread than 
in parental lines. Similar behavior has been observed with other in vivo models of 
metastatic spread by direct intra-venous injections of doxorubicin-resistant 
osteosarcoma U2OS and Saos-2 variants (MDR1 overexpression by gene 
amplification) in athymic nude mice, only when resistant-cells injected straight after 
treated medium culture, and not when cultured in medium free of drug for a week 
before injection25.  
In our CDX-models, the resistant lines at mice sacrificed retained their resistant 
phenotype. Times intervals between cell injection and detection of primary tumor 
growth and metastatic spread are still compatible with drug testing in vivo.  
 
These resistant-CDX models might be useful to further test new drug in 
osteosarcoma models and might complement other osteosarcoma models. 
However, they do not fully reflect the heterogeneity and complexity of osteosarcoma 
human tumor and does not give access to the immune system, as developed in 
immunocompromised mice. Patient derived xenograft models from relapsed 
samples might bring complementary knowledge on human osteosarcoma 
resistance to drug, while syngeneic (mice or dog) or humanized osteosarcoma 
models might partially give access to the immunity role in osteosarcoma resistance 
to treatment. 
 
 
Acknowledgments  
We thank the Platform of Preclinical Evaluation for providing immunocompromised 
mice and animal care, Olivia Bawa for performing the histology slides, Irene Villa for 
having scanned the histology slides and Alec Guyomard for some genetic samples 
analysis. To Noémie Assoun for help on some DNA/RNA extraction, Valerie Roufiac 
for help on IVIS spectrumCT system function, Carole Lecinse for critical reading of 
the manuscript and to the Portuguese Foundation for Science and Technology 
(FCT, http://www.fct.pt/) through the PhD fellowship to Maria Eugénia Marques da 
Costa (SFRH/BD/89137/2012). 
  
144 
 
References 
1.  Yang X, Yang P, Shen J, et al. Prevention of multidrug resistance (MDR) in 
osteosarcoma by NSC23925. Br J Cancer. 2014;110(12):2896-2904.  
2.  Wang J, Li G. Mechanisms of methotrexate resistance in osteosarcoma cell 
lines and strategies for overcoming this resistance. Oncol Lett. 2015.  
3.  Posthumadeboer. Mechanisms of Resistance Molecular involvement Drug 
Target Drug References. Oncol Discov. 2013. 
4.  Duan Z, Gao Y, Shen J, et al. miR-15b modulates multidrug resistance in 
human osteosarcoma in vitro and in vivo. Mol Oncol. 2017;11(2):151-166.  
5.  Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, Doxorubicin, and 
Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP 
Alone in Patients With Resectable High-Grade Osteosarcoma and Good 
Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 
Good Response Randomized Controlled Trial. J Clin Oncol. 
2015;33(20):2279-2287. 
6.  He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in 
osteosarcoma (Review). Oncol Lett. 2014;7(5):1352-1362.  
7.  Ottaviano L, Schaefer K-L, Gajewski M, et al. Molecular characterization of 
commonly used cell lines for bone tumor research: A trans-European 
EuroBoNet effort. Genes, Chromosom Cancer. 2010;49(1):40-51.  
8.  Lauvrak SU, Munthe E, Kresse SH, et al. Functional characterisation of 
osteosarcoma cell lines and identification of mRNAs and miRNAs associated 
with aggressive cancer phenotypes. Br J Cancer. 2013;109(8):2228-2236.  
9.  Marques da Costa ME, Daudigeos-Dubus E, Gomez-Brouchet A et al. 
Establishment and characterization of In vivo orthotopic bioluminescent 
xenograft models from human osteosarcoma cell lines in Swiss nude and 
NSG mice. Cancer Med. 2018;7(3):665-676. 
 
  
145 
 
10.  Uluçkan Ö, Bakiri L, Wagner EF. Characterization of Mouse Model-Derived 
Osteosarcoma (OS) Cells In Vitro and In Vivo. In: Humana Press, New York, 
NY; 2015:297-305.  
11.  Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary 
segmentation for the analysis of array-based DNA copy number data. 
Biostatistics. 2004;5(4):557-572.  
12.  Harttrampf AC, Lacroix L, Deloger M, et al. Molecular Screening for Cancer 
Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-
Institutional Prospective Molecular Stratification Trial. Clin Cancer 
Res. 2017;15;23(20):6101-6112. 
13.  Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast 
and bias-aware quantification of transcript expression. Nat Methods. 
2017;14(4):417-419.  
14.  Love MI, Huber W, Anders S. Moderated estimation of fold change and 
dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.  
15.  Tsubaki M, Satou T, Itoh T, et al. Overexpression of MDR1 and survivin, and 
decreased Bim expression mediate multidrug-resistance in multiple myeloma 
cells. Leuk Res. 2012;36(10):1315-1322.  
16.  Yang X-R, Xiong Y, Duan H, Gong R-R. Identification of genes associated 
with methotrexate resistance in methotrexate-resistant osteosarcoma cell 
lines. J Orthop Surg Res. 2015;10:136.  
17.  Guo Z, Zhang T, Wu J, Wang H, Liu X, Tian L. Genetic polymorphisms in 
COL18A1 influence the development of osteosarcoma. Int J Clin Exp Pathol. 
2015;8(9):11531-11536.  
18.  Gvozdenovic A, Boro A, Meier D, et al. Targeting αvβ3 and αvβ5 integrins 
inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse 
model. Oncotarget. 2016;7(34):55141-55154.  
  
146 
 
19.  Both J, Krijgsman O, Bras J, et al. Focal chromosomal copy number 
aberrations identify CMTM8 and GPR177 as new candidate driver genes in 
osteosarcoma. PLoS One. 2014;9(12):e115835.  
20.  Serra M, Reverter-Branchat G, Maurici D, et al. Analysis of dihydrofolate 
reductase and reduced folate carrier gene status in relation to methotrexate 
resistance in osteosarcoma cells. Ann Oncol. 2004;15(1):151-160.  
21.  Hattinger CM, Stoico G, Michelacci F, et al. Mechanisms of gene amplification 
and evidence of coamplification in drug-resistant human osteosarcoma cell 
lines. Genes, Chromosom Cancer. 2009;48(4):289-309.  
22.  Selga E, Oleaga C, Ramírez S, de Almagro MC, Noé V, Ciudad CJ. 
Networking of differentially expressed genes in human cancer cells resistant 
to methotrexate. Genome Med. 2009;1(9):83.  
23.  Yang J, Guo W, Wang L, et al. Cisplatin-resistant osteosarcoma cells possess 
cancer stem cell properties in a mouse model. Oncol Lett. 2016;12(4):2599-
2605.  
24.  Zahreddine H, Borden KLB, Wu JH. Mechanisms and insights into drug 
resistance in cancer. 2013;313(9):8-1.  
25.  Serra M, Scotlandi K, Manara MC, et al. Establishment and characterization 
of multidrug-resistant human osteosarcoma cell lines. Anticancer Res. 
1993;13(2):323-329.  
26.  Guo W, Healey JH, Meyers PA, et al. Mechanisms of Methotrexate 
Resistance in Osteosarcoma. Clin Cancer Res. 1999:621-627. 
27.  Fanelli M, Hattinger CM, Vella S, et al. Targeting ABCB1 and ABCC1 with 
their Specific Inhibitor CBT-1® can Overcome Drug Resistance in 
Osteosarcoma. Curr Cancer Drug Targets. 2016;16(3):261-274.  
28.  Piperno-Neumann S, Le Deley M-C, Rédini F, et al. Zoledronate in 
combination with chemotherapy and surgery to treat osteosarcoma (OS2006): 
  
147 
 
a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 
2016;17(8):1070-1080.  
29.  Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and 
metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and 
MET. Clin Cancer Res. 2014;20(11):2959-2970.  
30.  Wang J, Li G. Relationship between RFC gene expression and intracellular 
drug concentration in methotrexate-resistant osteosarcoma cells. 
funpecrp.com.br Genet Mol Res Mol Res. 2014;13(133):5313-5321.  
31.  Zhang Y, Mai Q, Zhang X, Xie C, Zhang Y. Microenvironment Signals and 
Mechanisms in the Regulation of Osteosarcoma. In: Osteosarcoma - Biology, 
Behavior and Mechanisms. InTechOpen, London, UK. 2017. 
32.  Creen V, Biteau K, Amiaud J, et al. Bone microenvironment has an influence 
on the histological response of osteosarcoma to chemotherapy: retrospective 
analysis and preclinical modeling. Am J Cancer Res. 2017;1;7(11):2333-
2349. 
  
148 
 
Supplementary data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  Supplementary Figure.3.S1: CGH differential analysis of parental and resistant cell lines. 
 
 
Saos-2 vs Saos-2-R/MTX 
Saos-2-B vs Saos-2-B-R/MTX 
HOS vs HOS-R/DOXO 
MG-63 vs MG-63-R/MTX 
 HOS vs HOS-R/MTX 
143B vs 143B-R/MTX 
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Supplementary Table.3.SI: Primers were used to amplify topoisomerase IIa 
(TOPO2A), multidrug resistance protein 1 (MDR1) or P-glycoprotein 1 (PgP), 
multidrug resistance associated protein 1 (MRP1) and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH – used as control) cDNAs by quantitative real-time PCR. 
 
 
 
Supplementary Table.3.SII: Acquired in vitro resistance to MTX and DOXO. IC50 values of 
the Parental and resistant cell lines to MTX and to DOXO Drug ON and Drug OFF and of 
DOXO Resistant cell line treated with etoposide (R/DOXO). IC50 values were calculated 
using Prisma version5 using cell proliferation data after 72h of treatment. 
 
Gene forward primer reverse primer 
MDR1 5’-TGGAGGAAGACATGACCAGG-3 5’-CAAGACCTCTTCAGCTACTGC-3’ 
MRP1 5’-TCTACCTCCTGTGGCTGAATCTG-3’ 5’-CCGATTGTCTTTGCTCTTCATG-3’ 
TOP2A 5’-TTGAAGACGCTTCGTTATGGG-3’ 5’-CCATCACAACTGGCCCTCTC-3’ 
GAPDH 5’ ATCCCATCACCATCTTCCAG-3' 5’ CCATCACGCCACAGTTTCC-3' 
 
 
 
IC50 
Resistance to MTX Resistance to Doxo R/DOXO Etoposide 
Parental 
Drug 
ON 
Drug 
OFF P9 
Parental 
Drug 
ON 
Drug 
OFF P9 
Parental 
Drug 
ON 
Drug 
OFF P9 
HOS 0.04 6.24 1.64 0.06 11.3 4.36 0.7 180 90.5 
HOS-
143B 
0.04 4.13 4.64 - - - ND ND ND 
Saos-2 0.05 2.05 1.78 - - - ND ND ND 
Saos-2-B 0.05 1.93 1.51 - - - - - - 
MG-63 0.05 2.91 0.1 - - - ND ND ND 
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Supplementary Figure.3.S2: In vitro characteristics of HOS and Saos-2-B parental and cell 
lines resistant to MTX and DOXO. A- Morphology; B- Doubling time; C -Migration potential 
with (0.01µM) and without (control) treatment. MTX resistant Cell lines were treated with 
MTX and the DOXO resistant cell line were treated with doxorubicin (DOXO).  Parental cell 
lines were treated with MTX and DOXO. 
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Supplementary Figure.3.S3: Characterization of luciferase-transfected osteosarcoma cells. 
Data shown for the two osteosarcoma parental cell lines (HOS-parental and Saos-2-B-
parental) and for the respectively methotrexate and doxorubicin resistant cell lines (HOS-
R/MTX, HOS-R/DOXO and Saos-2-B-R/MTX) after FACS selection showing a rate of more 
than 90% of luciferase positive cells. 
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Supplementary Table.3.SIII: Morphological and histological characteristics of all 
osteosarcoma bioluminescent orthotopic CDX: HOS-parental-CDX, HOS-R/MTX-CDX, 
HOS-R/DOXO-CDX, Saos-2-B-parental-CDX and Saos-2-B-R/MTX-CDX. BLI- In vivo and 
ex vivo bioluminescence; CT-Computed Tomography; Histo-Histology; FB-fibroblastic 
subtype; OB-Osteoblastic subtype; HG-High-Grade osteosarcoma; NA-Not Available; ND-
Not done; + -Positive detection; -  -Negative detection; Met-Metastases. 
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Abstract  
Osteosarcoma is a rare bone tumor of the adolescent and young adults in which 
resistance to chemotherapy and metastatic spread constitute the main prognostic 
factors. Despite multiple efforts to improve osteosarcoma treatment in the last four 
decades, survival has not improved and metastatic relapse, mainly in the lungs, 
constitutes the main cause of treatment failure. New drug identification and 
validation requires pre-clinical models that capture the diversity, heterogeneity of 
the patients’ tumors and mimic at best the human resistant disease. Therefore, we 
established and characterized patient-derived xenograft (PDX) osteosarcoma 
models in NSG mice, in a subcutaneous and an orthotopic bone (paratibial) setting, 
derived from human osteosarcoma biopsy samples of patients with refractory or 
relapse disease after at least one line of chemotherapy. From 3 sample patients one 
subcutaneous and one orthotopic PDX-model were obtained to each one (3 
subcutaneous and 3 orthotopic PDX-models). Morphological and molecular 
characterization using histology, whole exome and RNA sequencing revealed a high 
consistency between the models and their primary tumor at relapse from they are 
issued but also with the tumor at diagnosis of the patient. Secondary in vitro cell 
cultures issued from these 3 subcutaneous PDX models confirmed high resistance 
to chemotherapy, especially to methotrexate. Sensitivity testing to the multi-tyrosine 
kinase inhibitors cabozantinib, pazopanib and regorafenib in vitro showed high 
sensitivity to the prior two agents but resistance to regorafenib. Sensitivity to multi-
tyrosine kinase inhibitor will be further tested in vivo and compared to the clinical 
response observed in the patient.  
 
 
Key words: osteosarcoma, In vivo, Patient Derived Xenograft (PDX), paratibial, 
subcutaneous, resistance  
 
 
 
 
 
 
 
  
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
159 
 
Introduction 
Osteosarcoma (OS) is a rare disease of adolescents and young adults with no 
outcome improvement in the last 40 years1. Patients suffering from this highly 
malignant bone cancer2,3, especially those with metastatic disease at diagnosis, 
those with poor histological response to first line neoadjuvant chemotherapy and 
those who relapse at lung metastatic site, have a very dismal prognosis4–6. The last 
decade of multiple clinical phase II trials in relapse/refractory osteosarcomas have 
not translated in improved outcome7. Factors that contribute to this situation are the 
complexity of osteosarcoma genetics and epigenetics8, the importance of bone and 
immune microenvironment in the disease2,9, and the lack of suitable models 
representative of the diversity, complexity and heterogeneity of osteosarcomas, as 
well as of the chemo-resistant and metastatic behaviors, that could help for pre-
clinical testing of innovative effective therapies and for the identification of predictive 
biomarkers of efficacy2,10.  
Several in vivo cell-derived xenografts (CDX) in murine sub-cutaneous models and 
more rarely orthotopic CDX-models of human osteosarcoma were developed and 
characterized10–13. Most of these CDX derived from primary tumor samples at 
diagnosis and more rarely from metastatic or recurrent diseases8,11. Few were 
developed specifically for their metastatic potential14. Although they have provided 
important information in the understanding of osteosarcoma biology, these CDX-
models which derived from cell lines that might have been in in vitro culture for a 
long time, were not fully representative of the osteosarcoma heterogeneity15,16. In 
the last years, patient-derived xenograft (PDX) models have been developed to 
better mimic the biology and heterogeneity of human tumors15. However, few PDX 
models have yet been described for osteosarcoma, partly due the low engraftment 
rate and the relatively long time required for tumor establishment of this models17,18.  
Different programs are ongoing to established PDX models from different adult and 
pediatric tumor types, in Unites States (MAST protocol, NCT01050296)19 and 
Europe (MAPPYACTS trial, NCT02613962; ITCC-P4 within the IMI2 program). Very 
recently, 15 osteosarcoma orthotopic PDX models were published from either 
diagnostic (n=8) or recurrence samples (n=7, including 2 local relapses) (MAST 
protocol, NCT01050296)19 with no drug evaluation. 
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We will present here the establishment and characterization of new subcutaneous 
and orthotopic, paratibial osteosarcoma PDX models in NOD-SCID-γc-/- (NSG) 
mice, issued from relapsed osteosarcoma samples of patients accrued in the 
MAPPYACTS trial (NCT02613962, Molecular Profiling for Pediatric and Young 
Adult Cancer Treatment Stratification) at Gustave Roussy Institute (Villejuif, France) 
and some drug testing results. 
 
 
Methods 
Translational research context 
MAPPYACTS clinical trial (NCT02613962, Molecular Profiling for Pediatric and 
Young Adult Cancer Treatment Stratification) is a prospective, multicentric, clinical 
proof-of-concept study to stratify targeted therapies adapted to molecular profiling 
of relapsed and refractory pediatric tumors20,21. Ancillary studies included the 
development and characterization of experimental patient derived xenograft (PDX) 
models and primary cell lines.  
All models presented here have been developed from patients with 
refractory/relapsed osteosarcoma accrued at Gustave Roussy.  
 
Human refractory/relapsed osteosarcoma tumor sample collection  
Briefly, following informed consent, tumor samples were collected by surgical 
resection or CT or ultrasound-guided intentional tumor biopsy, with one piece 
immediately frozen for the clinical analysis and a fresh tumor sample obtained at the 
same time, immediately placed in transport media (DMEM media used with 1% 
antibiotics), conserved at 4°C for a maximum of 24 h or immediately transferred to 
the research laboratory at room temperature or soft frozen in FBS containing 10% 
DMSO. In patients, blood samples were collected at the same time as tumor 
samples and were submitted to FICOLL gradient separation, to extract constitutional 
DNA. 
The clinical part included both Whole Exome Sequencing (WES) and RNA 
Sequencing (RNAseq) on patients’ tumor tissues. Data interpretation of molecular 
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genetic alterations detected by WES and RNAseq and treatment recommendation 
were done within a multidisciplinary therapeutic molecular biology tumor board.  
For the development of preclinical models, the samples were immediately 
processed at their arrival at Gustave Roussy sites. The different procedures are 
described below.  
Frozen tumor sample at diagnosis issued from the patients with successful PDX 
models were collected and analyzed with the same technics (WES, RNAseq). 
 
Development of In vivo Orthotopic human osteosarcoma PDX models 
Experiments were validated by the CEEA26, CEEA PdL N°6, Ethic committee 
(approval number: 2015032614359689 V7) and carried out under conditions 
established by the European Community (Directive 2010/63/UE). Animals were 
purchased at Gustave Roussy (Villejuif, France) and maintained in the respective 
animal facilities following standard animal regulation, health and care, and ethical 
controls. 
Osteosarcoma PDXs were established from relapsed osteosarcoma patients by 
sample implantation in immunocompromised NOD.Cg-Prkdcscid II2rgtm1Wjl/SzJ 
(NSG) mice or in Nude mice. Under anesthesia with isoflurane (3% isoflurane, 
1.5l/min air), tumor samples were implanted either subcutaneously (~5 mm3) by 
performing a skin incision on the back and implanting the tumor sample in the flanks 
under the skin23 and/or on orthotopic position, paratibially (~2 mm3) between muscle 
and bone tibia after a 0.5 cm skin incision and a gentle activation of the periosteum 
(periosteum denudation)10.  For the first patients, implantation was also performed 
into the left kidney capsule (tumor sample of 2-5 mm3; engraftment confirmed with 
an Aplio XG ultrasound equipped with a probe of high frequency wide band, 7-14 
MHz; LTP 1202; Toshiba), to offer a vascularized hypoxic microenvironment to the 
tumor24. 
Subcutaneous and paratibial xenografts were detected by palpation, tumor gross 
apparition (caliper measurements), as well as bone structure alterations by CT scan 
imaging for paratibial model. Surgery and CT scan imaging were performed under 
anesthesia with 3% (v/v) isoflurane. To avoid bone pain, an analgesic 
(buprenorphine at 0.3 mg/kg) was applied in addition to the general anesthesia or 
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when symptoms appeared. Clinical status, tumor uptake and tumor growth were 
evaluated 1-3 times a week. The experiments lasted until tumors reached specific 
endpoints detailed in the ethical projects like significant weight loss or difficulty to 
walk. Tumor doubling time (Td) was determined in an exponential growth phase 
between 200 and 400 mm3, for the subcutaneous models23. 
If tumor growth was not detected 6 months after implantation, the mice were 
sacrificed, and considered as an engraftment failure. When tumor grew, the mice 
were sacrificed when tumor volume reach around 600 mm3 in the kidney capsule 
implantation, 1500 mm3 subcutaneously or when clinical signals (eg difficulties to 
move) started to appear in paratibial models. Then, for each further passage, the 
PDX tumor was divided in different pieces, one for new mice implantation 
subcutaneously and/or paratibially, one for soft congelation (frozen in FBS, +1% 
(v/v) DMSO), one for dry congelation (frozen in nitrogen) and one prepared for 
histology.  
 
In vivo CT scan imaging 
IVIS SpectrumCT (Perkin Elmer, Courtaboeuf, France) was used for images 
acquirement. This system allows the primary tumor and metastases detection by X-
ray tomography co-registered with optical images. The lower section of the body 
(area of the lower legs) was imaged for primary tumor detection and the chest to 
detect metastatic spread, especially to the lung.  
 
Histology 
Organs were fixed in 4% (v/v) paraformaldehyde, and embedded in paraffin. Tissues 
were stained with hematoxylin-eosin-safranin (HES) for morphology. Slides were 
examined using light microscopy (Zeiss, Marly-Le-Roy, France) and a single 
representative whole-tumor tissue section from each animal was digitized using a 
slide scanner NanoZoomer 2.0-HT (C9600-13, Hamamatsu Photonics). Histology 
was reviewed by a human bone expert pathologist.  
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In vitro primary and secondary cell culture 
Osteosarcoma cells from human osteosarcoma relapsed samples were cultured in 
vitro directly from the patient’s tumor sample (primary cultures) or from 
osteosarcoma PDX samples of our new growing models after passage 2 (secondary 
cultures). For both types of culture, each tumor sample was cut in several small 
pieces using a scalpel and then dissociated mechanically with a 22G needle in 
medium to prevent the tumor from drying out. The tumor preparation was 
resuspended in Dulbecco’s modified Eagle medium (DMEM, GIBCO/Invitrogen, 
Saint Aubin, France) supplemented with 20% (v/v) fetal bovine serum (FBS, 
GIBCO/Invitrogen, Saint Aubin, France), plated in T75 flasks and incubated at 37˚C 
in a humidified atmosphere (5% CO2 and 95% air). All the procedures were 
performed under sterile conditions. Mycoplasma test was performed each month by 
PCR. 
 
Compounds 
The compounds used (doxorubicin, methotrexate, cisplatin, etoposide), were 
purchased from Sigma Aldrich (St Louis, MO, USA), from Toronto Research 
Chemicals Inc (TRC - Toronto, Canada) (mafosfamide) and from LC Laboratories 
(US, Canada) (regorafenib, pazopanib, cabozantinib). All the compounds were 
diluted in dimethyl sulfoxide (DMSO) (Sigma Aldrich, St Louis, MO, USA) except 
cisplatin diluted in N,N-dimethylformamide (DMF) (Sigma Aldrich, St Louis, MO, 
USA) and stored at -20ºC at 10 mM stock solution.  
 
Treatment (MTS assay) 
Growth inhibition was determined using the CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay (MTS assay) (Promega Corporation, Charbonnieres, France), 
according to the manufacturer instructions and as performed before10.  
Cells issued from our PDX models were seeded in vitro in DMEM supplemented 
with 20% (v/v) FBS at 7000 cells/well in a 96-well plate and incubated at 37ºC under 
overnight. The cells were treated with different drugs at concentrations ranging from 
0 to 100 μM (doxorubicin, MTX, etoposide, mafosfamide, cabozantinib, regorafenib 
and pazopanib), or 0 to 50 μM (cisplatin). Seventy-two hours after, cell viability was 
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determined by adding 20 μl of MTS solution to each well. After 1-5h of incubation 
(cell line metabolism dependent) at 37ºC cell proliferation was measured at an 
emission wavelength of 490 nm in an automatic plate reader (Elx808; Fisher 
Bioblock Scientific SAS, Illkirch, France). The IC50 was calculated as the drug 
concentration that inhibits cell growth by 50% compared with control.  
 
Molecular characterization of human samples and in vivo PDX-models (WES 
and RNAseq) 
Human samples and osteosarcoma PDX samples, either subcutaneous or 
paratibial, were frozen in liquid nitrogen until the moment of extraction. Tumor DNA 
and RNA, and germline DNA were isolated using AllPrep DNA/RNA micro kit 
(Qiagen, Germany) according manufacturer's instructions.  
Whole Exome (WES) and RNA sequencing analysis was performed as previously 
described22.  Whole exome sequencing (WES) was performed from 500 ng of 
sample (tumor, using Agilent SureSelect V5 (50Mb) or Clinical Research Exome 
(54Mb) kit. The mutational load obtained using WES, was calculated by dividing the 
number of somatic non-synonymous mutations by the number of bases having a 
depth greater than or equal to 4 in the tumor BAM file. RNA sequencing libraries 
were prepared with TruSeq Stranded mRNA kit following recommendations: the key 
steps consist of PolyA mRNA capture with oligo dT beads 1 µg total RNA, 
fragmentation to approximately 400 bp, DNA double strand synthesis, and ligation 
of Illumina adaptors amplification of the library by PCR for sequencing. Libraries 
sequencing was performed using Illumina sequencers (NextSeq 500 or Hiseq 
2000/2500/4000) in 75 bp paired-end mode in both techniques and data sequencing 
were processed by bioinformatics analyses. For the optimized detection of potential 
fusion transcripts by RNAseq an in-house designed metacaller approach was used. 
 
Molecular comparison of human samples and in vivo PDX-models (WES and 
RNAseq) 
All molecular analysis results, from WES or RNAseq of the PDX samples will be 
reviewed and compared to the patient tumor analysis, both at the relapse 
corresponding to the PDX and at diagnosis. Molecular comparison is ongoing. 
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Statistical analysis  
The data were shown as the mean ± standard error of mean (SEM) using Graphpad 
Prism® Software version 5.00 (Graphpad Software Inc, La Jolla, CA, USA).  
 
Results  
Seventeen tumor/blood samples were collected from 16 patients with 
refractory/relapsed osteosarcoma accrued in MAPPAYACT trials and analyzed at 
Gustave Roussy (Fig.4.1). Fourteen of these samples issued from 13 patients were 
implanted in mice. One patient (#32) had two biopsies at different relapse as the 
first sample was not contributive for molecular analysis (lung nodule then lymph 
node). From the 14 patients, 4 fresh tumor samples were cultures in vitro (primary 
cultures). Secondary cultures (using PDX cells) from the 3 established PDX models 
were also performed.   
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Figure 4.1: Patient and sample flow chart.  *Patient (#32) had two different samples 
collected and implanted at different progression time.  
(P0) 
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Osteosarcoma PDX in vivo establishment  
A small fragment of 14 relapsed osteosarcoma samples were implanted directly 
from the patients in different body localizations of NSG mice (Table.4.I): in the 
kidney capsule (n=5), subcutaneously (n=8) and/or in paratibial (n=11). Only one of 
the 5 first samples implanted (#A32-2) grew in the kidney capsule no further than 
P1 and this technique was stopped. Tumor engraftment at P0 was observed in 2/14 
patients (#B77, #C17), at both subcutaneous and paratibial sites (#B77, #C17), in 
one paratibial site (#C94, no subcutaneous implantation performed) (Fig.4.1). The 
last sample #C04 with tumor engraftment at both site was frozen in FBS+1% DMSO 
and stored at -80ºC (frozen in a coolbox that allows a temperature decrease of 
1ºC/min) before subcutaneous and paratibial implantation. The median delay for 
tumor detection from implantation was of 2.6 months in both implantation sites (1.6-
4.2 months and 1.0-4.2 for subcutaneous and paratibial, respectively) (Table.4.I). 
Only three of these models were able to reach at least passage 2 (P2) in both 
localizations (MAP-GR-B77-OS-1, MAP-GR-C17-OS-1 and MAP-GR-B94-OS-1) 
leading to a PDX-establishment rate of 3/8 subcutaneously and 3/11 paratibially. All 
3 subcutaneous models have a tumor take rate of 100% and 50, 40 and 80% for the 
orthotopic models MAP-GR-B77-OS-1, MAP-GR-C17-OS-1 and MAP-GR-B94-OS-
1 respectively. In the implantation of the first growing MAP-GR-B77-OS-1 
subcutaneous model in nude mice, it was however observed a much slower tumor 
development than in NSG mice (Supplementary Fig.4.S1). For the following 
procedures, nude mice were not used. 
 
Table.4.I (next page): Patients characteristics and PDX development. M-male, F-female, 
PHR- poor histological response, GHR- good histological response, OS2006-first line 
treatment of osteosarcoma in France4 which can combine different chemotherapies: M-EI - 
methotrexate-etoposide-ifosfamide, AP- doxorubicin-platinum, API-AI - doxorubicin-
platinum-ifosfamide, EI - etoposide-ifosfamide, OS2TTP-second line treatment of relapsed 
osteosarcoma in France (NCT00978471) randomizing HD- high-dose-thiotepa, GEMOX- 
gemcitabin-oxaliplatin, VP16-Carbo- etoposide-carboplatin, EDX-endoxan- 
cyclophosphamide, CR- complete response, PR- partial response, SD- stable disease, PD- 
progressive disease, ?- disease not yet evaluated under therapy, PD- progressive disease, 
R- relapse, Met- metastatic, Px- in vivo passage n°x. 
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1-OS2006: M-EI, AP EGFR somatic mutation p.R23G*57 EDX/Rapamune (PD)
2-GD, EI, HD-Thio TSC2 germline mutation p. V221M + LOH Pembrolizumab (PD)
 Sorafenib (PD)
Denozumab (PD, 
Dead)
1- OS2006: M-EI, AP
2- GEMOX
3- VP16-carbo
4- MEK3475-051-04 
Pembrolizumab
Same as above Denozumab (PD)
5-EDX/Rapamune Pazopanib (SD)
MAP-GR-A56-OS-1 F 11.2 Lung, tibia GHR 0%* 1- OS2006: M-EI, AP no target
Lenvatinib (NE)  
myelodysplasia
11.7 R Met
Lung surgical 
resection
1-OS2006: M-EI FGF14: amplification 0.93 Mb (10 copies)
TP53:  deletion  1.6 Mb (1.1 copies)+ gain  2.05 Mb (3.4 copies)+ 
TP53/TTC19 fusion
CDK4 : amplification 0.56 Mb (9.6 copies)
PDGFRA amplification 1.4Mb (8.5 copies) OS2TTP: AP, HD-EDX 
TP53: heterozygous somatic pathogenic mutation p.XXXX+10 WEE1inh/Carbo 
ATRX heterozygous somatic pathogenic mutation p.L1189* MEK15394 (PD)
CDKN2A/2B heterozygous deletion 0.7 Mb (1.2 copies) Denosumab
1- OS2006  M-EI, AP CDK4 amplification 0,2 Mb (4,8Mb) Lenvatinib (PR-PD)  
Cabozantinib (?)
1- OS2006: M-EI, AP, Zometa TET2: pathogenic somatic mutation p.R1095* Pazopanib (SD-PD)
2- OS2TPP: EI, HD-thio IRF7 pathogenic somatic mutation p.R860* Olaparib/irrinotecan
3- EDX/rapamune
1- OS2006: M-EI, AP TP53 somatic mutation p.C135Y HD-Thio (PD)
2- OS2TPP: EI CDKN2A/2B heterozygous deletion Lenvatinib (SD)  
ATRX focal loss of one copy
1- OS2006: M-EI TP53 p.S241A somatic homozygous mutation pathogenic AP (PD)
2- API-AI RB1  c.1695+1G>T somatic homozygous mutation Pazopanib
IGF1R  focal amplification (>40 copies)
1- API-AI PDGFA amplification (5 copies) Lenvatinib (SD; PD )
2- EI CDKN2A/2B homozygous deletion Pazopanib (PD)
VEGFA amplification (5 copies)
TP53-PI4KB fusion
CCND3 amplification (5 copies)
RB1 somatic mutation p.Tyr321Ter 
IGF1R focal amplification(13 copies)
MAP-GR-C22-OS-1 M 16.8 Lung GHR 8? 1- OS2006: M-EI, API, AP NA
Surgery, Cryotherapy 
only
18.7 R Nº3 Met Lung biopsy
1- OS2006: M-EI
2- AP
NA
no
EDX/Rapamune (PD)
OS2TTP: AP
EI (PD-Dead)1- API-AI
Femur biopsy
Patient characteristics and treatment 
Lymph node biopsy 2.3 >P2 NA >P2
MAP-GR-A95-OS-2 F with giant cell 11.2 - PHR 45%* 12.1
PD/R 
Nº2
Met
Lung surgical 
resection
MAP-GR-C17-OS-1 F Osteosarcoma 16.0
Did not grow
MAP-GR-B77-OS-1 M Osteoblastic 14.4 - PHR 60%* 16.9 R Nº2 Met
MAP-GR-A32-OS-2
Characteristic at time of implantation
Osteosarcoma 
MetMAP-GR-B40-OS-1 M Osteoblastic 16.9 - PHR 25%*
MAP-GR-A80-OS-1 M
10% osteoblatic    
60% 
chondroblastic 
30% fibroblastic
19.3 -
MAP-GR-A78-OS-1 M
Paratibial PDXSC PDX*
H
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y
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Lymph node biopsyMetPD18.0M
MAP-GR-A32-OS-1 M Chondroblastic Not done
Lung biopsy Not done Not doneMAP-GR-A07-OS-1 M Osteoblastic 7.4 lung PHR 25%* 9.5
PD / R 
Nº2
Met
Did not grow
Chondroblastic 16.5 lung PHR 30%* 
18.0 PD Met Lung biopsy16.5 lung PHR 30%*
11.8 Telangectatic - GHR 2% 13.5 R Nº1 PT
21.9 R Nº2 Lung biopsy
Liver biopsy
P1 
From 
P0 PT
>P2  4.2 >P2
P2 since 
06-12-17 
Lung surgical 
resection
1,6 >P2 1 >P2
MAP-GR-C61-OS-1
GHR 6% 1- OS2006 : M-EI 19.7 R Nº1 Met
Lung Surgical 
resection
ongoing 
since       
7-7-17 
-
Fibroblastic 
ongoing 
since    7-
7-17    
GHR 1,5%* 12.9
PD /R 
Nº1
Met
Telangiectasic 16.2MAP-GR-B94-OS-1 M Lung GHR 0%* 17.3
PD/R 
N°2
Met
M
Chondroblastic & 
chondromyxoïde 
11.0 - Biopsy -
Biopsy 3,6
P2 since 
06-12-17     
-
Osteosarcomatosis: 
Lung, bone, skin 
lymph node
NA 16.5 R Nº1 Met
Did not grow Did not grow
NA Pazopanib
MAP-GR-C04-OS-1* F Fibroblastic 13.8 - PHR 28%* 15.3 R Nº1 PT
Did not grow
Not done
Did not grow
Did not grow
Did not grow
Did not grow
Did not grow
Did not grow
Did not grow
Not done
Not done
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Osteosarcoma PDX in vivo local growth rate and behavior 
In subcutaneous models, the time between implantation and the start of tumor 
growth detection depends on the initial tumor sample (shorter for MAP-GR-B77-OS-
1 than MAP-GR-C17-OS-1) and the passage number (longer at passage P0 than at 
P2) (Fig.4.2). Once primary tumor growth had started then the tumor growth rate 
appeared similar between samples and passages. At passage P2, SC-PDX growth 
started from days 7, 13 and 18 for MAP-GR-B77-OS-1, MAP-GR-C17-OS-1 and 
MAP-GR-B94-OS-1 respectively, and reached a size around 900 mm3 at days 30 
(MAP-GR-B77-OS-1) and 40 (MAP-GR-C17-OS-1 and MAP-GR-B94-OS-1) after 
implantation. The doubling time of subcutaneous tumors for passage 0 was 5.6, 8 
and 17 days for MAP-GR-B77-OS-1, MAP-GR-C17-OS-1 and MAP-GR-C04-OS-1 
and 4.6, 9 and 10 days for passage 2 for MAP-GR-B77-OS-1, MAP-GR-C17-OS-1 
and MAP-GR-B94-OS-1, respectively (Fig.4.2). Primary tumor growth evaluation 
was more difficult with paratibial-PDX models due to the localization. 
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Figure 4.2: Tumor engraftment, in vivo growth and morphologic characteristics of the 3 subcutaneous and paratibial PDX models in NSG mice: 
Tumor growth of subcutaneous models in passage 0 (A) for MAP-GR-B77-OS-1 (B77), MAP-GR-C17-OS-1 (C17)  and MAP-GR-C04-OS-1 
(C04) (MAP-GR-B94-OS-1 was not implanted at passage 0 in subcutaneous site) and passage 2 (B) for MAP-GR-B77-OS-1, MAP-GR-B94-
OS-1 (B94) and MAP-GR-C17-OS-1 (MAP-GR-C04-OS-1 has not reached the passage 2 for the moment) and tumor characteristics for 
different passages and at sacrifice day  for subcutaneous and paratibial models (C). *subcutaneous MAP-GR-C04-OS-1 grow from patient 
frozen sample. 
P0 P2 
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CT scan performed on the sacrifice day of the different passages detected intra-
tumor calcification in all models (paratibial and subcutaneous), although more 
pronounced in paratibial than in subcutaneous models (Fig.4.3). In paratibial models 
the observed abnormalities were similar to those presented by patients, with 
aggressive bone lesions, detection of aberrant new bone formation extending within 
the extra-osseous mass (osteocondensation), and some osteolysis (bone 
destruction). MAP-GR-B77-OS-1 developed on the tibia, however, tumor extra-
osseous growth was observed on the femur/pelvis. The three models (MAP-GR-
B77-OS-1, MAP-GR-C17-OS-1 and MAP-GR-B94-OS-1) showed more 
osteocondensation than osteolysis. MAP-GR-C17-OS-1 developed in the tibia with 
femur extension while MAP-GR-B94-OS-1 originated only in the tibia. MAP-GR-
B94-OS-1 was the model with more osteocondensation inside and outside the bone 
(Fig.4.3).     
HES staining confirmed the osteosarcoma nature of the primary tumors from both 
subcutaneous and paratibial PDX models. In both cases, proliferation consisted of 
osteoblastic cells (MAP-GR-B77-OS-1 and MAP-GR-B94-OS-1) with atypia and 
mitosis. Osteoid production was present with necrosis and cystic alterations. MAP-
GR-C17-OS-1 showed also a mix of osteoblastic and chondroblastic subtype. All 
the models showed pleomorphic cells and also anaplastic cells on the MAP-GR-
B77-OS-1(Fig.4.3 and Table.4.II). 
 
Osteosarcoma PDX in vivo metastatic potential  
No clinical signs or CT-scan abnormality at day of animal sacrifice permitted to 
detect metastasis. Metastases were detected only by histology at sacrifice time in 2 
paratibial PDX models. Metastases were detected for paratibial models in the lungs 
in MAP-GR-C17-OS-1, in the bone in MAP-GR-B94-OS-1, and in the spleen in the 
both models. No metastases were observed in the liver. No metastases were 
detected in subcutaneous models (Table.4.II) 
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Figure 4.3: Radiological and morphological primary tumor PDX characteristics by two different types of implantation (subcutaneous and 
paratibial). The small white arrows show osteocondensation, the biggest white arrows show osteolysis and the black arrows osteoid matrix 
(orange color).  B77- MAP-GR-B77-OS-1; B94 - MAP-GR-B94-OS-1; C17- MAP-GR-C17-OS-1; PT- Primary tumor; N – Normal tissue
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Table.4.II: Radiological and morphological characteristics of the primary tumor and metastases for the MAP-GR-B77-OS-1, MAP-GR-B94-OS-
1, MAP-GR-C17-OS-1 PDX established by two different types of implantation (subcutaneous and paratibial). Histo – Histology; HG – High-
grade; OB – Osteoblastic subtype; CB – Chondroblastic subtype; NA – Not applicable; ND – Not done.  
 
PDX 
Implantation 
type 
Primary tumor Metastases 
Histo- HES CT Histo- HES 
Sub-type 
Osteoid 
Matrix 
Cells 
morphology 
Necrosis Calcification Osteolysis Lung Bone Spleen Liver 
MAP-GR-
B77-OS-1 
Subcutaneous HG  OB 
Yes (+) 
 
Pleomorphic and  
anaplastic 
+ ++ - - NA - - 
Paratibial HG  OB 
Yes (++) 
 
pleomorphic + ++ + - - ND ND 
MAP-GR-
B94-OS-1 
Subcutaneous HG  OB Yes (+) pleomorphic + ++ - - NA - - 
Paratibial HG  OB Yes (+++) pleomorphic + ++++ ++ - + + - 
MAP-GR-
C17-OS-1 
Subcutaneous 
HG  
OB+CB 
Yes (+) 
( osteoid and 
chondroblastic) 
pleomorphic ++ ++ - - NA - - 
Paratibial 
HG  
OB+CB 
Yes (++) 
( osteoid and 
chondroblastic) 
pleomorphic ++ +++ ++ + - + - 
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Patient’s Characteristics  
Characteristics of these 13 patients with samples implanted in mice are described 
in Table.4.I. Samples were issued from 10 males and 4 females with a median age 
of 16.5 years (range 9.5-21.9) at time of biopsy/surgery. At diagnosis, disease was 
localized with good histological response (n=3), localized with poor histological 
response (n=4), metastatic with good histological response (n=3), metastatic with 
poor histological response (n=3). They received before biopsy/surgery in the frame 
of MAPPYACTS, one (n=5), two (n=4), three (n=1) or five (n=1) lines of treatment, 
with the five chemotherapeutic agents know to be efficient in phase-II trials 
(methotrexate, doxorubicin, cisplatin, ifosfamide and etoposide), except two patients 
that did not received methotrexate. In addition, one patient received zoledronic acid, 
two rapamune, and one pembrolizumab, before biopsy/surgery.  
The three patients from who PDX samples were obtained (#B77, #C17 and, #B94) 
presented very aggressive disease at diagnosis. 
MAP-GR-B77-OS-1 PDX models were issued from a 14-year-old boy. At diagnosis 
he presented with a localized osteoblastic osteosarcoma of the femur. Poor 
histological response (60% of residual viable cells) was observed after M-EI 
chemotherapy according to OS2006/sarcome09 trial25, post-operative treatment 
continues with AP. A first pulmonary relapse occurred at 18 months (M18) from the 
initial diagnosis treated by EI. The second lung metastatic relapse occurred at 12 
months of the first relapse and 6 months from the end of second line treatment. The 
cumulative dose of chemotherapy before MAPPYACTS inclusion was for 
methotrexate 96 g/m2, doxorubicin, 350 mg/m2, cisplatinum 600 mg/m2, ifosfamide 
72 g/m2, and etoposide 1800 mg/m2. The surgical resection of the lung metastasis 
at second relapse (M30 from diagnosis) was used for MAPPYACT molecular 
analysis and PDX establishment. He then received high-dose thiotepa, as 
consolidation treatment of this third complete remission. A third pulmonary 
progression occurred four months after the previous one (M34 from diagnosis). The 
disease was stabilized after four months of lenvatinib he underwent complete 
surgical excision and the patient was still alive at 42 months from initial diagnosis. 
Potential targetable molecular abnormalities were TP53 somatic mutation p.C135Y 
and homozygous deletion of CDKN2A/2B. 
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MAP-GR-B94-OS-1 PDX model was issued from a 16 year-old boy. At diagnosis he 
presented a telangiectatic osteosarcoma of the femur with an initial local vessel 
invasion and lung metastasis. Local and lung metastatic progression occurred 
during preoperative chemotherapy by M-EI (after cycle 1, week 7). The 
chemotherapy was switched for API-AI (2 cycles) leading to partial response at both 
local and metastatic site. Surgery of the primary tumor and lung metastasectomy 
showed no residual viable cell after these neoadjuvant chemotherapies. Several 
infectious complications delayed the post-surgery chemotherapy which continued 
with EI (4 cycles). A new local and metastatic progression (lung, liver and bone) 
occurred under treatment at 11 months from diagnosis (M11). The cumulative dose 
of chemotherapy before MAPPYACTS inclusion were for methotrexate 36g/m2, 
doxorubicin 240 mg/m2, cisplatinum 300 mg/m2, ifosfamide 84 g/m2, and etoposide 
1800 mg/m2. A liver metastasis of the second relapse (M11 of diagnosis) was 
biopsied for MAPPYACTS molecular analysis and PDX establishment. The patient 
had several surgeries of the metastases and for prosthesis infection, then received 
one cycle of AP and progressed (M15 from diagnosis). After 3 months of pazopanib 
a partial remission of the disease and a left asymptomatic pneumothorax were 
observed, then the disease progressed at 6 months of treatment.  The patient is still 
alive at 22 months from the initial diagnosis, with a recurrent disease and a 
persistent asymptomatic pneumothorax. Potential targetable molecular 
abnormalities were somatic homozygous mutations in TP53 (p.S241A) and RB1 
(c.1695+1G>T), and an IGF1R focal amplification (>40 copies). He also presented 
a germline ATM mutation p.D1637G. 
MAP-GR-C17-OS-1 PDX models were issued from a 16 year-old girl. At diagnosis, 
she had a rare presentation of osteosarcomatosis with a very large femoro-tibial 
mass associated with multiple bone, lung, lymph node, muscular and subcutaneous 
localizations. The treatment by API-AI achieved metabolic good partial response 
with minimal tumor volume shrinkage at all sites. Local and metastatic progression 
occurred under treatment after 4 API-AI cycles (M5 from diagnosis). The cumulative 
dose of chemotherapy before MAPPYACTS inclusion were for doxorubicin, 360 
mg/m2, cisplatin 400 mg/m2, and ifosfamide 60 g/m2. A right inguinal lymph node 
metastasis at first progression was biopsied for MAPPYACTS molecular analysis 
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and PDX establishment (M5 from diagnosis). One cure of EI was started but 
treatment was stopped due to very rapid disease progression and massive alteration 
of performance status. The patient died of progressive disease 4 months later (M9 
from diagnosis). Potential targetable molecular abnormalities were RB1 somatic 
mutation p.Tyr321Ter and IGF1R focal amplification (13 copies). 
 
Resistance/sensitivity to drugs of the different models   
Osteosarcoma primary and secondary in vitro cultures 
When tumor material was sufficient, in vitro primary tumor cell cultures directly 
derived from the patient tumor were tried (MAP-GR-A56-OS-1, MAP-GR-A80-OS-
1, MAP-GR-B77-OS-1 and MAP-GR-A095-OS-2). MAP-GR-A80-OS-1 and MAP-
GR-A095-OS-2 grew until passage 7 and 5, respectively, but no drug testing was 
performed due to fibroblasts contamination.  
Secondary cultures issued from the 3 PDX samples (in vivo passages) were grown 
in vitro. All models showed slow cell growth and high adherence, leading to 
difficulties on trypsinization (Fig.4.2). MAP-GR-B77-OS-1 reached passage 2 after 
1 month in culture and cell growth after passage 2 stopped, while MAP-GR-C17-
OS-1 and MAP-GR-B94-OS-1 reached passage 2 after 2/3 weeks and grew after 
passage 2 (Fig.4.2).  Drug testing in these cells confirmed high levels of resistance 
to usual chemotherapeutic agents used in osteosarcoma, especially for MTX with 
IC50>100µM (Table.4.III), much higher than the IC50s of our previously described  
MTX-resistant osteosarcoma cell line models26. 
As two patients received multi-tyrosine kinase inhibitor with either stable (#B77, 
lenvatinib) or partial response (#B94 pazopanib), we tested three of them in vitro 
(cabozantinib, regorafenib and pazopanib). Sensitivity to these drugs were different 
for a same patient. High resistance levels were observed with regorafenib 
(IC50>100µM). The cells derived from the PDX of the patient #B94 who had partial 
response to pazopanib had an IC50 of 46.7µM and a 20 times greater sensitivity to 
cabozantinib (Table.4.III). 
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Table.4.III: IC50 of different cell lines (parental and cell lines selected to be resistant) in 
comparison with the PDX-cells (MAP-GR-B77-OS-1, MAP-GR-B94-OS-1 and MAP-GR-
C17-OS-1) cultured and treated in vitro. The treatment was performed with: MTX, 
doxorubicin, etoposide, cisplatin, mafosfamide, cabozantinib, regorafenib and pazopanib.   
 
 
 
Discussion 
We established three new subcutaneous and orthotopic (paratibial denudated) 
osteosarcoma PDX models derived from refractory/relapse human samples in NSG 
female mice.  
The engraftment rate was of 30% with a median interval of 2.6 months, lower but 
quicker than the recent published series of 15 orthotopic osteosarcomas with 
another method (both mechanic and enzymatic dissociation, intercondylar femur 
cell injection in NSG female mice, engraftment rate of 48% with a median interval 
from implantation of 3.75 months, range 1.5-9)19.  
Both subcutaneous and paratibial PDX models mimic the human disease in terms 
of histology (osteoid formation) and in term of imaging for the orthotopic models with 
aggressive local bone tumor-induced abnormalities. Some of these models also 
 
Cells 
IC50 (µM) 
MTX DOXO ETOP CISP MAF Cabo Rego Pazo 
HOS 
Parental 0.04 0.05 0.7 4.80 12.7 6.5 ND ND 
R/MTX 6.24 0.07 0.67 5.38 16.8 5.76 ND ND 
R/DOXO 0.48 10.6 180 3 14.30 13.6 ND ND 
HOS-143B 
Parental 0.04 0.04 0.68 1.68 14.3 14.6 ND ND 
R/MTX 4.13 0.10 0.90 3.96 12.7 23 ND ND 
Saos-2 
Parental 0.05 0.05 2.97 4.28 17.6 18 ND ND 
R/MTX 2.05 0.10 5.21 6.44 23.90 23.9 ND ND 
Saos-2-B 
Parental 0.05 0.06 2.80 5.20 20.30 7,58 ND ND 
R/MTX 1.93 0.06 3.76 5.96 21 15,30 ND ND 
MG-63 
Parental 0.05 0.1 2 2.48 13.30 8.5 ND ND 
R/MTX 2,91 0.24 9.81 3.38 26.20 6 ND ND 
U2OS Parental 0.05 0.1 4.4 10 33 ND ND ND 
IOR/OS18 Parental 1.3 0.18 5.86 4.62 27.13 ND ND ND 
MAP-B77 - >100 0.18 76.3 22.6 57.6 ND ND ND 
MAP-B94 - >100 0.7 14.5 2.63 50 2.69 >100 46.7 
MAP-C17 - >100 0.19 17.5 6.09 13.2 20.6 >100 14.8 
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mimic the human disease in terms of spontaneous metastatic spread, especially 
when they developed in an orthotopic setting. The metastatic potential of the 
orthotopic PDX models were not described in Stewart et al19. Although molecular 
comparison (WES and RNAseq) between PDX (subcutaneous and paratibial) 
models and the corresponding patients tumor at relapse and diagnosis they are 
issued from are ongoing. Several comparisons will be performed to approach: first, 
the representativeness of the PDX models compared to the human relapse samples 
they are issued of; second, the similarities or differences between both 
subcutaneous and orthotopic PDX models; and finally, the clonal evolution and 
mechanism of resistance acquired between diagnostic and relapse samples of each 
patient with a PDX. General analyses will explore copy number abnormalities, 
mutations, fusions, and gene expression profiles, more specific analysis might 
include exploration of the known mechanisms of resistance to the several drugs 
either received by the patient before the MAPPYACTS biopsy (e.g RFC, DHFR for 
MTX, PgP for doxorubicin, etc) or used in patient after the MAPPYACTS biopsy (e.g. 
sumscan for MTKI) or in the PDX models. 
We expect that the molecular characteristic of the human relapse disease will be 
retained by the PDX models, as in a panel of 15 different PDX issued from pediatric 
tumor recently published, the 15 osteosarcoma PDX models had the best clonal 
preservation19.  
The primary growth properties of our PDX models when established (≥ passage P2) 
had also the advantage to be compatible with the timelines for drug testing at both 
sites. In vivo drug testing has not yet been done, and ethical authorization process 
is ongoing.  
In the meantime, we derived secondary in vitro cell culture from the subcutaneous 
PDX models that confirmed the high level of resistance to chemotherapeutic agents 
previously used in the patients, especially to methotrexate and including in one 
patient that did not receive it (#C17). We also observed differential sensitivity to 
different multi-tyrosine kinase inhibitors currently in clinical trial or not, with no 
sensitivity to regorafenib and inter-patient and intra-patient variability in term of 
sensitivity to cabozantinib and pazopanib. IC50 of cabozantinib was in the same 
range of those observed with human hepatoma cell lines27. Cabozantinib reverses 
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multidrug resistance hepatoma cell lines resistant to doxorubicin by modulating the 
function of P-glycoprotein27, but not in our previous HOS-DOXO-resistant cell line 
model.  
Several compounds will be also tested in vivo such as the multityrosine kinase 
inhibitor cabozantinib and other molecules or combination according to the 
molecular abnormalities detected in patient and PDX samples (e.g.  TP53 mutation 
and Wee1 inhibitor + carboplatin or other chemo or BRCAness phenotype and 
PARP inhibitor + irinotecan). No drug testing has been published yet on 
osteosarcoma PDX models19. 
 
Conclusion 
The establishment of osteosarcoma subcutaneous and orthotopic (paratibial 
denudated) PDX models derived from refractory/relapse human samples in NSG 
has been achieved. It was also demonstrated the advantages of these 
subcutaneous (rapid growth, easy detection) and orthotropic (interrelation of the 
tumor with the bone microenvironment) osteosarcoma PDX (preserved tumor 
heterogeneity) models in terms of drug testing. However, their development in 
immunocompromised mice (NSG) will not allow to access the immune 
microenvironment role in drug sensitivity/resistance. Several teams are now working 
in humanized PDX models. 
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Supplementary Figure.4.S1: Tumor growth characteristics by subcutaneous implantation in Nude and NSG mice for MAP-GR-B77-OS-1. A– 
Tumor growth in Nude versus NSG with the time; B – Tumor development characteristics 
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Osteosarcoma remains a disease which requires new treatments to improve 
disease outcome1–4. The main challenges are the metastatic spread of the disease 
and its resistance to currently used chemotherapeutic agents, which will ultimately 
lead to death.  Developing better and diverse preclinical models is crucial to take 
into account the complex genetic/epigenetic background, the heterogeneity of these 
tumors and the importance of the bone and immune microenvironment. 
The work performed during my thesis led to an essential contribution in developing 
new and diverse osteosarcoma pre-clinical models with metastatic potential and 
chemoresistance phenotype, to understand the mechanisms of resistance, and to 
finally use this panel of models to test new drugs in osteosarcoma and better predict 
the clinical behavior of the drugs in the patients. 
Osteosarcoma is the second highest cause of cancer related death in children and 
adolescents, affecting mainly the long bones5. It’s a very complex bone disease, 
where cells of origin, genetic/epigenetic alterations, osseous and immune 
microenvironment and others parameters play an important role in 
tumorigenesis. Treatment has improved with the chemotherapy implementation, 
unfortunately, in metastatic or recurrent patients, 5-year survival rates are reduced 
to only 20%. Metastases at diagnosis and resistance to chemotherapy are two 
prognostic factor of high risk of relapse in this disease1–4 (Fig.5.1). All these points 
show the importance of developing models, especially in an orthotopic setting, that 
allow understand better this disease (eg. resistance mechanism) as well as to test 
new drugs that leads to an increase of the patients’ survival.  
In this work, we used osteosarcoma cells from different sources (previously 
established cell lines and human relapse tumor samples) to access different 
degrees of sensitivity/resistance and different mechanisms of resistance to 
chemotherapy, and different metastatic potential. 
In vitro, a panel of previously established cell lines with different genetic background 
were modified by continuous exposure to different drugs, with high importance in 
osteosarcoma treatment (methotrexate and doxorubicin), to induce resistance, 
allowing exploration of the mechanism of acquired resistance (decrease RFC 
expression and/or increased DHFR expression in methotrexate resistant cells and 
increased PgP in doxorubicin resistant cells, with cross-resistance to etoposide)3,6. 
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We also used one previously established cell line issued from an already metastatic 
tumor at diagnosis, the IOR/OS18, that present spontaneous higher degree of 
resistance to the five anti-osteosarcoma drug tested (methotrexate, doxorubicin, 
etoposide, mafosfamide, cisplatinum). Two parental cell lines (HOS and Saos-2-B) 
were implanted in vivo in an orthotopic bone setting and posteriorly in vitro culture 
(cells derived from CDX models) showing increased level of resistance. The in vivo 
growth increased the level of resistance of these cells with a mechanism to be 
further explored. The cells that presented the highest degree of resistance to all five 
drugs were in vitro secondary cell culture of cells issued from our PDX models (PDX 
were established from human osteosarcoma samples of relapsed/refractory 
disease). 
  
To mimic at best the human disease which initiate in a bone microenvironment and 
spontaneously spread mainly to the lungs, we established different in vivo orthotopic 
models, either issued from established cell lines (CDX models) or from human 
relapsed tumor samples (PDX models) (Fig.5.1). We determined that Saos-2-B cell 
line injected intratibially in NSG mice allowed higher engraftment rate, primary tumor 
growth/bone abnormalities and metastatic spread than paratibial injection or Nude 
mice.  We developed another intra-osseous CDX from a cell line with a different 
genetic background (HOS), showing a very different in vivo behavior. Saos-2-B-
CDX were fast growing tumors with important extra-osseous masses and both 
osteolysis and osteocondensation, while HOS-CDX resulted in local disease with 
mainly bone destruction and no extra-osseous mass. Both models showed 
spontaneous metastases in the lung and rarely in the bone, more notorious in Saos-
2-B-CDX model than in HOS. However, unusual metastases in the spleen were also 
observed, as described in others osteosarcoma CDX models in 
immunocompromised mice (lymph node, kidney, ovary etc)7,8. The resistant 
counterpart cell lines induced in vitro were also injected in the same conditions in 
NSG mice (Saos-2-B-R/MTX-CDX, HOS-R/MTX-CDX and HOS-R/DOXO-CDX). 
Although the primary tumors behavior was not changed by the in vitro drug 
selection, their metastatic potential was clearly impaired (less and slower metastatic 
spread) compared to their parental counterpart. The main advantage of these CDX 
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models was their bioluminescent properties, which allowed to follow in vivo primary 
tumor growth and lung metastases spreading in real-time. The disadvantage of CDX 
models consisted of the nature of the cells used. Indeed, CDX models derived from 
in vitro cell lines which might have been in culture for long time, allowing genomic 
alterations (eg. adaptation to in vitro environment), and the lack of 
representativeness of the real osteosarcoma tumor heterogeneity9.  
To overcome this last difficulty, we developed three PDX models derived from 
patient tumor samples collected from metastatic site of relapse refractory disease. 
As our CDX, our PDX models mimic human osteosarcoma behavior in vivo.  
Morphologically, CDX resemble osteosarcoma but comparatively, PDX model 
morphology was closer to the human disease they were derived from. Lung 
metastases were not detectable in subcutaneous PDX models, but only in orthotopic 
PDX models, confirming that orthotopic settings better reflected the human 
osteosarcoma behaviors than the subcutaneous settings. Osteosarcoma PDX 
models allow the patient’s tumor heterogeneity preservation and the tumor cells 
growth in relation with their own stroma, better representing the tumor behavior 
observed in the patients10. A recent publication described 15 intra-osseous PDX 
osteosarcoma models which retain the molecular and cellular features of the patient 
tumors, the epigenetic landscape of their developmental origins and clonal 
preservation10. On other hand the assays on PDX models are currently ongoing and 
results will be further explored. The absence of bioluminescence renders in vivo 
follow up of tumor growth more difficult in the PDX orthotopic models, although 
easier when the tumor was implanted subcutaneously than in an orthotopic setting. 
However, the implantation site of the PDX models might differentially impact drug 
sensitivity, as described in an in vivo syngeneic osteosarcoma model11. The low 
patient material availability and the low engraftment rate make these models difficult 
to obtain. The IMI2-P4 consortium is working on increased availability of these PDX 
models and we are participating to this effort through our work on the PDX ancillary 
study of the MAPPYACTS trial. However, the use of immuno-compromised mice 
strain (NSG mice) to favor engraftment, do not allow access the role of the immune 
context in tumor development, metastatic spread and sensitivity/resistance to 
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treatments, which is also important in osteosarcoma5. The advantages and 
inconvenient of the models are described in Table 5.I. 
 
Globally, we have constituted a large panel of different in vitro and in vivo orthotopic 
(CDX, PDX) osteosarcoma models with various sensitivity/resistance to 
chemotherapy and metastatic potential that might prove to be useful for new drug 
testing. We have tested the effect of cabozantinib in all the in vitro models and 
showed that even in very chemoresistant models, cabozantinib efficacy can be 
observed. In vivo testing is awaited, and the results of the Phase-II trial in 
osteosarcoma will be available next year (NCT02243605)12. 
These models will be used to test several other drugs or combinations. The timelines 
of primary tumor growth and metastatic spread in both CDX and PDX models being 
compatible with the timelines of drug testing. Prioritization will be done based on the 
targetable molecular abnormalities of these different models (e.g. TP53 mutation 
and Wee1 inhibitor), on the literature (BRCAness genetic signatures and PARP 
inhibitors combination with chemotherapy)13,14 or upcoming new knowledge. 
Indeed, we are currently analyzing the OS2006 cohort of primary tumor biopsy 
sample at diagnosis and the MAPPYACTS osteosarcoma cohort at relapse, for both 
at DNA (CGH, WES) and RNA level (RNA seq), from which new target could be 
issued. Humanized mice will also developed for complementary information related 
to immune system influence in the osteosarcoma development.  
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Table 5.I: Several preclinical models used and/or developed in this work and their advantages and inconvenients. R/DOXO – Resistant to 
doxorubicin; R/MTX – Resistant to methotrexate; SC – subcutaneous; CDX – cell-derived xenografts; PDX – patient-derived xenografts 
 
 
 
Preclinical models Available models Resistant phenotype Metastatic potential Advantages Inconvenient 
In vitro      
Established cell lines      
Cell lines derived from sample at 
diagnosis 
Primary tumor Non   Non resistant 
 Metastases 
(IOR/OS18) 
yes (multi-drug) 
not accessible in vitro 
(approach by 
migration/invasion assays) 
Quick drug testing  
Resistant cell lines by continuous 
in vitro drug exposure 
5 to MTX yes to MTX  Mechanistic questions  
 HOS-R/DOXO yes to doxo/etoposide   
low levels of 
resistance and to few 
drugs 
Secondary culture derive from 
xenografts in NSG mice 
     
Secondary cultures of cells 
derived from the parental CDX 
 increased resistance level    
Secondary cultures of cells 
derived from the PDX 
 very high degree of 
resistance to multiple drugs 
 multi drug phenotype 
Slow growing, very 
adherent to flask 
In vivo in NSG Mice      
CDX      
Orthotopic parental CDX HOS, SaOS-2-B  SaOS-2-B > HOS Bone microenvironment 
Lack tumor 
heterogeneity 
Orthotopic resistant CDX 
R/MTX HOS and 
SaOS-2-B 
yes parental > resistant 
bioluminescence 
detection of primary 
tumors and metastases 
No access to immune 
contexture 
 HOS-R/DOXO yes parental > resistant   
PDX      
Paratibial PDX issued from 
relapsed human osteosarcoma 
#B77; #B94, #C17 yes  Bone microenvironment 
Difficult to follow in 
vivo 
Sub cutaneous PDX issued from 
relapsed human osteosarcoma 
#B77; #B94, #C17 yes paratibial > sc Tumor heterogeneity 
No access to immune 
contexture 
    Easier drug testing  
Follow up    
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Figure 5.1: Tumor development in human patients and the different in vitro and in vivo 
models developed in this thesis. At diagnosis, patients with osteosarcoma present as 
primary tumors with or without visible metastases or undetectable micro-metastasis. 
Relapses, usually metastatic, arise from either primary tumor or metastatic tumor, after 
chemotherapy pressure selection or not (non-proliferating micrometastases not sensitive to 
chemotherapy). In vitro and in vivo models have been derived from these different human 
disease states. Established in vitro cell lines were usually derived from sensitive primary 
tumors (a), more rarely form resistant metastatic samples (e.g. IOR/OS18 derived from 
metastases with intrinsic resistance) (c), or were rendered resistant by in vitro exposure to 
chemotherapy to a single agent Methotrexate or doxorubicin (b). CDX models were derived 
from these established cell lines.  PDX models were directly derived from human samples 
at relapse. CT=chemotherapy. 
 
 
 
 
Surgery 
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